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1Outline
2.Metastatic colorectal cancer
Metastatic colorectal cancer (CRC) is diagnosed in more than 1.2 million patients an-
nually and is responsible for more than 600,000 deaths per year worldwide (1). Patient 
survival  mainly depends on the development of distant metastases (mCRC), which 
occurs in half of the patients. During the last decade, the therapeutic options for mCRC 
patients have increased, where after the addition of two new chemotherapeutic agents, 
oxaliplatin and irinotecan, two classes of monoclonal antibodies (MAb), against the 
vascular endothelial growth factor (bevacizumab), and against the epidermal growth 
factor receptor (cetuximab and panitumumab) were introduced in the clinical prac-
tice. Currently, the combination or successive regimens with these agents resulted in 
study populations in a median overall survival of 20 months (2, 3).  However, these 
therapies cause in a subset of patients significant toxicity, such as diarrhoea, hand-foot 
skin reaction, fatigue, or sensory neuropathy (4-6). In addition, despite this improve-
ment in survival, eventually most patients have disease progression, as they become 
refractory to these treatments. Only patients with a limited number of metastases have 
a chance for cure by radical surgery, in general combined with chemotherapy, which 
results in a increased 5-year survival up to almost 50% (7, 8). However, initial curative 
resection of metastases often fails, due to inoperable disease discovered at laparotomy 
(9), or recurrent disease during follow-up, which occurs in >50% of the cases (10, 11). 
Moreover, only a minority of patients is eligible for this surgical resection of metasta-
ses and the chance of complete tumour resection depends on the number, localization 
and size of metastatic tumour lesions (12). Therefore, there is need for improved and 
early detection of small metastases to avoid futile major surgery (13), and prevent 
delay in the start of palliative chemotherapy. 
Currently, conventional imaging is performed with anatomical techniques, such as 
computed tomography (CT) and ultrasonography. However, these modalities require 
anatomic alterations to detect tumours, while their low contrast resolution limits the 
discrimination from soft tissues. Therefore, small tumours are missed, resulting in futile 
laparotomies and progression into overt-recurrences. Positron emission tomography 
(PET) with 18F-fluorodeoxyglucose (FDG) is a more recent molecular imaging tech-
nique. FDG accumulates in cells with increased glucose metabolism, such as cancer 
cells, granulocytes and macrophages. The increased uptake in tumours generally leads 
to high contrast images. Multimodality imaging with hybrid PET/CT combining 
anatomy depicted by CT with molecular information from PET, is now widely availa-
ble, and results in adequate diagnostic work-up of patients with CRC. FDG-PET/CT 
has high sensitivity and high negative predictive value for staging patients with CRC 
(14, 15), and therefore has an established role in the diagnostic process of patients 
with mCRC. In the pre-operative phase it changes patient management in >25% of 
patients, mainly by detecting extrahepatic disease (9, 16, 17). However, since FDG is 
a nonspecific tracer, it also has uptake in other tissues with increased metabolism (e.g., 
physiological uptake in the bowel, uptake in (post-surgical) inflammatory or infec-
3tious lesions). This may cause diagnostic dilemmas as malignant disease may then not 
be excluded with sufficient confidence (18-20).
Radiolabeled monoclonal antibodies
As indicated above, both diagnostic and therapeutic challenges remain in patients with 
mCRC, i.e. [1] the need for a sensitive, but also specific imaging modality to detect 
small CRC tumours at an early stage, and [2] the need for an effective and less toxic 
systemic therapy for mCRC or for adjuvant treatment after surgery. These needs could 
potentially be met by antibody-guided radionuclide targeting.  MAb directed against 
tumour-associated antigens can be used to selectively target radioactivity to tumour 
cells, while sparing normal tissues. These antibodies, or antibody-derived molecules, 
can be labelled with a wide variety of radionuclides, either for imaging or therapy. 
Moreover, imaging and therapy can be elegantly combined, a strategy designated as 
theranostics. Pre- and post-therapy imaging can be used to predict or measure the 
deposition of therapeutic agents.
Radioimmunotherapy (RIT) aims to selectively deliver radionuclides to the tumour 
lesions, and has some advantages over other therapeutic approaches for treatement of 
mCRC. For example, tumour cells that do not express the target antigen can still be 
killed due to crossfire effect, i.e. radiation emitted by radionuclides bound to neigh-
bouring tumour cells. Furthermore, in contrast to chemotherapeutics and unconju-
gated MAb for treatemt of mCRC, radiolabelled MAb do not induce drug resistance, 
alternation of downstream signalling pathways, nor increased growth factor receptor. 
Radioimmunotherapy in mCRC
For CRC, the mostly targeted tumour-associated antigen is carcinoembryonic antigen 
(CEA), which is overexpressed in 95% of CRC and is almost absent in normal tissues. 
CEA concentrations in tumours are on average 60-fold higher than in nonmalignant 
tissues (21). CEA is a glycoprotein consisting of 60% carbohydrate and a molecular 
mass of 180–200 kDa. CEA is attached to the cell membrane by a glycosyl phosphati-
dylinositol anchor and is released as a soluble form into the circulation probably by a 
phospholipase C or phospholipase D (22, 23). CEA is readily available on the outside 
of the membrane. Anti-CEA monoclonal antibodies bound to CEA-isotopes on the 
tumour cell surface are internalized, but this takes place only slowly and to a limited 
extent (24, 25). 
The efficacy of RIT using radiolabelled anti-CEA MAb in mCRC has been investi-
gated in various preclinical studies. Behr et al. demonstrated that in a nude mouse 
model for lung metastases of CRC, RIT with an 131I-anti-CEA antibody cured half 
of the animals whereas equitoxic chemotherapy only prolonged life for a few weeks 
(26). Koppe et al. compared the effect of different radionuclides used in RIT with a 
radiolabelled anti-CEA-IgG in a  mouse model with small peritoneal xenografts, and 
4showed that 177Lu and 131I were suitable radionuclides to be used in RIT (27). 
In a phase I/II clinical trial, Behr et al. investigated the pharmacokinetics, dosimetry, 
toxicity and antitumor activity of 131I-anti-CEA antibody in patients with CEA-
expressing tumors, mainly of colorectal origin. Tumour absorbed doses inversely cor-
related with the tumour size. Only modest antitumor effects were observed (28). The 
pivotal clinical study of RIT that demonstrated its therapeutic potential in mCRC 
patients, was a phase II trial performed by Liersch et al. in patients with small volume 
disease. An 131I-labelled anti-CEA IgG was given in an adjuvant setting to patients 
after liver metastasectomy. RIT resulted in an improved overall survival (OS) as com-
pared to a comparable group of patients who did not receive adjuvant therapy (5 years 
OS 42.1% and 15.8% for RIT and controls, respectively) (29, 30).
Although RIT is effective in non-Hodgkin’s lymphoma, which has led to the registra-
tion of two radiolabelled anti-CD20 MAb preparations (31-34), the efficacy of RIT 
in solid tumours is modest, mainly because these tumour lesions are less radiosensitive. 
To improve therapeutic efficacy of RIT in solid tumours, further escalation of radio-
activity doses is required to guide higher absorbed doses to these tumours. However, 
radiolabelled MAb are not the solution as these have a slow blood clearance, causing 
continuous radiation exposure of the bone marrow due to  long-circulating radioactiv-
ity. This results in dose-limiting bone marrow suppression without sufficient radiation 
doses being delivered to solid tumours. Therefore, to guarantee acceptable absorbed 
doses to normal tissue, the tumour-to-normal tissue ratios should be improved.
Different approaches of engineering or modification of antibodies have been devel-
oped to accelerate blood clearance of the radioactive agent and to improve targeting of 
tumours: MAb fragments  such as Fab, F(ab’)2 fragments have been produced, as well 
as other MAb-derived constructs such a single-chain antibodies (scFv), minibodies 
and diabodies (35-38). Using these MAb fragments red marrow doses are indeed re-
duced, at the expense, however, ofincreased radiation doses to the kidneys, due to renal 
excretion and tubular retention of the radionuclides. Several methods to lower the 
kidney radiation doses have been developed (39, 40), but these may be insufficiently 
efficient to prevent renal failure.  
Pretargeting
A very promising technique to improve tumour-to-normal tissue ratios is pretargeting. 
In pretargeting, the targeting of the tumour and the delivery of the radionuclide to the 
tumor are separated in two steps. For this purpose, MAb have been developed, which 
have affinity for a tumour-associated antigen as well as for a smaller radiolabelled mol-
ecule. First, the unlabelled MAb construct is infused, and when the MAb has cleared 
from the blood and has accumulated in the tumour, the radiolabelled small molecule 
is administered which is subsequently trapped in the tumour by the other binding site 
of the MAb (Figure 1). These smaller radiolabelled molecules used in pretargeting 
5extravasate more rapidly, thus targeting the tumours faster while also clearing  more 
rapidly from the circulation than the full-sized radiolabelled MAb in conventional 
radioimmunodetection or RIT (41). 
Two main MAb-based pretargeting approaches can be distinguished: strategies that 
use (strept)avidin and biotin, and those that use bispecific monoclonal antibodies 
(bsMAb) (41). The first approach is based on the extremely high affinity of the non-
mammalian avidin or bacterial analog streptavidin to biotin (Ka=10
15 M-1) (42, 43). 
Various strategies were developed, mainly using biotin as the radionuclide carrier. A 
streptavidin-conjugated IgG was used to pretarget the tumour and to capture the 
radiolabeled biotin. In another method a MAb-biotin conjugate is administered first, 
followed by a (strept)avidin injection followed by injection of the radiolabelled biotin. 
The biotin-avidin-based strategies has several disadvantages compared to the strategy 
with bsMAb. Firstly, (strept)avidin is immunogenic and cannot be humanized (44). 
Furthermore, due to the extremely high affinity of avidin for biotin, these two agents 
also strongly bind in the circulation, leading to enhanced circulatory half-life of the 
labelled compound and reduction of tumour uptake. Therefore, a clearing agent is 
needed to remove the excess antibody conjugate from the blood prior to administra-
tion of the radiolabelled compound (41).
BsMAb contain both a Fab-fragment that binds the tumour-associated antigen as 
well as a Fab-fragment that binds to a hapten. A hapten is a chemical structure that 
can induce an antibody response when it is coupled to a carrier molecule, but not by 
itself. The anti-hapten antibodies can be induced in mice. Both parts of the bsMAb 
A: Antigens are 
overexpressed 
on the cell 
membrane of 
tumour cells.
B: The MAb is in-
fused intravenously, 
slowly accumulates 
in the tumour, 
and binds to the 
tumour-antigens. 
C: The excess of 
MAb that has 
not targeted the 
tumour has to 
be sufficiently 
cleared from 
the circulation. 
D: The radiolabelled 
smaller molecule is 
injected, and is rap-
idly trapped in the 
tumour by the MAb. 
E: The excess of 
the smaller radiola-
belled compound 
is rapidly from 
the blood. 
Figure 1: Schematic representation of pretargeting strategy. The tumour is pretargeted with a bispecific 
MAb, and in the second step a smaller radiolabelled molecule is administered (41).
A    B     C       D        E
 capillary
    tumour cell
6can be humanized with standard techniques. Due to the lower affinity of the bsMAb-
hapten binding (Kd = 10-9 M) as compared to avidin-biotion binding (Kd = 10-15 M), 
bsMAb-hapten complexes that are formed in the circulation again dissociate. So, for 
pretargeting with bsMAb no clearing agent is required, which makes its clinical imple-
mentation less complicated than pretargeting with avidin-biotin (41). 
Initially, bsMAb were developed that bind chetal-metal complexes, such as DTPA-
111In as haptens. These chetal-metal haptens could either be used as separate agents, 
or they could be conjugated to a peptide. To improve the tumour binding properties 
of the radiolabelled peptide, two haptens can be conjugated, resulting in a divalent 
peptide (45). Le Doussal et al. demonstrated that divalent peptides had higher tumour 
uptake and stability, a phenomenom known as affinity enhancement (46).  A pretar-
geting system based on an anti-CEA × anti-DTPA-indium bsmAb and a 131I-labelled 
di-DTPA-tyrosyl-lysine peptide was studied in patients with CEA-expressing tu-
mours. In patients (n=29) with recurrent medullary thyroid carcinoma, a statistically 
significant increase in the survival was observed compared to historical controls (47). 
The binding affinity of an anti-chelate MAb may be affected by the chelated metal. 
Therefore, a more flexible system was developed with an antibody that has affinity for 
another part of a hapten-peptide complex than the chelating moiety. Recently, pep-
tides substituted with two haptens, histamine-succinyl-glycine (HSG), in combina-
tion with anti-tumor x anti-HSG bsMAb were designed (48). The di-HSG-peptides 
can be conjugated with various chelating moieties (DTPA, DOTA, N3S-chelates, etc.), 
and consequently with a wide variety of radionuclides, like 111In and 99mTc for SPECT 
imaging (49), with 124I, 68Ga or 18F for PET imaging (50, 51), or with 131I, 90Y and 177Lu 
for pretargeted RIT (48).
Until recently, the bsMAbs used in pretargeting were either produced by fusing two 
hybridoma Ab-producing cells using the quadroma technology or by chemical con-
jugation of Fab-fragments. Karacay et al. demonstrated that a bsMAb with divalent 
reactivity for the tumour antigen leads to higher tumour uptake of a divalent hapten 
(52). Therefore, a new method, called the Dock-and-Lock (DNL) technology, has 
been developed to produce humanized trivalent Fab bsMAb constructs (molecular 
size: 157 kDa) with two binding sites for the tumour-associated antigen and one 
anti-HSG-Fab fragment to bind the HSG-groups on the radiolabeled peptide (53, 
54). The DNL technology is based on the dimerization and docking sequences of 
cAMP-dependent protein A-kinase. Two anti-tumour Fab fragments are fused with 
the dimerization sequence. The dimeric sequence of the anti-tumour F(ab)2 has high 
affinity for a sequence that is fused to the anti-hapten Fab (=docking). Furthermore, 
cysteine residues are placed on four location to form disulfide bridges to stabilize the 
trivalent bispecific antibody construct (=locking) (54, 55). DNL constructs have 
been developed for different tumour types and their specific antigens, such as B-cell 
lymphoma, pancreatic cancer, prostate cancer and significant responses have been 
reported in animals with subcutaneous xenografts (45, 56).  
7Pretargeting agents for CRC
For CRC the trivalent anti-CEACAM5 x anti-HSG bsMAb construct, TF2 (mo-
lecular weight 157 kDa), and IMP288 peptide (1456 Da) have been produced by 
IBC Pharmaceuticals, Inc., and Immunomedics, Inc. (Morris Plains, NJ, USA). TF2 
is engineered from the 679 anti-HSG monoclonal antibody, and two humanized anti-
CEACAM5 Fab-fragments derived from the humanized anti-CEACAM5 MAb, 
hMN-14 antibody, or labetuzumab (21). MAb 679 binds to HSG with a high affin-
ity (Ka ~ 1010 M-1), while it does not react with histamine (Ka < 104 M-1) (57), and 
hMN-14 has a high affinity for CEACAM5 (Ka ~ 109 M-1) (58). 
IMP288 is a DOTA-conjugated D-Tyr-D-Lys-D-Glu-D-Lys tetrapeptide in which 
both ε-NH2 groups of the lysine residues are substituted with a HSG-moiety: 7,10-tet-
ra-azacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA)-D-Tyr-D-Lys(HSG)-D-
Glu-D-Lys(HSG)-NH2 (Figure 2) (51). A particular favourable characteristic of this 
peptide is the lack of reabsorption in the kidneys. 
Radionuclides 
For immuno-PET 124I has been used with directly radiolabeled antibody constructs for 
a large part because radioiodine will not be retained in normal tissues, and thus more 
reasonable tumour/tissue ratios can be achieved (58). However, the costs and rela-
tively poor imaging properties of 124I are considerable barriers to the development of 
B: Chemical structure of IMP288, a 
DOTA-conjugated D-Tyr-D-Lys-D-Glu-
D-Lys tetrapeptide in which the lysine 
residues are substituted with a HSG-
moiety (59) (Reprinted by permission of  the 
American Association of Cancer Research).
Figure 2: Pretargeting agents for CRC.
A: Schematic representation of the components of 
TF2, formed by the DNL method. The Fab of an anti-
CEA antibody, hMN14, is dimerized. The dimerized 
construct is linked to the anti-HSG Fab, resulting in a 
tri-Fab bsMAb construct (53) (Reprinted by permission 
of the Society of Nuclear Medicine)
A          B
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8products based on this radionuclide. The short physical half-life of 18F (110 min.) and 
68Ga (68 min.) can be used effectively in pretargeting to enhance detection sensitivity. 
The half-life of 68Ga very well matches the fast kinetics of the peptide in the pretarget-
ing system.   A further advantage of 68Ga is the availibility of a 68Ge/68Ga generator that 
can be eluted twice daily, avoiding the need for an on-site cyclotron. 
For RIT the selection of the radionuclide is crucial to obtain an optimal balance be-
tween the therapeutic effect and the side effects. The β-emitting radionuclides that are 
most often used in RIT are 131I,  90Y and 177Lu. There are several factors that must be 
taken into account when determining which of these is most suitable for a particular 
application. The physical properties, like half-life and energy of the beta particles, as 
well as differences in biological processes influence their impact. The physical half-life 
should match the blood clearance rate and the tumour residence time of the radiola-
belled agent. 177Lu has a relatively long half-life (6.7 days) compared to 90Y (2.7 days). 
Furthermore, 177Lu has low-energy beta particles (Emax= 498 keV), with a maximum 
penetration range in tissue of 2.5 mm, while 90Y has a high energy (Emax= 2.28 MeV), 
resulting in a longer penetration range in tissue (maximum 12.0 mm). Therefore, 177Lu 
may be useful in the treatment of small volume or micro metastatic cancer, and 90Y 
would be more appropriate for larger tumours, especially when the intratumoural 
distribution is heterogeneous. 
The in vivo processing after tumour-binding is different for radioiodine (131I) than for 
radiometals (177Lu, 90Y). A radiolabelled peptide can be internalized by the target cell. 
Subsequently, it is enzymatically degraded in the lysosomes. In that case, radioiodine 
is again excreted from the cells, while radiometals will be trapped in the lysosomes. 
Therefore, the use of radiometals may result in longer tumour retention of the beta-
emitter, causing higher absorbed doses (27). 
Dosimetry
Ionizing radiation due to energy emitted by radiopharmaceuticals and deposited in tis-
sues, may cause changes in atoms or molecules and thus damage cells. This might result 
in biologic effects: either therapeutic effects or toxicity, depending on the amount of 
radiation and the organ. The energy absorbed per unit mass (absorbed dose) is expres-
sed in joules per kilogram, or grays (Gy).
The measurement and calculation of the absorbed dose is called radiation dosimetry. 
The absorbed dose can be calculated for the total body or for specific organs of interest 
(target organs). Some organs might contain significant concentrations of the radionu-
clide (source organs). 
The absorbed dose can predict the therapeutic potential of new radiopharmaceuticals. 
Knowledge of the absorbed dose in healthy organs after administration of that radiop-
harmaceutical is mandatory to estimate the risk for radiation-related side-effects of 
healthy tissues.  In RIT, red bone marrow and nephrotoxicity could be dose-limiting, 
9and therefore estimation of the radiation doses to the bone marrow and kidneys are 
crucial to determine the maximum dose that can be administered safely. A maximum 
absorbed dose of 2 Gy to the bone marrow is generally accepted to be safe (59, 60). 
Based on data from external beam radiotherapy a kidney dose of 23 Gy results in a 
5% probability of developing radiation nephropathy within five years (61). In clinical 
trials with radiolabeled peptides, radiation doses that did not exceed 27 Gy to the 
kidneys, rarely caused long term renal failure (62, 63).
For accurate estimation of the absorbed dose in organs of interest, quantification of the 
time dependent activity distribution in the total body and the tissues is necessary. The 
most frequently used techniques to determine the residence times of the activity in the 
tissues are: [1] whole body gamma camera imaging at various time points and [2] serial 
measurements of radioactivity concentration in blood, urine and feces. These data can 
be used to calculate the cumulated activity, i.e.  the sum of all nuclear transitions in 
the region. The cumulated activity divided by the administered activity is called the 
residence time. To convert residence times of the source organs into absorbed dose for 
target doses, not only the uptake and retention of activity in the source organs are im-
portant, but also other factors should be taken into account. Factors such as the physi-
cal half-life of the radionuclide, the types and energies of the emitted radiations, the 
sizes, shapes and distances of the source and target organs and the tissue between those 
organs determine the absorbed dose. To incorporate these factors in the calculations, 
the Medical Internal Radiation Dose (MIRD) scheme has been developed. It beholds 
conversion factors calculated for different phantoms (adult male/female, newborn, 
children  etc.), hundreds of different radionuclides and all source and target organs 
(64). A FDA-approved software package that calculates the absorbed dose values using 
the MIRD scheme is the OLINDA/EXM program (Vanderbilt University, 2003).  
Image vs blood-based methods to estimate the radiation dose to the red marrow 
The red bone marrow dose can be calculated using two different methods: image-based 
or blood-based. In the image-based method, scintigraphic images are used to draw a 
region of interest (ROI) over a part of the body with high bone marrow contents, e.g. 
lumbar vertebrae, or skull. When planar images are used, the lumbar vertebrae will 
suffer from overlap of abdominal organs. Therefore, a part of the skull, i.e. the cranium, 
can be used as ROI for the red marrow, avoiding overlapping organs. The ROI of the 
cranium should be drawn as two separate left and right parts, to exclude the central, 
blood-rich part of the skull (65). The red bone marrow mass in the cranium is defined 
as the 0.119  fraction of the total red bone marrow mass in the body, as described in 
the ICRP23’s Reference Man (66). 
A second method for red marrow dose estimates is the blood-derived method as de-
scribed by Shen et al. (67, 68). The blood-based method can only be applied if [1] no 
bone marrow or bone metastases are present, [2] the radiolabeled agents administered 
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do not bind to any blood, bone marrow, or bone components, and [3] the radiola-
beled agents administered do not show aspecific retention in bone marrow. Weight 
and height of the individual patient are used to calculate the total blood mass (69, 70). 
This methods calculates the red marrow dose as a sum of the marrow self-dose (source 
organ = target organ) and the absorbed dose of the other organs. For the self-dose, 
the blood activity concentration is used as a surrogate for the bone marrow concen-
tration, as the activity in the circulating blood is distributed within the  extracellular 
fluid space of the red marrow. To convert the blood concentration into a bone marrow 
concentration, the patient’s haematocrit and the extracellular fluid fraction are used. 
For the other organs that could be a source to the red marrow, the mean total body 
absorbed dose has been found to approximate the contributions of all separate organs, 
when corrected for the patient-specific body weight (71). 
The most widely used method for dosimetry is planar whole body gamma camera 
imaging. Because overlapping organs and inhomogeneous background distribution 
might cause measurement errors, SPECT imaging could improve the accuracy of 
dosimetry, also for tumours. However, quantitative SPECT imaging is much more 
time-consuming and complex than calculation based on planar imaging. 
Scope of the studies described in this thesis
The goal of this thesis was to examine the feasibility, specificity and sensitivity of pre-
targeted immuno-PET with anti-CEACAM5 x anti-HSG bsMAb (TF2) and 68Ga- 
or 18F-labelled di-HSG-peptide (IMP288) as imaging modality for CEA-positive 
colorectal xenografts in mice, both in subcutaneous as well in orthotopic tumours. 
Moreover, the feasibility of image-guided therapy using pretargeted immunoSPECT 
with TF2 and 111In-IMP288 for monitoring tumor targeting and –growth in mice, 
and for individual activity dosing in patients was investigated. 
Furthermore, the therapeutic efficacy and toxicity of  pretargeted RIT with TF2 and 
177Lu-IMP288 was studied in the same animal models, as well in a first clinical dose-
finding study in patients with advanced colorectal cancer. 
Finally, the added value of 3D voxel based dosimetry to estimate tumour and red 
marrow absorbed doses was determined. 
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tumours with a bispecific antibody and a 68Ga- and 18F- 
labelled hapten-peptide in mice with human tumour 
xenografts 
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Abstract 
Background
18F-Fluorodeoxyglucose (18F-FDG) is the most common molecular imaging agent in 
oncology, with a high sensitivity and specificity for detecting a number of cancers. 
Antibodies could enhance specificity; therefore, procedures were developed for radi-
olabelling a small (1.5 kD) hapten-peptide with 68Ga or 18F to compare their specificity 
to 18F-FDG for detecting tumours using a pretargeting procedure. 
Methods
Mice were implanted with carcinoembryonic (CEA; CEACAM5)-expressing LS174T 
human colonic tumours, a CEA-negative tumour, or an inflammation was induced in 
thigh muscle. A bispecific monoclonal (bsMAb) anti-CEA x anti-hapten antibody 
was given to mice, and 16 h later, 5 MBq of 68Ga- or 18F-labelled hapten-peptides were 
administered intravenously.  
Results
Within 1 h, tissues showed high and specific targeting of the 68Ga-IMP288, with 
10.7 ± 3.6 %ID/g uptake in the tumour and very low uptake in normal tissues (e.g., 
tumour/blood 69.9 ± 32.3), in a CEA-negative tumour (0.35 ± 0.35 %ID/g), and 
inflamed muscle (0.72 ± 0.20 %ID/g). 18F-FDG localized efficiently in the tumour 
(7.42 ± 0.20 %ID/g), but also in the inflamed muscle (4.07 ± 1.13 %ID/g) and in a 
number of normal tissues; thus, pretargeted 68Ga-IMP288 provided better specificity 
and sensitivity. PET/CT images reinforced the improved specificity of the pretarget-
ing method. 18F-labelled IMP499 distributed similarly in the tumour and normal tis-
sues as the 68Ga-labelled IMP288, indicating that either radiolabelled hapten-peptide 
could be used. 
Conclusions
Thus, pretargeted immuno-PET performs exceptionally well with short-lived radio-
nuclides, and is a highly sensitive procedure that is more specific than 18F-FDG-PET.
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Introduction
Radiolabelled antibody targeting of tumour-associated antigens often requires several 
days for adequate visualization of tumours due to the slow pharmacokinetics and ac-
cretion of intact antibodies in tumours (1). The use of antibody fragments and en-
gineered antibody formats (such as F(ab’)2, Fab’, diabodies, minibodies or scFv) has 
improved radioimmunodetection only to a limited extent. Tumour uptake of most 
antibody fragments is much lower than that of an IgG, resulting in reduced signal 
strength in the tumours, which can contribute to uncertainties in interpretation (2). 
Pretargeting techniques were developed to improve radioimmunotargeting of tumours 
(3-5). In pretargeting, an unlabelled bifunctional reagent with affinity for the tumour 
and a small radiolabelled molecule is given in advance of the radiolabelled compound 
(3, 4, 6). Two main antibody-based pretargeting approaches can be distinguished: 
strategies that use (strept)avidin and biotin, and those that use bispecific monoclonal 
antibodies (bsMAb). The disadvantages of the biotin-avidin-based approaches are 
the immunogenicity of (strept)avidin and the need for a clearing agent to remove the 
antibody conjugate from the blood (3). A bsMAb, which can be humanized to reduce 
immunogenicity, will bind a tumour-associated antigen and a hapten. Coupling 2 
haptens together improves peptide uptake and stability by a process known as affin-
ity enhancement (7). Chelate-metal complexes, such as DTPA-In, have been used as 
haptens (8). More recently, peptides substituted with the hapten, histamine-succinyl-
glycine (HSG), in combination with anti-HSG bsMAbs have provided a more flex-
ible system, because these HSG-substituted peptides can be conjugated with various 
chelating moieties (DTPA, DOTA, N3S-chelates, etc.). As a result they can be labelled 
with a wide variety of radionuclides, like 111In and 99mTc for SPECT imaging (6), with 
124I for PET imaging (9, 10), or with 131I, 90Y and 177Lu for pretargeted radioimmuno-
therapy (11). 
Previous studies illustrated the enhanced sensitivity of pretargeted imaging for detect-
ing cancer (6,10,12), with superior results of pretargeting compared to the directly 
radiolabelled antibody fragment. In a micrometastatic human colon cancer model, 
tumour nodules no larger than 0.3 mm in diameter were detected in the lungs of athy-
mic mice with the 124I-labelled di-HSG-peptide (12). This study highlighted the excep-
tional sensitivity of the pretargeting procedure, but herein we also wanted to examine 
the specificity of pretargeting, and therefore included a model of sterile inflammation. 
Earlier studies were performed with 124I because it was commercially available and the 
chemistry for iodination was well known. However, 124I is not an ideal radionuclide 
for PET imaging due to its high-energy positrons and considerable expense. Its long 
half-life (t½ = 4.2 days) has been an advantage for directly radiolabelled antibodies 
that require extended periods for adequate contrast to develop, which only takes 1 h 
with pretargeting, making this method more amenable to short-lived positron emit-
ting radionuclides. There are currently two radionuclides with exceptional imaging 
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properties for PET, namely 68Ga and 18F, and their half-lives are well matched with 
the pharmacokinetics of the radiolabelled peptide (68Ga t½ = 68 min; and 18F, t½ 
= 110 min). 68Ga is a relative newcomer to nuclear medicine, and in addition to its 
physical properties, it is readily available in a nearly carrier-free state from an in-house 
68Ge/68Ga generator. 
Herein we report the first pretargeting studies with this 68Ga-labelled peptide. 18F has 
been the gold standard for PET studies. It is abundantly available and inexpensive, but 
the chemistry involved in preparing labelled products can be challenging. We recently 
reported a simplified approach for preparing 18F-labelled peptides that involves the 
formation of 18F-aluminum complexes that can then be simply bound to a chelate on 
a peptide (13). Thus, another objective of this study was to compare a 68Ga- and an 
18F-labelled peptide with pretargeting. 
In summary, we show the feasibility of using 68Ga- or 18F-labelled di-HSG-peptides in 
pretargeting, and further demonstrate the improved specificity afforded by pretarget-
ing by including a comparison of 18F-FDG and an inflammation model. 
Methods
Pretargeting reagents TF2, IMP288 and IMP499
The bsMAb, TF2, and the peptides IMP288 and IMP499, were provided by 
Immunomedics (Morris Plains, NJ, USA). TF2 is an engineered trivalent bispe-
cific antibody composed of a humanized anti-histamine-succinyl-glycine (HSG) Fab-
fragment derived from the 679 anti-HSG monoclonal antibody (14), and two human-
ized anti-CEA Fab-fragments derived from the hMN-14 antibody or labetuzumab 
(14, 15), formed into a 157 kD protein by the Dock-and-Lock procedure (16, 17). The 
immunoreactive fraction of TF2 for binding to CEA, determined in a Lindmo assay 
(18) on fixed LS174T cells, exceeded 85%. Gel fitration chromatography showed that 
TF2 could bind >90% of 68Ga-IMP288 peptide. TF2 was labelled with 125I (Perkin 
Elmer, Waltham, MA) by the iodogen method (19), to a specific activity of 58 MBq/
nmol. 125I-labelled TF2 was purified by eluting the reaction mixture with PBS, 0.5 
% w/v bovine serum albumin (BSA) (Sigma Chemicals, St. Louis, MO, USA) on a 
PD-10 column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden). 
IMP288 was synthesized and purified as described by McBride et al. (10). It is a DOTA-
conjugated D-Tyr-D-Lys-D-Glu-D-Lys tetrapeptide in which both lysine residues are 
substituted with a HSG-moiety via their ε-aminogroup: 7,10-tetra-azacyclododecane-
N,N’,N’’,N’’’-tetraacetic acid (DOTA)-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2 
(Figure 1A). A similar peptide, IMP499, was conjugated with 1,4,7-tri-azacyclonon-
ane-N,N’,N’’-triacetic acid (NOTA) instead of DOTA, to facilitate labelling with 18F 
(Figure 1B). To improve the conjugation of the NOTA chelator an alanine residue was 
used as a spacer (13).
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Labelling of IMP288 or IMP499
IMP288 was labelled with 111In (Covidien, Petten, The Netherlands) at 32 MBq/
nmol under strict metal-free conditions. Briefly, 11 MBq 111In was added to 12 µg 
IMP288 in 0.25 M ammonium acetate (NH4Ac) buffer, pH 5.6, and after 20 min at 
95 oC , 10 µL 50 mM ethylenediaminetetraacetic acid (EDTA) was added to complex 
any unbound 111In. 
IMP288 was labelled with 68Ga eluted from a TiO-based 1,110 MBq 68Ge/68Ga gen-
erator (Cyclotron Co. Ltd., Obninsk, Russia) using 0.1 M ultrapure HCl ( J.T. Baker, 
Deventer, The Netherlands). Five, 1-ml fractions were collected and the second frac-
tion was used for labelling the peptide. One volume of 1.0 M HEPES buffer, pH 7.0, 
was added to 3.4 nmole IMP288. Four volumes of 68Ga eluate (380 MBq) were added 
and the mixture was heated at 95 oC for 20 min. EDTA (50 mM) was added to a final 
concentration of 5 mM to complex the non-chelated 68Ga3+, followed by purification 
on a 1-mL Oasis HLB-cartridge (Waters, Milford, MA). After washing the cartridge 
with water, the peptide was eluted with 25% ethanol. 
IMP499 was labelled with 18F as described by McBride et al. (13). [18F]Fluoride (555-
740 MBq; B.V. Cyclotron VU, Amsterdam, The Netherlands) was eluted from a QMA 
cartridge with 0.4 M KHCO3. Four 200-µL fractions were collected in vials contain-
ing 3 µL 2 mM AlCl3 in 0.1 M sodium acetate buffer, pH 4. The fraction with highest 
activity was used. The Al[18F]2+ activity was added to a vial containing IMP499 (230 
µg) and ascorbic acid (10 mg). The mixture was incubated at 100 °C for 15 min, then 
Figure 1. Chemical structures of IMP288 (A) and IMP449 (B). Both are Tyr-D-Lys-D-Glu-D-Lys 
tetrapeptides in which both lysine residues are substituted with a HSG-moiety via their ε-aminogroup. 
IMP288 is conjugated with DOTA: 7,10-tetra-azacyclododecane-N,N’,N’’,N’’’-tetraacetic acid and 
IMP449 is conjugated with NOTA: 1,4,7-tri-azacyclononane-N,N’,N’’-triacetic acid. 
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purified by reversed phase-high performance liquid chromatography (RP-HPLC; 
Phenomenex Onyx monolithic C18 column, Torrance, CA), using a linear gradient 
of 97% A to 100% B in 30 min (Buffer A: 0.1% TFA in water; Buffer B: 0.1% TFA in 
acetonitrile, flow rate: 3 mL/min). After adding one volume of water, the peptide was 
purified on a 1-mL Oasis HLB cartridge. After washing with water, the radiolabelled 
peptide was eluted with 50% ethanol. 
Quality control of the radiolabelled preparations 
Radiochemical purity was determined using instant thin-layer chromatography 
(ITLC) on silica-gel strips (Pall Life Sciences, Ann Arbor, MI) using 0.1 M citrate 
buffer, pH 6.0 as the mobile phase. The colloid content of the radiolabelled peptide 
was determined by ITLC-SG using a 1:1 v/v solution of 0.15 M NH4Ac, pH 5.5, 
MeOH as the mobile phase.
111In-IMP288, 68Ga-IMP288 and 18F-IMP499 were analyzed by RP-HPLC (Agilent 
1100 series, Agilent Technologies, Palo Alto, CA) on a RP C18 column (Alltima, 5 µm, 
4.6 x 250 mm, Alltech, Deerfield, IL), using a flow rate of 1.0 ml/min with a linear 
gradient of 97% A and 3% to 100% B, over 15 min buffer A: 0.1 % TFA in water 
and buffer B: 0.1 % TFA in acetonitrile. Radiochemical purity of 125I-TF2, 111 In- and 
68Ga- IMP288 and 18F-IMP499 preparations always exceeded 95%. 
Animal experiments
All studies were approved by the institutional Animal Welfare Committee of the 
Radboud University Medical Centre Nijmegen, and conducted in accordance with 
their guidelines (revised Dutch Act on Animal Experimentation, 1997). Male nude 
BALB/c mice (6-8 weeks old), weighing 20-25 grams, received a subcutaneous injec-
tion with 0.2 mL of a suspension of 1 x 106 LS174T, a CEA-expressing human colon 
carcinoma cell line (CCL-188, American Type Culture Collection, Rockville, MD, 
passage 7). In some studies, animals were co-implanted with SK-RC52 cells, a human 
renal cancer cell line that is negative for CEA (20). The CEA production of LS174T 
in the ATCC seed stock was 1944 ng per milion cells in 10 days. Homogenized tissue 
of subcutaneous LS174T and SK-RC52 tumours during 10 days, grown in nude 
BALB/c mice, showed that the LS174T tumour had a CEA content of 17745 ng per 
million cells, whereas the SK-RC52 tumour had no detectable CEA content. Studies 
were initiated when the tumours reached a size of about 0.1-0.3 g. 
In separate studies, animals bearing an LS174T xenograft in one hind leg were injected 
in the other hind limb muscle with 50 µl of turpentine to induce an inflammatory 
reaction (21). 
TF2 was given intravenously and 16 hours later, radiolabelled IMP288 was given in 
0.2 mL. This interval was shown previously to be sufficient to clear TF2 from the 
circulation (15). In some studies, 125I-TF2, (0.4 MBq) was co-injected with unlabelled 
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TF2. One hour after the injection of 68Ga-labelled peptide, and two hours after injec-
tion of 18F-IMP499, mice were euthanized by CO2 /O2, and blood was obtained by 
cardiac puncture. 
PET images were acquired with an Inveon animal PET/CT scanner (Siemens 
Preclinical Solutions, Knoxville, TN) with an intrinsic spatial resolution of 1.5 mm 
(22). The animals were placed in a supine position. PET emission scans were acquired 
for 15 min, preceded by CT scans for anatomical reference (spatial resolution 113 
µm, 80 kV, 500 µA, exposure time 300 msec). Scans were reconstructed using Inveon 
Acquisition Workplace software (version 1.2, Siemens Preclinical Solutions, Knoxville, 
TN, USA) using a 3D ordered subset expectation maximization/maximum a poste-
riori (OSEM3D/MAP) algorithm with the following parameters: matrix 256 x 256 x 
159, pixel size 0.43 x 0.43 x 0.8 mm3 and MAP prior β of 0.5. 
After imaging, tumour and organs of interest were dissected, weighed and counted 
in a gamma counter with appropriate energy windows for 125I, 111In, 68Ga or 18F. The 
percentage-injected dose per gram tissue (%ID/g) was calculated.
Statistic analysis
All mean values are given ± standard deviation. Statistical analysis was performed 
using a non-parametric, two-tailed Mann Whitney test using GraphPad InStat soft-
ware (version 4.00, GraphPad Software). The level of significance was set at p<0.05.
Results
Dose optimization
The effect of the TF2 dose on tumour targeting with a fixed amount of IMP288 (0.01 
or 0.1 nmole; 15 or 150 ng, respectively) was determined. Groups of five mice were 
injected intravenously with 0.10, 0.25, 0.50 or 1.0 nmol TF2, labelled with a trace 
amount of 125I (0.4 MBq). Two hours after injection of 111In-IMP288 (0.01 nmol, 0.4 
MBq), the biodistribution of the radiolabels was determined. 
TF2 cleared rapidly from blood and normal tissues. Eighteen hours after injection, the 
blood concentration was less than 0.45 %ID/g at all TF2 doses tested. TF2 tumour 
uptake was 3.5 %ID/g, independent of TF2 dose up to 1.0 nmol (data not shown). At 
all TF2 doses, 111In-IMP288 accumulated effectively in the tumour, with increasing 
uptake associated with higher TF2 doses (Figure 2A). At the 0.01 nmole 111In-IMP288 
dose, tumour uptake peaked at 26.2 ± 3.8 %ID/g. With 0.01 nmol of IMP288, the 
highest tumour targeting and tumour-to-blood ratios were achieved with 1.0 nmol 
TF2 (TF2:IMP288 molar ratio = 100:1). The kidneys had the highest normal organ 
accretion of 111In-IMP288 (1.75 ± 0.27 %ID/g); all other normal tissues had very low 
uptake.
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With 68Ga-labelled IMP288, a minimum of 5-10 MBq 68Ga was required for PET im-
aging performed 1 h after injection. At a maximum specific activity of 50-125 MBq/
nmol at the time of injection, at least 0.1-0.25 nmol of 68Ga-IMP288 had to be admin-
istered. A separate group of LS174T-bearing mice received the same TF2:IMP288 
molar ratios as were tested above, but with 0.1 nmol IMP288, 1.0, 2.5, 5.0 or 10.0 
nmol of TF2 was administered. The percent uptake of TF2 in the tumour decreased 
from 3.21 ± 0.61 %ID/g at the 1.0 nmole dose to 1.16 ± 0.27 %ID/g with 10.0 nmol, 
suggesting the antigen in the tumour was saturated. In contrast to the results at the 
0.01 nmole dose, tumour uptake with 0.1 nmole of 111In-IMP288 was not affected by 
the TF2 dose, but it did not exceed about 15 %ID/g at all doses tested (Figure 2B). 
Based on these data, a bsMAb dose of 6.0 nmol was selected for targeting 0.1-0.25 
nmol of 68Ga-IMP288 to the tumour.
PET imaging
Five mice bearing an LS174T CEA-expressing tumor in the right flank and SK-RC52, 
a CEA-negative tumour in the left flank were administered 6.0 nmol 125I-TF2 intrave-
nously. After 16 h, the mice received 5 MBq 68Ga-IMP288 (0.25 nmol, specific activ-
ity of 20 MBq/nmol). A separate group of three mice received the same amount of 
68Ga-IMP288 alone, without pretargeting with TF2. PET/CT scans of the mice were 
acquired 1 h after injection of the 68Ga-IMP288. 
Figure 2. Biodistribution of 111In-IMP288 1 h after i.v. injection, following pretargeting with escalating 
doses TF2 in BALB/c nude mice with a s.c. CEA-expressing LS174T tumour. Two peptide doses were 
tested (A: 0.01 nmol 111In-IMP288; B: 0.10 nmol 111In-IMP288). Values are given as means ± standard 
deviation (n=5). 
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The biodistribution of 125I-TF2 and 68Ga-IMP288 in mice are shown in Figure 3A. 
High uptake of the bsMAb (2.17 ± 0.50 %ID/g) and peptide (10.7 ± 3.6 %ID/g) in 
the tumour was observed, with very low accretion in the normal tissues (tumour-to-
blood ratio for 68Ga-IMP288: 64 ± 22). Most importantly, targeting of 68Ga-IMP288 
in the CEA-negative tumour SK-RC52 was very low (0.35 ± 0.35 %ID/g). Likewise, 
tumours that were not pretargeted with TF2 had a low uptake of 68Ga-IMP288 (0.20 
± 0.03 %ID/g), indicating that the specific accumulation of IMP288 in the CEA-
expressing LS174T tumour was derived from the pre-localization of the bsMAb. 
The specific uptake of 68Ga-IMP288 in the CEA-expressing tumour pretargeted with 
TF2 was clearly visualized in the PET image acquired 1 h after injection, without any 
localization in the negative tumour (Figure 3B). Uptake in the tumour was evaluated 
quantitatively by drawing regions of interest (ROI), using a 50% threshold of maxi-
mum intensity. A region in the abdomen was used as background region. The tumour-
to-background ratio in the image of the mouse that received TF2 and 68Ga-IMP288 
was 38.2 at 1 h. 
In the next studies, two groups of five mice bearing a s.c. LS174T tumour in the right 
hind leg and an turpentine-induced inflammatory focus in the left thigh muscle were 
examined to assess the specificity of the pretargeting procedure compared to 18F-FDG. 
Three days after the induction of the inflammatory lesion, one group of mice received 
6.0 nmol TF2, followed 16 h later by 5 MBq 68Ga-IMP288 (0.25 nmol). The other 
group received 18F-FDG (5 MBq). Mice were fasted for 10 hours prior to the injection 
and anesthetized and kept warm at 37 oC until euthanasia, 1 h post-injection. 
Figure 4A shows an example of a mouse that received the TF2-pretargeted 68Ga-
IMP288, showing efficient accretion of the radiolabelled peptide in the tumour, while 
the inflamed muscle was not visualized. In contrast, both tumour and inflammation 
were visible in the mice that received 18F-FDG (Figure 4B). In mice given 68Ga-IMP288, 
the tumour-to-inflamed tissue ratio by SUV analysis was 5.4 and the tumour-to-back-
ground ratio was 48. 18F-FDG uptake had a tumour-to-inflamed muscle ratio of 0.83, 
and the tumour-to-background ratio was 2.4.
At necropsy, uptake of 68Ga-IMP288 measured in the inflamed muscle was only 0.72 
± 0.20 %ID/g, but tumour uptake was 8.73 ± 1.60 %ID/g (p<0.05, Figure 5). The 
tumour-to-blood ratio of 68Ga-IMP288 in these mice was 69.9 ± 32.3; the inflamed 
muscle-to-blood ratio was 5.9 ± 2.9; and the tumour-to-inflamed muscle ratio was 
12.5 ± 2.1. 18F-FDG accreted efficiently in the tumour (7.42 ± 0.20 %ID/g, tumour-
to-blood ratio 6.24 ± 1.5, Figure 5), but also accumulated substantially in the inflamed 
muscle (4.07 ± 1.13 %ID/g), with an inflamed muscle-to-blood ratio of 3.4 ± 0.5, and 
a tumour-to-inflamed muscle ratio of 1.97 ± 0.71.
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Figure 3B: PET/CT image 
(3D volume rendered) of 
a BALB/c nude mouse 
with a s.c. LS174T CEA-
expressing tumour in the 
right flank (arrow) and a s.c. 
SK-RC52 tumour, a non-
CEA-producing, tumour in 
the left flank (arrowhead), 
that received 6.0 nmol TF2 
and 5 MBq 68Ga-IMP288 
(0.25 nmol) intravenously 
with a 16-hour interval, 
imaged one hour after 68Ga-
IMP288 injection (B).
Figure 4. PET/CT images of 
a BALB/c nude mouse with 
a s.c. LS174T tumour (0.1 g) 
on the right hind leg (arrow) 
and a inflammation in the 
left thigh muscle (arrow-
head), that received 5 MBq 
18F-FDG, and one day later 
6.0 nmol TF2 and 5 MBq 
68Ga-IMP288 (0.25 nmol) 
with a 16-hour interval. The 
animal was imaged one hour 
after 18F-FDG and 68Ga-
IMP288 injections. The 
panel shows the 3D volume 
rendering of the pretargeted 
immuno-PET scan (A) and 
of the FDG-PET scan (B), 
and the transverse sections 
of the tumour region of the 
pretargeted immuno-PET 
scan (C), and of the FDG-
PET scan (D).
Figure 3A: Biodistribution of 6.0 nmol 125I-TF2 (0.37 MBq) and 0.25 
nmol 68Ga-IMP288 (5 MBq), 1 h after i.v. injection of 68Ga-IMP288 in 
BALB/c nude mice with a s.c. LS174T and SK-RC52 tumour. Values 
are given as means ± SD (n=5) (A). 
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Finally, the pretargeted immuno-PET imaging method was tested using the 
18F-labelled peptide, IMP499. Five mice received 6.0 nmol TF2, followed 16 h later by 
5 MBq 18F-IMP499 (0.25 nmol). Three additional mice received 5 MBq 18F-IMP499 
without prior administration of TF2, while two mice were injected with Al[18F]2+ (3 
MBq). Uptake of 18F-IMP499 at 1 h in tumours pretargeted with TF2 was high (10.6 
± 1.7 %ID/g) (Figure 6), whereas it was very low in the non-pretargeted mice (0.45 ± 
0.38 %ID/g). Al[18F]2+ accumulated in the bone (50.9 ± 11.4 %ID/g), while uptake 
of IMP499 peptide in the bone was very low (0.54 ± 0.2 %ID/g), indicating that 
the 18F-IMP499 was stable in vivo. Importantly, the biodistribution of 18F-IMP499 
in the TF2 pretargeted mice was very similar to that of 68Ga-IMP288, indicating the 
suitability for either of these radiolabelled agents for use in pretargeted PET imaging. 
Pretargeted immuno-PET images with 18F-IMP499 showed the same intensity in the 
tumour as those with 68Ga-IMP288, but the resolution of the 18F-images was better 
than the 68Ga-images (Figure 7). The tumour-to-background ratio of the 18F-IMP499 
signal was 66.
Figure 5. Biodistribution of 5 MBq FDG 
and 5 MBq 68Ga-IMP288 (0.25 nmol) 1 h 
after injection, following pretargeting with 
6.0 nmol TF2 in BALB/c nude mice with a 
s.c. CEA-expressing LS174T tumour. Values 
are given as means ± standard deviation 
(n=5).
Figure 6. Biodistribution of 0.25 nmol 18F-IMP449 
(5 MBq) 1 hour after injection, following pretarget-
ing with 6.0 nmol TF2 16 hours earlier, biodistri-
bution of 18F-IMP449 without pretargeting, or 
biodistribution of Al[18F]2+ in BALB/c nude mice 
with a s.c. CEA-expressing LS174T tumour. Values 
are given as means ± standard deviation.
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Discussion
Several important conclusions can be made from the present study. Pretargeting af-
fords the possibilities of utilizing antibody-based imaging techniques with short-lived 
radionuclides, such as 68Ga and 18F, that are ideally suited for PET imaging. Before 
the use of 18F-FDG and PET imaging, radiolabelled antibodies were being developed 
commercially for the detection of colorectal, ovarian, lung, and prostate cancers using 
single-photo computed emission tomography imaging systems (23). However, all of 
these imaging methods suffered from relatively poor contrast, even when radiolabelled 
antibody fragments were used (24). Unquestionably, the advent of 18F-FDG provided 
the necessary platform for the development of molecular imaging based on the newly 
developed PET imaging systems, and as a result, most of these antibody-imaging 
agents have been withdrawn from the market. Since then, molecular engineering has 
fostered a new era for antibodies, making it possible to craft many different forms with 
more favorable blood clearance and targeting potential (25). Still, many of these new 
constructs require considerable time for good tumour uptake and contrast to develop, 
and therefore radionuclides with longer half-lives, such as 64Cu and 124I, are often used. 
Figure 7. Static PET/CT imaging study of a BALB/c nude mouse with a subcutaneous LS174T tumour 
(0.1 g) on the right side, that received 6.0 nmol TF2 and 0.25 nmol 18F-IMP449 (5 MBq) intravenously 
with a 16-hour interval. The animal was imaged one hour after injection of 18F- IMP449. The panel 
shows the 3D volume rendering (A: posterior view), and cross-sections at the tumour region (B: coro-
nal, C: sagittal, D: transversal).
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For example, Cai et al. reported an attempt to use a directly radiolabelled 18F-anti-
CEA diabody for imaging (26). While this type of construct has very favorable phar-
macokinetic properties, maximum tumour uptake in LS174T xenografts obtained at 1 
h post- injection was only 2.7 %ID/g, along with 2.0 %ID/g in the blood and higher 
uptake in the other major organs. Low, but favorable tumour/tissue ratios required 
4-6 h to develop. 124I has been used with directly radiolabelled antibody constructs for 
a large part because radioiodine will not be retained in normal tissues, and thus more 
reasonable tumour/tissue ratios can be achieved than with a radiometal (27). However, 
the added expense and relatively poor imaging properties of this radionuclide are con-
siderable barriers to the development of products based on 124I. As our studies show, 
the short physical half-life of 18F and 68Ga can be used effectively in pretargeting to 
enhance detection sensitivity. 
The half-life of 68Ga is well matched to the kinetics of the IMP288 peptide in the pre-
targeting system. 68Ga can be eluted twice daily from a 68Ge/68Ga generator, avoiding 
the need for an on-site cyclotron. However, the high energy of the positrons emitted 
by 68Ga (1.9 MeV) limits the spatial resolution of the acquired images to 3 mm, while 
the intrinsic resolution of the microPET system is as low as 1.5 mm (22). In the clini-
cal setting, the penetration range of 68Ga positrons does not reduce the resolution of 
the images. For these studies, the procedure to label IMP288 with 68Ga was optimized, 
resulting in a one-step labelling technique. We found that purification on a C18/HLB 
cartridge was required to remove the 68Ga colloid that is inevitably formed when the 
peptide was labelled at specific activities exceeding 150 GBq/nmol at 95 oC. 68Ga col-
loid accumulates in tissues of the reticuloendothelial system (liver, spleen, and bone 
marrow), deteriorating image quality, but it could be effectively reduced by rapid puri-
fication on a C18-cartridge. Radiolabelling and purification for administration could 
be accomplished within 45 minutes.
18F, the most widely used radionuclide in PET, has an even more favorable half-life 
for pretargeted PET imaging (t½ = 110 min). Therefore, in this study, the NOTA-
conjugated peptide, IMP499, was labelled with 18F, as recently described by McBride 
et al. (13). We showed that this method produces a preparation that is stable in vivo. 
Similar to labelling with 68Ga, it is a one-step procedure, which currently requires 
HPLC purification to remove the unlabelled peptide to enhance specific activity. 
Labelling yield was as high as 50%. Interestingly, the biodistribution of 18F-IMP499 
was similar to that of 68Ga-labelled IMP288, suggesting that the new labelling method 
using NOTA to chelate Al[18F]2+ turns the 
18F-label into a residualizing radionuclide. 
Presumably, the peptide undergoes proteolytic degradation in the lysosomes and its 
radiolabelled catabolite, containing Al[18F]2+-NOTA, is trapped in the lysosomes, as 
has been described for radiometals.
In contrast to FDG-PET, pretargeted radioimmunodetection is a tumour-specific 
imaging modality. Although a high sensitivity and specificity for FDG-PET in detect-
ing recurrent colorectal cancer lesions has been reported in patients (28), FDG-PET 
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images could lead to diagnostic dilemmas in discriminating malignant from benign, 
highly metabolic lesions, such as inflammation. Earlier studies in animal models have 
highlighted the improvements that an antibody-based pretargeting procedure can 
provide in comparison to 18F-FDG, focusing primarily on its enhanced sensitivity 
(12) . In this study, we addressed the specificity of pretargeting in relation to its abil-
ity to discriminate inflammatory lesions from cancer. As expected, 18F-FDG had high 
uptake in the tumour, but this was only 2-fold higher than the uptake in the inflam-
matory lesion. In contrast, tumour uptake was at least 10-fold higher in the tumour as 
compared to the inflammatory lesion with the antibody-based pretargeting method. 
Additionally, we showed that pretargeting specifically localizes in the intended target, 
with a 30-times higher concentration in the antigen-positive tumour than in a nega-
tive tumour. Thus, with evidence for appreciable improvements in both sensitivity and 
specificity, bsMAb-based pretargeting procedures could provide important new tools 
for detecting cancer. 
This pretargeting method is a 2-step process that first requires the administration of 
the unlabelled bsMAb. Rather than using a clearing agent, the bsMAb are designed 
in a manner to minimize their residence time in the blood. Despite its size equaling 
that of an IgG (i.e., 157 kD), TF2 is cleared very quickly. The long circulatory half-life 
of IgG is only partly determined by its large size, and is mainly due to the presence of 
the CH2 domain, which enables recycling via FcRn-receptors (29). It has been shown 
that CH2 domain-deleted variants of IgG (121 kDa) clear much faster from the blood 
than intact IgG (30, 31). TF2 is an engineered trivalent antibody derived from three 
Fab-fragments and lacks any CH2 domain. 
These studies also provide new insights into this pretargeting method. Earlier studies 
examined the effects of increasing the bsMAb with a fixed amount of the peptide in 
mice with GW-39 human colonic tumours. It was reported that beyond a 10:1 molar 
ratio of bsMAb:peptide, the amount of peptide that could be delivered to the tumour 
did not increase (32). Using a low peptide dose level (0.01 nmol), we found tumour 
uptake in the LS174T model increased as the moles of bsMAb were increased from 
0.1 to 1 nmole, reaching a maximum uptake of ~25 %ID/g with 1 nmole of TF2 (i.e., 
a 100:1 mole ratio) with minimal changes in blood and normal tissue uptake.  
Compared to earlier studies, a number of factors contributed to the need for inject-
ing considerably more hapten-peptide in these studies, including the size and age 
of the 68Ga-generator, yields after purification, and the natural decay of the product 
that required a minimum of 5 MBq to be administered for imaging. Thus, a separate 
biodistribution study was performed to examine a similar dose-response with 10-fold 
more IMP288 (0.1 nmole). Despite administering increasing amounts of TF2 at the 
same mole ratios used with 0.01 nmole of IMP288, tumour uptake remained highly 
favorable, but remained at a constant level of ~15 %ID/g over a TF2 dose range of 1 
to 10 nmoles. TF2 tumour uptake showed a constant level of ~3 %ID/g over a dose 
range from 0.1 to 1.0 nmol, but at the 2.5 nmol dose the percent uptake began to 
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decline, reducing to ~1 %ID/g at 10 nmole. As a result, at the high IMP288 dose (0.1 
nmol), increasing the TF2 dose did not result in higher tumour uptake of radiola-
belled IMP288. These data suggest that at TF2 doses exceeding 2.5 nmol, saturation of 
CEA in the tumour (with TF2) occurs. Thus, in pretargeting, exceptionally favorable 
targeting at lower specific activities can be achieved, but a higher fractional uptake 
results at its highest specific activity. 
Conclusions
Pretargeted immuno-PET with an anti-CEA bsMAb and a 68Ga- or 18F-hapten-
peptide is a rapid, highly specific and sensitive imaging modality for the detection 
CEA-positive tumours.  
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Abstract
Background
In this study, pretargeted immuno-PET with a bispecific monoclonal anti-carcinoem-
bryonic antigen (CEA; CEACAM5) x anti-hapten antibody (bsMAb) and a small 
(1.5 kD) peptide labelled with 68Ga was compared to 18F-FDG-PET for detecting 
intraperitoneal (i.p.) CEA-expressing human colonic tumour xenografts in nude mice. 
Methods
Two groups of female BALB/c nude mice were inoculated with LS174T human co-
lonic tumour cells i.p. One group received 5 MBq 18F-FDG, and the other received i.v. 
injections of the bsMAb, followed 16 h later with 5 MBq of 68Ga-labelled peptide. One 
hour after the radiolabelled peptide or FDG was given, micro-PET/CT images were 
acquired. Thereafter, the uptake of the 68Ga or 18F in dissected tissue was determined. 
Results
Within one hour, high uptake of 68Ga-labelled peptide in the tumour lesions (23.4 ± 
7.2% ID/g) and low background activity levels were observed  (e.g., tumour-to-intes-
tines ratio 58 ± 22). This resulted in clear visualization of all intra-abdominal tumour 
lesions ≥ 10 µL, and even some tumours as small as 5 µL (2mm diameter). 18F-FDG 
efficiently localized in the tumours (8.7 ± 3.1 % ID/g), but also showed physiological 
uptake in various normal tissues (e.g., tumour-to-intestines ratio, 3.9 ± 1.1). 
Conclusions
Pretargeted immuno-PET with bsMAb and a 68Ga-labelled peptide could be a very 
sensitive imaging method for imaging colonic cancer, disclosing occult lesions. 
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Introduction
Colorectal cancer is a frequently diagnosed cancer type. It is the third most common 
cancer in both men and women in the Western world (1, 2). The overall five-year sur-
vival is 40–60% (3, 4). The prognosis is mainly determined by the presence of local 
or distant metastases, especially in the liver and peritoneum, which occur in half the 
patients. Only patients with a limited number of liver or lung metastases have a chance 
for cure by extensive surgery, in general combined with chemotherapy. However, up 
to half of the patients selected for metastasectomy have inoperable disease at lapa-
rotomy (5). Therefore, preoperative staging for detecting extrahepatic disease is crucial 
to avoid futile major surgery (6). Specific detection of malignant colorectal tumour 
lesions could be achieved by (pretargeted) antibody-guided radionuclide imaging. 
The combination of the specificity of antibody targeting and the sensitivity of PET is 
very promising. Radiolabelled antibodies have been tested for the detection of several 
cancer types. However, imaging with radiolabelled whole antibodies requires a rela-
tively long interval between injection and imaging acquisition for adequate contrast to 
develop, due to the slow accretion of intact antibodies in tumours and their slow clear-
ance (7). Pretargeting techniques were developed to improve radioimmunotargeting 
of tumours (8). A two-step pretargeting method using bispecific monoclonal antibod-
ies (bsMAb) has been developed. First an unlabelled bsMAb with affinity for both the 
tumour and a small radiolabelled molecule is injected. When the bsMAb has cleared 
from the blood and has accumulated in the tumour, a radiolabelled, hapten-conju-
gated peptide is administered that clears rapidly from the blood and the body, but is 
trapped in the tumour by the anti-hapten binding arm of the bsMAb (9-11). Such a 
pretargeting method allows imaging within one hour after injection of the radiola-
belled peptide, with high contrast, in animal models. Coupling two haptens together 
improves peptide uptake and stability by a process known as affinity enhancement 
(12). Chelate-metal complexes, such as DTPA-In, have been used as haptens (13). 
FDG-PET/CT has an established role in the work-up of patients with metastasized 
colorectal cancer, and could change patient management in >25% of patients (14-16). 
Other clinical indications for PET-scanning in patients with colorectal cancer are the 
detection of disease recurrence and characterization of undefined lesions on conven-
tional imaging (17-20). However, since FDG is a nonspecific tracer, it also has uptake 
in other tissues (e.g., physiological uptake in the bowel, uptake in (post-surgical) in-
flammatory or infectious lesions). FDG-PET frequently causes diagnostic dilemmas 
in assessing peritoneal disease (21-24). 
In the present study, we examined the sensitivity of pretargeting with a bispecific 
monoclonal anti-carcinoembryonic antigen (CEA) x anti-histamine-succinyl-glycine 
(HSG) antibody, TF2, and a 68Ga-labelled peptide, IMP288. Pretargeted immuno-
PET was compared to 18F-FDG-PET in a preclinical orthotopic model in mice with 
small, intraperitoneally growing, CEA-expressing colonic tumour lesions. 
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Methods
Pretargeting reagents TF2 and IMP288
The bsMAb, TF2, and the peptide IMP288, were provided by Immunomedics 
(Morris Plains, NJ, USA). The preparation of TF2 and binding properties have previ-
ously been described (25-29). Gel fitration chromatography showed that TF2 bound 
>90% of 68Ga-IMP288 peptide. IMP288 was synthesized and purified as described 
by McBride et al. (30). IMP288 is a DOTA-conjugated D-Tyr-D-Lys-D-Glu-D-
Lys tetrapeptide in which both lysine residues are substituted with a HSG-moiety 
via their ε-aminogroup: 7,10-tetra-azacyclododecane-N,N’,N’’,N’’’-tetraacetic acid 
(DOTA)-D-Tyr-D-Lys(HSG)-D-Glu-D-Lys(HSG)-NH2. 
TF2 was labelled with 125I (Perkin Elmer, Waltham, MA) by the iodogen method as 
described previously (31), to a specific activity of 58 MBq/nmol. 125I-labelled TF2 was 
purified by eluting the reaction mixture with PBS, 0.5 % w/v bovine serum albumin 
(BSA) (Sigma Chemicals, St. Louis, MO, USA) on a PD-10 column (GE Healthcare 
Bio-Sciences AB, Uppsala, Sweden). IMP288 was labelled with 68Ga as described 
previously (32). Radiolabelling and purification for administration could be accom-
plished within 45 minutes. The final product was adjusted to have a specific activity of 
20 MBq/nmol at the moment of injection. 
18F-FDG was obtained from B.V. Cyclotron VU, Amsterdam, The Netherlands.
Quality control of the radiolabelled preparations 
Radiochemical purity of the radiolabelled TF2 and IMP288 preparations was deter-
mined as described previously (32). In all experiments, the radiochemical purity of 
125I-TF2, and 68Ga-IMP288 preparations exceeded 95%. 
Animal experiments
All studies were approved by the Institutional Animal Welfare Committee of the 
Radboud University Nijmegen Medical Centre, and conducted in accordance with 
their guidelines (revised Dutch Act on Animal Experimentation, 1997). Animals 
were accustomed to laboratory conditions for one week before use and housed in indi-
vidually ventilated cages isolators under standard laboratory conditions (temperature 
20-24 °C, relative humidity 50-60 %, 12-h light-dark cycle), with free access to animal 
chow and water. 
Female nude BALB/c mice (6-8 weeks old), weighing 20 to 25 g, received an intraperi-
toneal injection of 0.5 mL of a suspension of 1 x 106 LS174T cells, a CEA-expressing 
human colon carcinoma cell line (CCL-188; passage 7; American Type Culture 
Collection). 
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PET imaging
Three weeks after tumour cell inoculation, one group of five mice was injected intra-
venously with 5.0 nmol TF2 (0.2 mL), labelled with a trace amount of 125I (0.4 MBq). 
Sixteen hours later, 68Ga-IMP288 (5 MBq/025 nmol) was administered intravenously 
in 0.2 mL as described previously (32). The other group of five mice received 5 MBq 
18F-FDG intravenously (i.v.). Mice were fasted for 10 hours before the 18F-FDG-
injection and anesthetized and kept warm at 37°C. Mice were euthanized one hour 
after the injection of 68Ga-IMP288 or 18F-FDG by CO2/O2 asphyxiation, followed by 
cardiac puncture to obtain blood. 
PET/CT scans of the mice were acquired one hour after the injection of 68Ga-IMP288 
or 18F-FDG with an Inveon animal PET/CT scanner (Siemens Preclinical Solutions) 
having an intrinsic spatial resolution of 1.5 mm (33). The animals were placed in a 
supine position. PET emission scans were acquired for 15 minutes, preceded by CT 
scans for anatomical reference (spatial resolution 113 μm; 80 kV; 500 μA; exposure 
time 300 ms). Scans were reconstructed using Inveon Acquisition Workplace soft-
ware (version 1.5; Siemens Preclinical Solutions) using a three-dimensional ordered 
subset expectation maximization/maximum a posterior algorithm with the following 
parameters: matrix 256 x 256 x 159; pixel size 0.43 x 0.43 x 0.8 mm3; and maximum a 
posteriori prior β 0.5. 
After the scans, mice were dissected and the abdomen were systematically and meticu-
lously examined for tumours. The location of each lesion was documented, weighed, 
measured, and then the activity in each lesion was determined in a gamma counter. 
The other organs of interest were weighed and counted in a gamma counter with 
standards prepared from the injected products, using appropriate energy windows for 
radionuclide of interest. The percentage of the injected dose per gram tissue (% ID/g) 
was calculated. The correlation between the weight and uptake of 125I-TF2 as 68Ga-
IMP288 per lesion was calculated. 
Immunohistochemistry
Immunohistochemical analysis of CEA was performed on 4 µM thick formalin-fixed, 
paraffin-embedded tissue sections. The sections were deparaffinized in xylol and 
rehydrated through a graded ethanol into water. Endogenous peroxidase, slides was 
blocked with 3% hydrogen peroxide in phosphate buffered saline (10 min at room 
temperature). Then sections were blocked with 20% normal goat serum (Vector 
Laboratories Inc., Burlingame, USA) in 1% bovine serum albumin (BSA)-PBS (30 
min at RT). Subsequently, tumour sections were incubated with a 1:12000 dilution of 
polyclonal rabbit anti-CEA antibody (A0115, Dako, Glostrup, Denmark) overnight 
at 4°C, followed by incubation with a goat-anti-rabbit biotinylated secondary anti-
body (1/200 in 1% BSA-PBS) (Vector Laboratories Inc., Burlingame, USA) for 30 
min RT. Finally, avidin–biotin–enzyme complex (Vector Laboratories) was applied 
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for 30 min at 37°C and 3,39-diaminobenzidine was used to develop the tumour sec-
tions. Human coloncarcinoma was used as a positive control, and substitution of the 
primary antibody with 1% BSA-PBS was used as the negative control. 
Analysis of the PET images
PET/CT images were scored by a blinded, independent, experienced nuclear physi-
cian (W.O.), being asked to record the presence of intra-abdominal tumour lesions. 
When lesions were present, he was asked to draw a region of interest (ROI) around 
the tumour. Each lesion was given a number on a 1-3 scale that defined the reader’s 
confidence in that the uptake was related to a tumour (definitely, probably or possibly 
tumour). The imaging findings were then compared with the tumour lesions found 
at dissection. The detection rates for tumours <10 μL and ≥10 μL were calculated, 
corresponding with a sphere diameter of < 2.7 or ≥ 2.7 mm respectively.
Statistical analysis
Statistical analysis was performed using the SPSS software (Chicago, IL) and 
GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego USA). 
Means and standard deviations were used to describe continuous data, unless stated 
otherwise. Correlations were determined using a Spearman’s correlation test. The level 
of significance was set at p<0.05. 
Results
Tumour growth
Three weeks after the intraperitoneal injection of the LS174T cells, mice did not show 
clinical signs of discomfort or change in body weight. At dissection, the abdomen 
contained multiple solid tumour lesions (median n=10 per mouse; range 4-17). Most 
frequent localizations were at the rectovesical pouch, mesentery, subhepatic, -splenic 
and -phrenic space. Some tumour nodules were adjoining in groups of two or three le-
sions. Three-dimensional caliper measurements indicated that the maximum diameter 
of the tumour lesions varied between 1 and 15 millimetres (median 5), and weights 
varied between 0.3 and 650 mg (median 16 mg). 
Biodistribution 
The biodistribution of 125I-TF2 and 68Ga-IMP288 in the mice is shown in Figure 1A. 
High uptake of the bsMAb (3.73 ± 1.2% ID/g) and peptide (23.4 ± 7.2% ID/g) in 
the tumour lesions was observed, with very low accretion in the normal organs. This 
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resulted in high tumour-to-normal-tissue ratios of 68Ga-IMP288 (e.g., tumour-to-
intestine ratio: 58 ± 22, tumour-to-liver ratio: 15 ±3). 18F-FDG localized efficiently in 
the tumours (8.7 ± 3.1 % ID/g) (Figure 1B), but with physiological uptake in various 
normal tissues, with lower tumour-to-normal tissue ratios (e.g., tumour-to-intestines 
3.9 ± 1.1, tumour-to-liver: 2.9 ± 0.5). 
Tumour uptake both of 125I-TF2 and 68Ga-IMP288 correlated inversely with tumour 
size, as shown in Figure 2A and 2B (Spearman’s ρ=-0.66, p<0.05, and Spearman’s ρ=-
0.63, p<0.05, respectively). 
PET/CT images
Immuno-PET with TF2 and 68Ga-IMP288 resulted in clear delineation of the tu-
mours. An example of a PET/CT image is shown in Figure 3A. It shows the cross sec-
tions through several tumours lesions. The photographs show their localization in the 
abdomen as well as their size. Apart from the activity in the bladder, very low uptake 
in normal tissues was seen. Due to the highly specific uptake in the tumour lesions and 
low background concentration, the immuno-PET/CT images could even be used to 
guide the localization of tumour lesions during dissection. Tumours that were more 
difficult to find macroscopically, because they were localized in the retroperitoneal 
cavities or posterior to the liver, were easily seen and localized on the images. 
Interestingly, one lesion that was macroscopically doubtful to be a tumour, and show-
Figure 1A: Biodistribution of 6.0 nmol 125I-TF2 (0.37 MBq) and 0.25 nmol 68Ga-IMP288 (5 MBq), 
1 h after i.v. injection of 68Ga-IMP288 in BALB/c nude mice with intraperitoneal.CEA-expressing 
LS174T tumours. Values are given as means ± standard deviation (n=5). 
Figure 1B: Biodistribution of 0.25 nmol 68Ga-IMP288 (5 MBq), 18F-FDG (5 MBq), 1 h after i.v. injec-
tion in BALB/c nude mice with intraperitoneal CEA-expressing LS174T tumours. Values are given as 
means ± standard deviation (n=5). 
40
Figure 2: Correlation between tumour uptake of 125I-TF2 (A) and 68Ga-IMP288 (B) and tumour size 
(Spearman’s rho = -0.66, p<0.05, and Spearman’s rho = -0.63, p<0.05, respectively).
ing minimal uptake on immuno-PET, had an activity concentration as low as 0.49% 
ID/g. This uptake level was much lower than that of the other lesions in the same 
animal (range 16.3-29.6 % ID/g). This lesion with the low uptake was shown by im-
munohistochemistry to consist >90% of necrotic tissue and infiltrated leukocytes, 
lacking CEA-expression, and had only a small rim of vital tumour cells (Figure 4), 
which explains its low signal on immuno-PET. 
In contrast, it was more difficult to discriminate the tumour lesions from other intra-
abdominal structures on the FDG-PET images, because the uptake in the tumours 
was only slightly higher than in the intestines, as is shown in Figure 3B. FDG-PET 
images showed physiological uptake in the brain and the myocardium. To illustrate the 
low uptake of the pretargeting peptide in the background, the immuno-PET/CT and 
FDG-PET/CT images of mice without intraperitoneal tumours, which were imaged 
according the same scanning protocol, are shown in Figure 3C and 3D. In pretargeted 
immuno-PET/CT images, only a low signal in the kidneys was observed, whereas no 
uptake was observed in the other normal organs. The FDG-PET/CT image of the 
animal without abdominal tumours clearly showed uptake in the bowel. 
Sensitivity
There was a major difference in the number of detected lesions with immuno-PET/
CT compared with FDG-PET/CT. Table 1 shows the number of tumours that were 
correctly aligned by the independent nuclear physician for each imaging method. For 
pretargeted immuno-PET all tumour lesions ≥10 μL were detected (100%, 23/23). 
Separate analysis for the smaller lesions, <10 μL, showed a detection rate of 20% 
(3/15). The score on the probability scale was ‘definitely positive’ for 88% of the delin-
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Figure 3: 3D-volume rendering of the pretargeted immuno-PET scan (A) and of the FDG-PET/CT 
scan (B) of BALB/c nude mice with intraperitoneal LS174T tumours, that received 6.0 nmol TF2 
and 5 MBq 68Ga-IMP288 (0.25 nmol) with a 16-hour interval (A) or 18F-FDG (B). The animals were 
imaged one hour after 68Ga-IMP288 or 18F-FDG injection. Digital pictures were made during dissection 
to localize and measure individual tumours. On the pretargeted immuno-PET/CT images (A), all dis-
sected tumours were very clearly distinguishable, except for the two very small tumours (1.2 and 4.7 μL 
respectively). In the FDG-PET/CT images (B) arrows are pointed at the localizations where tumours
Figure 4: Two tumour lesions dissected from the ab-
domen of a BALB/c nude mouse that received 68Ga-
IMP288 after pretargeting with TF2. One lesion (A: left 
lesion) showed normal vital tumour cells on microscopic 
HE- and CEA-stained images (B: HE, 5x zoom; C: 
HE, 20x zoom, D: CEA, 20x zoom), and high specific 
tumour uptake of 68Ga-IMP288 (17.7 % ID/g). On the 
contrary, another lesion in the same animal (A: right 
lesion) showed much lower tumour activity concentra-
tion (0.49% ID/g) in biodistribution and a much lower 
signal on the PET/CT images. This result was explained 
by the HE-sections and CEA-stained images showing 
>90% of non-vital tumour tissue (necrosis and infil-
trated lymphocytes), lacking CEA-expression (E: HE, 
5x zoom; F: HE, 20x zoom, G: CEA, 20x zoom).
 were found at dissection, but the signal was difficult to be 
discriminated from intestines. Figure 3c and 3d show the 
PET/CT images of mice without intraperioneal images 
after TF2 and 68Ga-IMP288 injection (C) or 18F-FDG 
injection (D).
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eated lesions. In contrast, in the FDG-PET images, the detection rate of the tumours 
≥10 μL was only 48% (13/27). A similar small proportion of the smaller lesions were 
found by FDG-PET/CT compared to immuno-PET/CT (25%, 3/12). Interestingly, 
the nuclear medicine physician was much less confident about aligning the ROIs in 
the FDG-PET/CT images. For none of the lesions he scored ‘definitely positive’, and 
only ‘possibly positive’ for 69% (11/16). 
Table 1: Number of tumours that were correctly aligned by the independent nuclear physician for pre-
targeted immuno-PET/CT and FDG-PET/CT, and confidence rate defined by the reader. 
Pretargeted 
immuno-PET/CT FDG-PET/CT
Tumours > 10 μL
Disssected 23 27
Detected in images 23 (100%) 13 (48%)
Tumours < 10 μL
Disssected 15 12
Detected in images 3 (20%) 3 (25%)
Probability assigned 
by nuclear physician
Definitely positive 23 (88%) 0
Possibly positive 3 (12%) 11 (69%)
Probably positive 0 5 (31%)
Discussion
This study showed that pretargeted immuno-PET is a very sensitive imaging modal-
ity to detect CEA-expressing tumour lesions in an orthotopic mouse model. The 
intraperitoneal tumours were clearly delineated with a high tumour-to-background 
contrast, providing high sensitivity: all tumour lesions ≥10 μL were detected with this 
method, at a very good confidence rate. The smallest lesions that were detected had 
a volume as low as 5-8 µL, which is in the same range of the spatial resolution of the 
dedicated animal PET scanner. 
The animal model used in this study was well characterized by Koppe et al (34). The 
human colon carcinoma cell line LS174T has a reproducible growth pattern in 
BALB/c nude mice after intraperitoneal injection. Three weeks after tumour cell in-
oculation small tumour nodules were observed in the rectovesical pouch, mesentery, 
subhepatic, -splenic and -phrenic space. The preclinical model mimics peritoneal dis-
ease of patients with metastasized colorectal cancer (35). 
In a previous imaging study, we demonstrated the feasibility of pretargeted immuno-
PET using 68Ga- or 18F-labelled di-HSG-peptides in mice with subcutaneous tumours 
(32). In the current study, the activity concentration of the 68Ga-labelled IMP288 in 
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the intraperitoneal tumours was similar to that in the subcutaneous tumours (32, 36). 
In our intraperitoneal tumour model the variation in tumour size was much wider than 
in the subcutaneous model. Our biodistribution results showed an inverse relationship 
between tumour weight and activity concentration. This correlation corresponds with 
the findings of other investigators (37-40). Sharkey et al. showed specific uptake of 
124I-labelled peptide after pretargeting with TF2 in microdisseminated human colon 
cancer colonies in the lungs of nude mice. In that model, high tumour-to-non-tumour 
ratios were obtained, illustrating the excellent tumour targeting potential of the pre-
targeting strategy (41). 
FDG-PET/CT has shown high sensitivity and negative predictive value in diagnosing 
CRC (42, 43). Therefore, it was used in the present study as a reference method. The 
imaging quality of FDG-PET in this preclinical study was optimized by minimizing 
uptake of FDG in other organs by anaesthesia, fasting and warming of the animals 
(44). Its uptake in the myocardium, brain, intestines and liver is comparable to the 
clinical situation. The ratios between normal and tumour tissue might have been 
appeared to be less favourable than in patients, which might have compromised the 
detection of the tumours. 
Based on our preclinical results we feel that pretargeted immuno-PET can be of ad-
ditive value in the clinical setting. When staging patients with primary tumours in 
detection of eventual metastases, a highly sensitive and specific imaging method is re-
quired. Furthermore, in patients to be screened prior to curative liver metastatectomy, 
the disclosure of occult extrahepatic lesions will prevent useless operations. Moreso, 
immuno-PET can help to select patients who could undergo radioimmunotherapy. 
As the pretargeting system with the DOTA-conjugated peptides is very flexible, it can 
be labelled with a broad variety of radionuclides, like 90Y and 177Lu for pretargeted 
radioimmunotherapy, or with 111In and 99mTc for SPECT imaging. Our preclinical 
results show similar biodistribution of the 111In/177Lu- or 68Ga-peptide labelled (36). 
Images about targeting of known, non-biopsied lesions, can confirm antigen expres-
sion and accessibility of the therapeutic dose. Information on the biodistribution and 
pharmacokinetics can help to adjust treatment regimes by providing dosimetry data. 
This could be used to optimize dosing and to avoid toxicities. 
For clinical application, 68Ga has some major advantages. It is readily available in a 
nearly carrier-free state from an in-house 68Ge/68Ga generator. IMP288-DOTA can 
be stably and rapidly labelled with 68Ga. Its half-life matches the pharmacokinetics of 
the peptide. In the present study, the positron range of 68Ga (median range 3.5 mm) 
might have limited image resolution. Visser et al showed that with the intrinsic spatial 
resolution (approximately 1.5 mm) of our state of the art small-animal PET scanner, 
the finite positron range has become the limiting factor for the overall spatial resolu-
tion and activity recovery in small structures imaged with 68Ga (33). Combined with 
the partial volume effect, this could explain the lower detection rate of the smallest 
tumour lesions with pretargeted immuno-PET, despite of the higher radioactivity 
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concentration of TF2 and 68Ga-IMP288 in the smaller tumours. 
Due the flexibility of the di-HSG-peptides, the use of other PET-radionuclides for this 
pretargeting system can be explored. 18F, the most widely used positron emitting radio-
isotope, would be suitable due to its short positron range in tissue (0.62 mm), which 
might increase the image resolution. McBride and, subsequently, Laverman, McBride 
and colleagues developed an innovative and rapid method for labelling peptides with 
18F based on a metal chelator (45, 46). The biodistribution and PET-images in the 
subcutaneous LS174T tumours in nude mice showed the feasibility of this approach 
(32). Translation of this preclinical imaging method to the clinical situation will show 
the effect of the intrinsic resolution of the clinical PET-scanner in combination with 
the spatial resolution of the radionuclide. 
Conclusions
In summary, this study indicates that pretargeted immuno-PET with TF2 and 68Ga-
IMP288 is a specific and sensitive method for detecting colon cancer in a preclinical 
model. Further clinical trials should focus on the diagnostic accuracy of pretargeted 
immuno-PET and determine its additional value in the clinical setting.
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Abstract 
Background
Pretargeted radioimmunotherapy (PRIT) with bispecific antibodies in combination 
with a radiolabelled peptide reduces the radiation dose to normal tissues, especially 
the bone marrow. In this study, the optimization, therapeutic efficacy and toxicity 
of  PRIT of colon cancer with a 177Lu-labelled peptide was determined in mice with 
CEA-expressing human tumours.
Methods
To obtain the optimal therapeutic efficacy, several strategies were evaluated to increase 
the total amount of radioactivity targeted to subcutaneous (s.c.) LS174T colon cancer 
tumours in BALB/c nude mice. First, the maximum amount of bispecific anti-CEA 
x anti-hapten antibody, TF2, and the peptide, IMP288, that could be targeted was 
determined. Furthermore, the tumour targeting of repeated administrations of ra-
diolabelled IMP288 was investigated. Mice received one TF2 injection followed by 
multiple IMP288 gifts (3 h interval), or multiple cycles with each IMP288 admin-
istration preceded by a new TF2 injection (72 h interval). PRIT was administered 
at maximum doses of TF2, and 177Lu-labelled IMP288 in groups of nine mice with 
s.c. LS174T tumours. Mice received  one, two or three successive cycles treatment 
(26 MBq/mouse/cycle) or carrier only. Primary endpoint was survival; secondary 
endpoints were tumour growth, body weight, bone marrow and renal toxicity.
Results
The highest amount of radioactivity delivered to a s.c. colon tumour was achieved by 
administering 5.0 nmol TF2 and 0.28 nmol IMP288 in three successive cycles with 
each IMP288 preceded with a new TF2 injection (72 h interval). PRIT effectively 
delayed tumour growth and prolonged survival significantly. Higher activity doses, 
administered in successive cycles, correlated with longer survival: the median survival 
of untreated mice was 13 days (range 6-20), whereas that of mice treated with one, 
two or three cycles of PRIT was 24 (range 24-31), 45 days (range 38->130), and 65 
days (range 48->130), respectively.  Toxicity was limited: no significant changes in 
mean body weight were measured. Minimal  changes in leukocyte counts were measured 
two and three weeks p.i., with full recovery within seven weeks after treatment. Platelet 
counts were unaffected. Serum creatinine was not increased significantly, thus there was 
no indication of acute renal toxicity.
Conclusions
This study indicates that in mice PRIT is an effective treatment modality against colon 
cancer with limited toxicity.
51
Introduction
The survival of patients with colorectal cancer depends mainly on the development of 
distant metastases. In patients with metastasized disease, chemotherapy with capecit-
abine, oxaliplatin and irinotecan used in combination protocols prolongs median 
overall survival from 8.0 months to 11.7 months (1). The addition of bevacizumab to 
those chemotherapy schedules increases median overall and progression free survival 
by 3.7-4.7 months (2), resulting in an overall survival of more than 20 months in pa-
tients with metastatic disease (3). 
Novel systemic strategies are needed for patients who become refractory or intolerant 
to these treatments.  Radioimmunotherapy (RIT), the selective targeting of tumour-
associated antigens expressed on the tumour cells with radiolabelled antibodies, is an 
attractive candidate. This concept has been investigated extensively and has proven 
to be effective in patients with non-Hodgkin lymphoma (4-7), leading to approval 
of two radiolabelled anti-CD20 monoclonal antibody preparations: 90Y-ibritumomab 
tiuxetan (Zevalin®, Bayer Schering Pharma AG) and 131I-tositumomab® (Bexxar, 
GlaxoSmithKline). While RIT has not been as successful in solid tumours, presum-
ably because these tumours are less radiosensitive, an 131I-labelled anti-CEACAM5 
IgG given to colorectal cancer patients as an adjuvant therapy after resection of hepatic 
metastases improved survival compared to a contemporaneous group of patients  (8, 
9).  The activity dose in RIT is limited by myelotoxicity as a result of the continu-
ous radiation exposure of the red marrow by the slow-clearing antibody.  Pretargeting 
techniques were developed to circumvent this problem (10). In pretargeting, an un-
labelled bifunctional reagent, with affinity for the tumour and a small radiolabelled 
molecule, is administered to pre-localize in the tumour (11-13). In this approach, a 
bispecific monoclonal antibody (bsMAb) is administered intravenously and given 
time to accumulate in the tumour and clear from the circulation. Then, a radiolabelled 
hapten-peptide is given that clears rapidly from the blood and body, but is trapped 
in the tumour by the anti-hapten binding arm of the bsMAb. This greatly reduces 
the radiation dose to normal tissues, especially the bone marrow.  The retention of 
the radiolabelled hapten-peptide in the tumour is enhanced when two haptens are 
included in the hapten-peptide (14). 
In our pretargeting system, peptides are substituted with the hapten histamine-succinyl-
glycine (HSG), creating a flexible pretargeting system, because these HSG-substituted 
peptides can be conjugated with various chelating moieties (DTPA, NOTA, DOTA, 
N3S-chelates, etc.), so that the peptide can be radiolabelled stably with a variety of 
radionuclides, such as 111In and 99mTc for SPECT imaging (13), with 18F and 68Ga for 
PET imaging (15-18), or with 131I, 90Y, and 177Lu for pretargeted radioimmunotherapy 
(PRIT) (19). 
Until recently, the bsMAbs used in pretargeting were either produced by chemical con-
jugation of Fab-fragments or via the quadroma technology. A new method, the Dock-
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and-Lock (DNL) technology as described previously (20, 21).  Using DNL constructs 
to target B-cell lymphoma and pancreatic cancer, significant therapeutic responses 
have been reported in animals with subcutaneous xenografts, using a 90Y-labelled di-
HSG-peptide (22. 23).  The DOTA-di-HSG-peptide can also be stably labelled with 
177Lu. Herein, we report the optimization, therapeutic efficacy and toxicity of an anti-
CEA DNL bsMAb construct in combination with a 177Lu-labelled di-HSG peptide in 
mice bearing carcinoembryonic antigen (CEA)-expressing tumours.
Methods
Pretargeting reagents TF2 and IMP288 
The trivalent anti-CEACAM5 x anti-HSG bsMAb construct, TF2 (MW 157 kDa), and 
IMP288 peptide (molecular weight 1456 Da) were provided by IBC Pharmaceuticals, 
Inc., and Immunomedics, Inc. (Morris Plains, NJ, USA). The preparation and binding 
properties of TF2 have previously been described (21, 24-26). Size-exclusion chro-
matography showed that TF2 could bind >90% of the added 111In-IMP288 peptide. 
IMP288 was synthesized and purified as described by McBride et al. (16).  
In some studies 125I-TF2 (0.4 MBq), was co-injected with unlabelled TF2 to confirm 
tumour accretion. IMP288 was labelled with either 111In for biodistribution studies or 
with 177Lu for radioimmunotherapy. Mice received TF2 and IMP288 intravenously 
in 0.2-0.3 mL phosphate-buffered saline (PBS), 0.5% bovine serum albumin (BSA).
TF2 was radioiodinated with a trace amount of 125I (Perkin Elmer, Waltham, MA) by 
the iodogen method and 125I-labelled TF2 was purified as described previously (27). 
IMP288 was labelled with 111In (Covidien, Petten, The Netherlands) at a specific 
activity of 32 MBq/nmol and with 177Lu (IDB Holland BV, Baarle Nassau, The 
Netherlands) at a specific activity of 86 MBq/nmol and radiolabelling was performed 
as described previously (18).
Radiochemical purity of the radiolabelled TF2 and IMP288 preparations was deter-
mined using instant thin-layer chromatography (ITLC) on silica-gel strips (Pall Life 
Sciences, Ann Arbor, MI).  The percentage of radiolabelled TF2 was determined 
using 0.1 M citrate buffer, pH 6.0, as the mobile phase. To determine the percentage 
of radiolabelled IMP288  0.1 M NH4Ac : 0.1 M EDTA was used as the mobile phase. 
Furthermore, 111In-IMP288 and 177Lu-IMP288 were analyzed by RP-HPLC as de-
scribed previously (18). Radiochemical purity of 125I-TF2, 111 In- and 177Lu- IMP288 
preparations always exceeded 95%. 
Animal experiments
The experiments were performed in male nude BALB/c mice (6-8 weeks old), weighing 
20-25 g. Mice were accustomed to laboratory conditions for at least one week before 
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experimental use and were housed under non-sterile standard conditions in filter-
topped cages with free access to animal chow and water. All studies were approved by 
the institutional Animal Welfare Committee of the Radboud University Nijmegen 
Medical Center, and conducted in accordance with their guidelines (revised Dutch 
Act on Animal Experimentation, 1997). 
Tumour xenografts were induced by subcutaneous inoculation of 0.2 mL of a suspen-
sion of 1 x 106 LS174T cells, a CEA-expressing human colon carcinoma cell line 
(American Type Culture Collection, Rockville, MD, USA). TF2 and IMP288 were 
injected intravenously in 0.2-0.3 mL, with an interval of 16 hours, as this period was 
shown to be sufficient to clear TF2 from the circulation, to allow for IMP288 tumour 
targeting without significant complexation in the circulation. 
Biodistribution studies
In this study, the maximum amount of IMP288 that could be captured by LS174T 
tumours (0.02-0.2 g) was assessed. First, the optimal TF2 dose that could bind the 
maximal amount of IMP288 in the tumour was determined.  Groups of 5 tumour-
bearing nude mice were injected intravenously with 1.3, 2.5, 5.0 or 10.0 nmol TF2 
(~0.2 to 1.57 mg), labelled with a trace amount of 125I (0.4 MBq), and 16 hours later, 
0.10 nmol IMP288 was given. One hour after injection of IMP288, all mice were 
euthanized by CO2/O2  asphyxiation. Blood was obtained by cardiac puncture, and 
tumour and organs of interest were dissected, weighed and counted in a gamma coun-
ter with standards prepared from the injected products, using appropriate energy win-
dows for radionuclide used. The percentage-injected dose per gram tissue (% ID/g) 
was calculated.  
Subsequently, the maximum amount of IMP288 that could be captured under these 
pretargeting conditions was assessed. Therefore, groups of five mice received 5.0 nmol 
of TF2 intravenously, and 16 hours later, 0.035, 0.070, 0.140, 0.280 or 0.410 nmol 
IMP288 (50, 100, 200, 400 or 600 ng, respectively) was given, labelled with a trace 
amount of 111In (0.4 MBq). One hour later, all mice were euthanized for determina-
tion of tumour uptake and organ distribution.  
In a third experiment, the accumulation and retention in the tumour of the maximum 
TF2 and IMP288 doses was investigated. Tumour-bearing nude mice received 5.0 
nmol 125I-TF2 (0.4 MBq) intravenously, and 16 h later, 0.28 nmol of 111In-IMP288 
(0.4 MBq). Groups of 5 mice were euthanized at 1, 6, 24 and 48 hours for determina-
tion of tumour uptake and organ distribution.  
The radioactivity of 177Lu that could be delivered was limited by the maximum peptide 
mass, as the maximum specific activity of 177Lu-IMP288 was 90 MBq/nmol. A single 
dose of 25 MBq/0.28 nmol IMP288, which was the maximal IMP288 dose that was 
specifically targeted to the tumour, was well below the maximum tolerated radioac-
tivity level. Therefore, our treatment strategy included the use of repeated treatment 
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cycles. Biodistribution studies were performed to assess two different approaches. The 
first strategy examined was to administer multiple injections of the radiolabelled pep-
tide after a single injection of the bsMAb. The tumour uptake was measured in three 
groups of five mice that received one 5.0-nmol dose of TF2, and then 16 h later, one, 
two or three injections of 0.28 nmol IMP288 were given, with each IMP288 injection 
separated by 3 h. In the multiple-dosed groups, only the last dose of IMP288 was 
labelled with 111In.
The second strategy investigated whether subsequent injections of IMP288 could be 
targeted more efficiently by preceding each IMP288 with a new TF2 injection. Three 
groups of five mice received one, two or three cycles of 5.0 nmol TF2 combined 16 
h later with 0.28 nmol IMP288, with each cycle separated by 72 h. In the multiple-
dosed groups, the last  dose of TF2 was labelled with 125I and the last  dose of IMP288 
was labelled with 111In. One hour after the injection of 111In-labelled peptide, mice 
were euthanized and dissection and analyses were performed as described above.  
Pretargeted radioimmunotherapy studies
The therapeutic efficacy of PRIT with TF2 and 177Lu-IMP288 was determined 
by random assignment of 9 mice with subcutaneous LS174T xenografts per group. 
Therapy studies were initiated 10 days after tumour inoculation, when the median 
tumour size was 40 mm3 (range: 12-120 mm3).  They received one, two or three treat-
ment cycles of TF2 (5.0 nmol) and 177Lu-IMP288 (26 MBq/0.28 nmol per cycle), or 
PBS, 0.5% BSA, with each cycle separated by 3 days, because this regime resulted in 
the highest absolute amount of radiolabelled peptide in the tumours. 
The primary endpoint was overall survival. The secondary endpoint was toxicity, with 
special attention to myelosuppression and acute renal toxicity. This was evaluated by 
monitoring general condition, body weight, blood cell counts and creatinine levels. 
Animals were observed daily by independent, experienced biotechnicians, measuring 
body weight and tumour size twice weekly. Standardized humane endpoints used to 
euthanize animals were: failure to eat/drink and losing ≥15% of body weight in 1 or 
2 days, or losing ≥20% of their starting weight, or in the case of tumour progression, 
when tumour size exceeded 1.0 cm3 or excessive ulceration. Tumour size was measured 
in three dimensions (length, width and height) with a caliper, and tumour volume 
was calculated, assuming tumours were ellipsoid shaped, using the formula: tumour 
volume (mm3) = 4/3π  x (length/2) x (width/2) x (height/2). 
Blood samples of 0.1 mL were collected via submandibular bleeding, prior to therapy 
for baseline full blood counts and serum creatinine, and weekly starting two weeks 
after therapy. White blood cell counts and platelet counts were analyzed by the 
ADVIA 120 Hematology System (Siemens Medical Solutions Diagnostics, Deerfield, 
USA). Serum creatinine was analyzed by Aeroset (Abbott Diagnostics, USA). Timing 
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of the white blood cell and platelet count measurement were scheduled to determine 
the nadir, at two and three weeks after the first injection of 177Lu-IMP288, and bone 
marrow recovery at seven weeks post-injection (p.i.). 
Statistic analysis
All mean values are given ± standard deviations. Statistical analysis was performed 
using a non-parametric, two-tailed Mann Whitney test and Kruskal Wallis test using 
SPSS software (version 16.0). Survival curves were compared using the Log-rank test. 
The level of significance was set at p<0.05.
Results
Determination of the maximum peptide dose
The maximum amount of TF2 and IMP288 that could be targeted specifically to 
LS174T tumours was determined. As shown in Figure 1A, the percentage uptake of 
TF2 in the tumour decreased from 3.21 ± 0.61% ID/g at the 1.0 nmol dose to 1.16 
± 0.27% ID/g at 10.0 nmol. Figure 1B illustrates that the absolute amount of TF2 
accreted specifically in the tumour (subtracting the blood concentration), illustrating 
that the total amount in the tumour did not increase at administered doses >5.0 nmol 
(i.e., antigen saturating dose). Therefore, the 5.0 nmol dose was selected for further 
PRIT experiments. 
The maximum amount of IMP288 that could be captured in the tumour with this 
amount of TF2 was determined.  At 1 h post-injection, 111In-IMP288 accumulated 
effectively in the tumour at all peptide doses, with very low uptake in all normal tissues. 
The highest tumour uptake in terms of % ID/g was obtained at the 0.035 and 0.070 
nmol IMP288 doses (18.8 ± 8.1 % ID/g and 23.3 ± 6.6% ID/g, respectively, P=0.33, 
Mann-Whitney exact test, two-tailed), with decreasing uptake at higher IMP288 doses 
(14.2 ± 6.6% ID/g, 9.6 ± 3.0% ID/g and 6.5± 2.2% ID/g at 0.140, 0.280 or 0.410 
nmol, respectively) (Figure 1C). Most importantly, the absolute amount of peptide 
targeted to the tumours did not increase at injected peptide doses higher than 0.28 
nmol IMP288 (Figure 1D). Therefore, this dose was selected for PRIT, as it would 
result in the highest amount of radioactivity in the tumour. For example, although 
0.07 nmol of 177Lu-IMP288 would allow 23% ID/g uptake, based on the specific 
activity of 90 MBq/nmol for 177Lu-IMP288, only 6.3 MBq of 177Lu-activity could 
be administered, delivering 1.45 MBq to the tumour, whereas with 0.28 nmol, even 
though the percent uptake is lower (~10% ID/g),  25.2 MBq could be administered, 
delivering 2.5 MBq to the tumour. 
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Blood and tumour retention
Using 5.0 nmol TF2 and 0.28 nmol IMP288, tumour uptake and tissue distribu-
tion were examined over a 48-h period following an 111In-IMP288 injection (Figure 
2). TF2 cleared rapidly from blood and normal tissues, with <0.1% in the blood 17 
hours after injection (1 h after 111In-IMP288), but with tumour uptake averaging 1.3 
± 0.22% ID/g (Figure 2A). At this same time, 111In-IMP288 tumour uptake was 11.3 
± 2.7% ID/g, with the kidneys having the highest uptake among normal tissues, aver-
Figure 1:  A and B show the biodistribution and specific tumor targeting of escalating bsMAb doses 
(1.0-10.0 nmol 125I-TF2, 0.4MBq) in BALB/c nude mice with 0.02-0.2  g  s.c. LS174T tumors. The 
bsMAb was followed by the injection of 0.10 nmol IMP288 16 h later, and one hour after that injection, 
the mice were euthanized. C and D show the biodistribution and specific tumor targeting of escalating 
peptide doses (0.035-0.41 nmol 111In-IMP288, 0.4 MBq), injected 16 h after pretargeting with TF2 
(5.0 nmol). Specific tumor targeting of 125I-TF2 and 111In-IMP288 was calculated as nmol per gram 
tumor, corrected for the blood concentration. Values represent means ± standard deviation (n=5).
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Figure 2.  The accumulation and retention of 125I-TF2 (A) and 111In-IMP288 (B) in BALB/c nude 
mice with s.c. LS174T tumors. TF2 (5.0 nmol) and IMP288 (0.28 nmol) were injected, with animals 
necropsied at 1, 6, 24 and 48 hours post-111In-IMP288 injection. Values represent means ± standard 
deviation (n=5).
aging 1.5 ± 0.3 % ID/g at this 1-h interval (Figure 2B).  Tumour uptake of TF2 and 
IMP288 gradually decreased over time at a somewhat similar rate.  Tumour-to-blood 
ratio exceeded 1,400:1 at all time points. 
Successive cycles of therapy
The data from the previous study indicated that maximum radioactivity dose of 177Lu-
IMP288 that could be administered with 0.28 nmol of IMP288 was far below the 
expected MTD.  Therefore, we evaluated the efficiency of successive doses of IMP288 
(i.e., administering one dose of 5 nmol TF2, and 16 h later 3-hourly one, two or three 
0.28 nmol 111In-IMP288 injections, or one, two or three cycles of 5 nmol TF2, fol-
lowed 16 h later by 0.28 nmol 111In-IMP288 every 3 days).  
The successive administrations of 111In-IMP288 after one injection of TF2 resulted in 
significantly lower uptake of the second and third injection of peptide compared to 
the first injection (8.0 ± 1.1 % ID/g and 6.2 ± 1.0 % ID/g versus 14.3 ± 1.5 % ID/g, re-
spectively; Mann-Whitney exact test, two-tailed: p<0.05) (Figure 3A).  Administering 
an extra second and third dose of TF2 before each successive dose of IMP288, with a 
3-day interval, resulted in similar tumour accretion of the second and third injections 
of bsMAb to that seen with the first injection (2.6 ± 0.4% ID/g, 2.0 ± 0.4% ID/g and 
2.3 ± 0.1% ID/g at first, second and third dose respectively). Most importantly, in 
this regime the first and second doses of 111In-IMP288 had similar uptake (14.7 ± 1.1 
% ID/g and 14.3 ± 1.5 % ID/g, respectively, p=0.91, Mann-Whitney exact test, two-
tailed), but by the third cycle, the 111In-IMP288, uptake was slightly lower compared 
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to the first and the second injection (10.9 ± 2.8 % ID/g,, p= 0.018, Mann-Whitney 
exact test, two-tailed) (Figure 3B). Renal uptake also increased slightly with each 
progressive dose, but tumour/kidney ratios were always favorable (9.3 ± 1.3, 7.0 ± 
1.0, and 4.3 ± 1.1 after the first, second and third cycle respectively). Thus, this latter 
approach was selected for therapeutic evaluation.
Pretargeted radioimmunotherapy
PRIT effectively delayed tumour growth compared to the control mice (Figure 4). 
Tumours in all untreated mice rapidly increased in size, while in the treated mice, the 
tumours did not start growing until day 14, 24 and 41 after one, two and three cycles 
of PRIT, respectively. 
The survival of the animals in the four groups of mice is depicted in Figure 5. PRIT 
prolonged survival: the median survival of untreated mice was 13 days (range 6-20), 
whereas the median survival of mice treated with one, two, and three cycles PRIT was 
24 (range 24-31), 45 (range 38->130), and 65 days (range 48->130) respectively, with 
significant differences between all pairs of survival curves (p<0.001, Log-Rank test), 
except for two cycles PRIT compared to three cycles (p=0.22, Log- Rank test). 
Figure 3. Biodistribution of successive administrations of 111In-IMP288, 3-hourly (A) and of successive 
cycles of TF2 combined with 111In-IMP288, 3-daily (B). A: Three groups of five mice received one 
injection of 5.0 nmol TF2 and 16 h later with one, two or three injections of 0.28 nmol IMP288, with 
each IMP288 injection separated by 3 h. B: Three groups of five mice received one, two or three cycles 
of 5.0 nmol TF2 and 0.28 nmol IMP288, with each cycle separated by 72 h. In each group, the last (or 
only) dose of IMP288 was labeled with 111In. One hour after the IMP288-injection of labeled peptide, 
all mice were euthanized. Values represent means ± standard deviation (n=5).
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Toxicity due the PRIT was minimal.  For all groups at all time points, body weight 
remained >93% of baseline, with no significant changes in mean body weight between 
the control and treated animals (P=0.85, Kruskal-Wallis test).  Hematologic toxicity 
in the PRIT groups is illustrated by the leukocyte and platelet counts at two, three and 
seven weeks post-injection (p.i.) (Figure 6A and 6B). Seven weeks p.i., five animals 
of the group that received two cycles had already been euthanized due to excessive 
Figure 4.  Tumor growth in mice that received one, two and three cycles of TF2 (5.0 nmol) and 177Lu-
IMP288 (26 MBq/0.28 nmol per cycle), or PBS. The size of the tumors of individual mice is depicted.
Figure 5. The survival of the animals in groups of 9 mice that were treated with one, two or three treat-
ment cycles of TF2 (5.0 nmol) and 177Lu-IMP288 (26 MBq/0.28 nmol per cycle), or PBS. 
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tumour growth, while all mice that received three cycles of treatment were still alive. 
No differences in leukocyte and platelet counts were observed between the two- or three-
cycle groups, so data of both groups were combined. A minimal, but statistically signifi-
cant, decrease in leukocyte counts was measured two and three weeks after the start of 
treatment (median baseline counts, 6.9 x 109/L; two and three weeks p.i.,  4.5 x 109/L  and 
4.6 x 109/L, respectively; p<0.001, Mann-Whitney exact test, two-tailed). Full recovery 
was observed at seven weeks after treatment (median counts seven weeks, 7.4 x 109/L; 
compared to baseline: P=0.95, Mann-Whitney exact test, two-tailed). No decrease in 
platelet counts was observed (median baseline counts, 972 x 109/L; two and three weeks, 
964 and 991 x 109/L, respectively; compared to baseline: P=0.94, Mann-Whitney exact 
test, two-tailed).  Serum creatinine at six and eight weeks after therapy was not increased 
significantly, as shown in Figure 6C (median = 14.0, 18.0 and 14.0 µmol/L at baseline, 6, 
and 8 weeks after therapy, respectively; Kruskal Wallis: P=0.94), indicating no evidence 
of acute nephrotoxicity in the treated mice.
Figure 6.  Leukocyte counts (A), platelet counts 
(B), and serum creatinine (C) in mice that were 
treated with two or three treatment cycles of TF2 
(5.0 nmol) and 177Lu-IMP288 (26 MBq/0.28 
nmol per cycle). 
Blood cell counts were measured prior to therapy, 
two and three weeks p.i., and at seven weeks p.i. 
Serum creatinine was measured prior to therapy 
and at six and eight weeks after therapy.  
Data represent individual determinations.
A    B  
C 
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Discussion
In this study we investigated the optimization of the pretargeting procedure for ra-
dioimmunotherapy using a new humanized recombinant DNL-bsMAb, TF2, with 
binding to CEACAM5, and the hapten, HSG, using a 177Lu-labelled di-HSG-DO-
TA-peptide, IMP288. We demonstrate that using the optimal dose schedule, it can 
be an effective treatment modality for the treatment of CEA-positive human colonic 
tumours growing in mice. 
All targeted therapies are limited by the amount and accessibility of the antigen.  In this 
model system, where small tumour xenografts were used, the amount of radioactivity 
that could be delivered in a single treatment was limited by the amount and specific ac-
tivity of IMP288 that could be given with antigen-saturating amounts of the bsMAb. 
We recently reported an evaluation of this same pretargeting system for PET imaging 
using 68Ga- and 18F-labelled peptides (18), and found, like in this study, 5 nmol (800 
µg) of TF2 saturated the amount of antigen in LS174T tumours.  Thus, this amount 
of bsMAb was the upper limit that should be used in this pretargeting setting (28). 
Using 5 nmol of TF2, the optimal IMP288 dose was next determined, finding that 
0.28 nmol of IMP288 essentially saturated the amount of bsMAb-binding sites. At 
IMP288’s maximum specific activity of 90 MBq/nmol, no more than 26 MBq of 177Lu 
could be administered.  However, because pretargeting greatly minimizes radiation 
exposure, this amount was much lower than the MTD.  Therefore, other strategies 
that could increase the total amount of radioactivity administered were evaluated.    
Biodistribution studies revealed the amount of radioactivity delivered to a tumour 
from a single 177Lu-IMP-288 injection could be increased nearly 2-fold by adminis-
tering an additional 2 successive doses of the IMP288 after a single TF2 injection. 
However, further improvements could be achieved by administering successive cycles 
of the bsMAb followed by IMP288, and therefore this latter approach was selected. 
As expected, higher activity doses, administered in successive cycles, correlated with 
longer survival. Despite this clear trend, the survival achieved with 3 cycles was not 
significantly better than with 2 cycles. Evenmore, tumour volume curves in the groups 
of mice that received 2 or 3 cycles were quite similar.  This could be due to the fact that 
by the third cycle tumour uptake had declined (11% ID/g) compared to the first two 
administrations (14% ID/g). 
The limited toxicity observed indicates that the maximum tolerated dose had not been 
reached in these experiments. Three subsequent treatment cycles did not compromise 
body weight, blood counts or acute kidney function. The decrease in leukocyte counts 
(40% of baseline levels) was moderate, with rapid recovery in most animals. The 
kidneys had the highest 177Lu-activity concentration of the normal organs, since the 
peptide is cleared by urinary elimination. A small fraction of the dose is reabsorbed 
by the proximal tubular cells and thus retained in the kidney. Serum creatinine was 
not increased after treatment, suggesting the absence of radiation nephritis; however, 
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since radiation effects on the kidneys can take many months to manifest, further stud-
ies would be required to assess the risk for chronic renal toxicity, which has been ob-
served in preclinical and clinical testing of peptide radionuclide radioimmunotherapy 
(29-31). 
We initiated studies with 177Lu primarily because the most promising results with 
radiolabelled antibodies in solid tumours have been observed in the treatment of 
small-volume disease (≤3 cm) or in an adjuvant setting (32). 177Lu is well suited for the 
treatment of small-volume disease with minimal radiation, given the medium-energy 
beta (maximum energy 0.497 MeV, mean energy 0.149 MeV, maximum penetration 
depth 2.5 mm). With an 11% abundance of 208 keV photons, the biodistribution of 
the 177Lu-labelled IMP288 peptide by gamma camera imaging will be possible in a 
clinical setting, providing important insights into the kinetics of tumour binding and 
retention in patients. 
In the current animal study, the wash-out of 177Lu-IMP288 from the tumour was simi-
lar to that of the TF2 bsMAb. In this pretargeting approach, the kinetics of tumour 
binding might not take full advantage of 177Lu’s 6.7 day physical half-life.  In contrast, 
the half-life of 90Y (64.1 h) is more consistent with the pharmacokinetics of IMP288, 
but its longer tissue penetration range (maximum 12.0 mm) would be more appro-
priate for treating tumours >0.5 cm in diameter (33-34).  Because of its high energy 
(maximum energy 2.28 MeV, mean energy 0.935 MeV), a single dose of a 90Y-labelled 
di-HSG peptide can be given to nude mice at or near MTD level with significant 
therapeutic effects  (23, 31).  In contrast, in this model the lower energy of 177Lu is 
less toxic, which allows for multiple dosing strategy improving therapeutic outcome 
well below the MTD. On the other, multiple treatment cycles might add to the com-
plexity of PRIT, so one should aim administering MTD in one therapy cycle. The in 
vivo effects of these beta-emitters should be compared in the same animal model, or 
ultimately in clinical trials, to reveal the optimal combination for therapeutic effects 
and bone marrow and kidney toxicity. 
Attempts to further enhance the activity dose in RIT for solid tumours are restricted 
by myelotoxicity. Therefore, PRIT was developed as an alternative primarily to circum-
vent problems associated with the long residence time of the antibody in the blood 
(11).  Several pretargeting approaches have been developed, with preclinical evidence 
universally indicating PRIT’s benefits over direct targeting in terms of reduced toxicity 
with similar or improved efficacy (11, 19).  The clinical experience with pretargeting 
has been limited. Kraeber-Bodéré et al. optimized PRIT with a chemically conjugated 
bsMAb using a humanized anti-CEACAM5 Fab’ x murine anti-DTPA Fab’ and 1.9-
5.5 GBq of an 131I-di-DTPA -peptide, in patients with metastasized CEA-expressing 
tumours  (35-36). The tumour responses in the eight patients with colorectal cancer 
were modest, while patients with medullary thyroid cancer had much better therapeu-
tic responses. However, this last group of patients experienced dose-limiting leuko- or 
thrombocytopenia, most likely due to diffuse metastatic involvement of the bone 
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marrow, while the patients with colorectal cancer only had mild hematologic toxicity 
(grade II).  These results illustrate the relevance of determining the most effective and 
tolerable treatment strategy and dosing schedule for each different patient population. 
Conclusions
In conclusion, in this study we show that pretargeted radioimmunotherapy with an 
anti-CEA bsMAb and a 177Lu-labelled peptide could be an effective treatment modal-
ity for the treatment of CEA-positive colonic tumours.  
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Abstract
Background
The prospects for using pretargeted immuno-SPECT with a bispecific anti-
carcinoembryonic antigen (CEA; CEACAM5; CD66e) x anti-hapten monoclonal 
antibody (bsMAb), TF2, and a small (1.5 kD) peptide, IMP288, labelled with 111In 
to monitor the response to pretargeted radioimmunotherapy (PRIT) using 177Lu-
IMP288 in a nude mouse-human colon cancer model implanted in the peritoneal 
cavity was examined.
Methods
First, tumour uptake of 111In-IMP288 and 177Lu-IMP288, as determined by immuno-
SPECT, was validated by ex vivo counting. Two groups of female BALB/c nude mice 
with i.p. LS174T tumours received i.v. injections of TF2, followed by 10 MBq of 
111In-IMP288 or 90 MBq of 177Lu-IMP288. A control group of non-tumour-bearing 
mice received TF2 and 111In-IMP288. One hour after the radiolabelled IMP288 
was given, micro-SPECT/CT images were acquired, and subsequently animals were 
dissected. Furthermore, a survival study was performed in three groups of ten mice 
with i.p. tumours: mice received TF2 and 177Lu-IMP288 (60 MBq), non-pretargeted 
177Lu-IMP288 (60 MBq), or PBS.  Immuno-SPECT scans were acquired directly 
after therapy, and at 14 and 45 days after therapy. Tumour growth was analyzed in 
the successive scans in each animal. 
Results
111In- and 177Lu-labelled IMP288 had identical in vivo distribution. The activity 
measured in the pretargeted immuno-SPECT images correlated well with the uptake 
measured in the dissected tumours (Pearson’s r = 0.99, p<0.05). In the therapy study, 
the SPECT images showed rapid and selective tumour targeting with very high 
tumour-to-background contrast (30 ± 12) as early as one hour after injection. The 
successive images of the treated mice showed delayed tumour growth in the PRIT 
group, which corresponded with their prolonged survival. 
Conclusion
Pretargeted immuno-SPECT with TF2 and 111In- or 177Lu-IMP288 can be used 
to predict and confirm tumor targeting and monitor the therapeutic effect of 
pretargeted radioimmunotherapy. 
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Introduction
Radiolabelled antibodies can be used for the diagnosis, detection and therapy of 
cancer. The diagnostic images acquired after injection of the radiolabelled antibody 
preparation can potentially predict the efficacy of radioimmunotherapy, an 
approach designated as theranostics. Theranostics is a useful concept for developing 
personalized targeted radionuclide therapies and has been applied for a long time 
in Nuclear Medicine. For example, diagnostic information obtained from pre-
therapeutic PET or SPECT can ensure that the treatment is targeted specifically to 
tumours, which could aid in patient selection, and dosimetric analysis potentially 
could predict the benefit/risk ratio of a planned radionuclide therapy. This analysis 
also might aid in identifying the most appropriate prescribed therapeutic dose 
optimized for their  radionuclide therapy (90Y, 177Lu, 213Bi, etc.). Finally, imaging data 
could potentially assess therapeutic response, including the detection of unsuspected 
sites of disease. The feasibility of this approach has been shown in neuroendocrine 
tumours using 111In- or 68Ga-labelled somastatin analogues for diagnosis and the 
same peptides labelled with 177Lu- or 90Y for radionuclide therapy (1, 2).  
In this study, the potential of theranostics for combined pretargeted 
radioimmunodetection and –therapy was evaluated. Pretargeting is a strategy that 
was developed to improve the imaging and therapeutic characteristics of directly 
radiolabelled monoclonal antibodies. Radiolabelled antibodies require several days 
to localize tumours effectively, due to the slow pharmacokinetics and accretion of 
intact antibodies in tumours. This slow uptake and clearance rate delays tumour 
detection by imaging and increases bone marrow toxicity for therapy. Pretargeting 
techniques achieve rapid accretion of the radionuclide in the tumour in combination 
with rapid blood clearance by first administering a non-radiolabelled bispecific 
monoclonal antibody (bsMAb). After the bsMAb localizes in the tumour and 
clears from the circulation, a small radiolabelled hapten-peptide is given, which 
leaves the bloodstream quickly, being trapped in the tumour by the anti-hapten arm 
of the bsMAb, while the remainder clears rapidly from the blood and is excreted 
via the kidneys. Coupling two haptens to the peptide improves peptide uptake, a 
phenomenon known as affinity enhancement (3).  Chelate-metal complexes, such 
as DTPA-In, have been used as haptens (4).  More recently, peptides substituted 
with the hapten, histamine-succinyl-glycine (HSG), in combination with anti-
HSG antibody binding have provided a more flexible system, because these HSG-
substituted peptides can be conjugated with various chelators (DOTA, NODA/
NOTA, N3S-chelates, etc.), allowing stable complexes with many radionuclides, 
such as 111In and 99mTc for SPECT (5-8),  68Ga and 18F for PET(9-13),  or  90Y and 
177Lu for pretargeted radioimmunotherapy (PRIT) (5, 8).  Including tyrosine in the 
peptide core also enables radioiodination (e.g., 124I or 131I) (7, 14).
For the studies described herein, a fully humanized anti-CEA x anti-HSG bsMAb 
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(TF2) (15), and a HSG-substituted hapten-peptide (IMP288) were applied in a 
nude mouse model for peritoneal dissemination of human cancer (13). Previous 
preclinical studies illustrated the enhanced sensitivity and specificity of this 
pretargeting system compared to FDG-PET (7, 12, 13). 
The aim of the present study was to investigate whether pretargeted immuno-SPECT 
could predict the effectiveness of PRIT. 
Materials and Methods
Pretargeting reagents TF2 and IMP288
The bsMAb, TF2, and the peptide IMP288, were provided by Immunomedics 
and IBC Pharmaceuticals (Morris Plains, NJ, USA). The preparation of TF2 
and its binding properties have been described previously (15, 16). Gel filtration 
chromatography showed that TF2 bound >90% of radiolabelled peptide. 
IMP288 was synthesized and purified as described by McBride et al. (14). It is a 
DOTA-conjugated D-Tyr-D-Lys-D-Glu-D-Lys tetrapeptide in which both lysine 
residues are substituted with a HSG-moiety via their ε-aminogroup: 7,10-tetra-
azacyclododecane-N,N’,N’’,N’’’-tetraacetic acid (DOTA)-D-Tyr-D-Lys(HSG)-D-
Glu-D-Lys(HSG)-NH2. IMP288 was labelled with 
111In (Covidien, Petten, The 
Netherlands) at a specific activity of 36 MBq/nmol and with 177Lu (IDB Holland 
BV, Baarle Nassau, The Netherlands) at a specific activity of 321 MBq/nmol, under 
strict metal-free conditions. After adding 100 MBq 111In to 4 µg (2.8 nmol) IMP288 
or 900 MBq 177Lu to 4 µg (2.8 nmol) IMP288 dissolved in 0.1 M 2-(N-morpholino)
ethanesulfonic acid (MES) buffer, pH 5.5, the mixture was incubated for 20 min at 
95 oC in a heating block. Subsequently, 10 µL 50 mM ethylenediaminetetraacetic 
acid (EDTA) was added to complex any unbound 111In or 177Lu. Radiochemical 
purity of the radiolabelled IMP288 preparations was determined by RP-HPLC as 
described previously (5). In all experiments, the radiochemical purity of radiolabelled 
IMP288 exceeded 95%. 
Mice received TF2 and IMP288 intravenously in 0.2-0.3 mL phosphate-buffered 
saline (PBS), 0.5% bovine serum albumin (BSA).
Animal experiments
All studies were approved by the institutional Animal Welfare Committee of the 
Radboud University Medical Centre Nijmegen, and conducted in accordance 
with their guidelines (revised Dutch Act on Animal Experimentation, 1997).  The 
experiments were performed in female nude BALB/c mice (6-8 weeks old) weighing 
20 to 25 g. Mice were acclimated to laboratory conditions for at least one week 
before experimental use and were housed under non-sterile standard conditions 
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in filter-topped cages with free access to animal chow and water. Tumour growth 
was induced by an intraperitoneal (i.p.) injection of 0.5 mL of a suspension of 106 
LS174T cells, a CEA-expressing human colon carcinoma cell line (CCL-188; 
passage 7; American Type Culture Collection), resulting in tumour nodules (1-3 
mm) in the peritoneal cavity after 2-4 weeks (17). 
Biodistribution and imaging studies
To investigate whether 111In-IMP288 could be used as a surrogate for 177Lu -IMP288 
with pretargeted immuno-SPECT, the biodistribution of 111In-IMP288 and 177Lu 
-IMP288 was determined by micro-SPECT and by counting of dissected tumours. 
Two groups of five nude mice with i.p. tumours and one group of three mice without 
tumours (negative control) were injected intravenously with 5.0 nmol TF2 (0.2 mL). 
Sixteen hours later, 0.28 nmol IMP288 (0.2 mL) was administered intravenously. 
One group received 111In-labelled IMP288 (10 MBq), and the other group received 
177Lu-labelled IMP288 (90 MBq). One hour after injection of the radiolabelled 
peptide, mice were euthanized by CO2/O2 asphyxiation. The control group of mice 
without any tumour received the same dose of TF2 and 111In-IMP288. Before 
imaging, the total-body activity of each mouse was measured in a dose calibrator. A 
blood sample (50-100 µL) was drawn by cardiac puncture. Mice were imaged using 
an USPECT-II/CT scanner (MILabs, Utrecht, The Netherlands) with the 1.0-mm 
diameter pinhole rat collimator tube. The animals were placed in a supine position. 
SPECT scans were acquired for 60 min, followed by CT scans for anatomical 
reference (65 kV, 612µA, exposure time 240 msec). 
After imaging, mice were dissected and the abdomen was systematically and 
meticulously examined for the presence of tumours. The location of each lesion 
was documented, and individually weighed, size measured, and the radioactivity 
detected in a gamma counter. The other organs of interest were weighed and counted 
in a gamma counter with standards prepared from the injected products, using 
appropriate energy windows for the radionuclide of interest. The percentage of the 
injected dose per gram tissue (%ID/g) was calculated. 
Image analysis
Scans were reconstructed with MILabs reconstruction software, using an ordered-
subset expectation maximization algorithm, with a voxel size of 0.375 mm. Images 
were analyzed with the Inveon Research Workplace software (version 2.2; Siemens 
Preclinical Solutions). Images were scored for the presence, number and localization 
of intraperitoneal tumours. 
To estimate the absolute tumour uptake (% ID) from the images, calibration factors 
for 111In and 177Lu were determined; whole-body activity as measured in the scans 
was correlated to the activity measured in the animals measured in the dose calibrator. 
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VOIs were drawn around the tumour lesions. A VOI in the lower left abdomen 
(large intestines) was used as background activity. The activity concentrations in 
the tumours derived from the images were compared with the tumour uptake as 
measured in the gamma counter, assuming a tissue density of 1.0 g/mL. 
PRIT study
The design of the PRIT study is summarized in Figure 1. Three groups of ten 
mice were inoculated i.p. with LS174T tumour cells. Two weeks after tumour cell 
inoculation, mice were given 5.0 nmol TF2 followed 16 h later with 60 MBq 177Lu-
IMP288 (previously determined to be the maximal tolerated dose). The two control 
groups received PBS or 60 MBq 177Lu-IMP288 without pretargeting of TF2 on the 
same day that the treatment group received radiolabelled IMP288. 
One hour after the PRIT group received the 177Lu-IMP288, a baseline immuno-
SPECT scan was acquired. The control groups were scanned after a diagnostic injec-
tion of 111In-labelled IMP288 pretargeted with TF2, one day after therapy (Figure 1). 
Follow-up scans were acquired in all remaining animals of all groups at 14 and 45 
days after therapy, after a diagnostic injection of 111In-labelled IMP288 pretargeted 
with TF2. Animals were scanned under general anesthesia (isoflurane and O2). The 
same imaging acquisition protocol, reconstruction, and calibration were used as in 
the biodistribution and imaging study. The scans were analyzed by drawing VOIs 
around tumour lesions, calculating the fraction administered dose, and by comparing 
the measurements of the same lesions in the follow-up scan and in the baseline scan, 
tumour growth of each tumour lesion was monitored. 
Animals were observed daily by independent, experienced biotechnicians. When 
the humane endpoint was reached (failure to eat/drink and losing ≥15% of body 
weight in 1 or 2 days, or losing ≥20% of their starting weight, or in the case of 
tumour progression/abdominal distention or visual hemorrhagic ascites), mice were 
euthanized by CO2/O2  asphyxiation. All remaining animals were euthanized 120 
days after therapy. 
Statistical analysis
Biodistribution, SPECT and survival data were statistically analyzed using the 
software GraphPad Prism version 5.00 for Windows (GraphPad Software, San Diego 
USA). Means and standard deviations were used to describe continuous data, unless 
stated otherwise. Comparisons were analyzed using a non-parametric, two-tailed 
Mann Whitney test. Correlations were determined with the Pearson’s correlation 
test. Survival was described with median survival times and survival curves were 
compared using the Log-rank test. The level of significance was set at p<0.05. 
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Results
Biodistribution and imaging study
Mice did not show clinical signs of discomfort or change in body weight for up 
to three weeks after inoculation of the LS174T tumour cells. Nevertheless, upon 
macroscopic inspection of their abdomen, multiple solid tumours were found, 
predominantly located at the rectovesical pouch, mesentery, subhepatic, -splenic 
and -phrenic spaces. Median number of tumour lesions per animal was 5 (range 
0-9). Three-dimensional caliper measurements revealed that the median diameter 
of the tumour lesions was 5 mm (range 1-16 mm), corresponding with a median 
weight of 22 mg (range 0.6 to 840 mg). Two out of 10 mice did not develop any 
macroscopically visible tumours. 
The biodistribution of 111In-IMP288 and 177Lu-IMP288 1 h p.i. in the mice that were 
pretargeted with TF2 was identical (Figure 2). Uptake of 111In-IMP288 and 177Lu-
IMP288 in the tumour lesions was similar (6.9 ± 2.7 % ID/g vs 7.1 ± 2.7 %ID/g, 
respectively, Mann-Whitney, p>0.05). Likewise, blood concentrations at 1 h p.i. were 
the same (0.17± 0.13 %ID/g vs 0.16 ± 0.08 %ID/g, respectively, Mann-Whitney, 
p>0.05). At 1 h p.i., the ratios of uptake in the tumour to that in the other organs were 
31.0 ± 30.8 (blood), 66.2 ± 23.4 (intestine), 3.7 ± 2.4 (kidney), and 27.4 ± 20.5 (liver) 
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Figure 1: Treatment schedule for the three different therapy groups and the timing of the baseline 
and follow-up SPECT studies. 
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for 111In-IMP288 and 34.6 ± 11.4 (blood), 58.0 ± 18.0 (intestine), 4.2 ± 0.3 (kidney), 
and 40.4 ± 49.1 (liver) for 177Lu-IMP288, respectively. Normal tissue biodistribution 
of 111In-IMP288 in the non-tumour-bearing mice was not significantly different from 
that of the tumour-bearing animals (data not shown), indicating that the presence of 
the intraperitoneally growing tumours did not affect clearance of the peptide from the 
normal tissues. 
Image analysis
Clear and specific targeting of the tumour lesions was seen in SPECT images that 
were acquired one hour after injection of 111In- and 177Lu-IMP288. A typical example 
of an immuno-SPECT image of a tumour-bearing mouse is shown in Figure 3A. 
The corresponding photographs show all the tumours that were dissected from the 
abdomen of this animal. Each lesion was clearly visualized in the SPECT images. An 
example of a SPECT image of a non-tumour-bearing mouse is shown in Figure 3B, 
showing renal uptake and only very low accretion in the other normal organs. 
Normal tissue uptake was low in the majority of the tumour- and non-tumour-
bearing mice. In some mice, low uptake in spleen (3/15), uterus and ovaries (2/15), 
and intestines (2/15) was seen, which could easily be discriminated from tumour 
lesions by their activity concentration, shape and location. 
Figure 2: Biodistribution of 0.25 nmol 
111In- or 177Lu-IMP288, following pretar-
geting with 6.0 nmol 125I-TF2 (interval 
16 h), 1 h after i.v. injection, in BALB/c 
nude mice with Intraperitoneal, CEA-
expressing LS174T tumours. 
Values are given as means ± standard 
deviations (n=5). 
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Using the lower left abdomen as background region, tumour-to-background ratios 
were very high: 30 ± 12, and did not differ between the groups that received the 111In- 
or 177Lu-labelled peptide (33 ± 15 vs 27 ± 9, Mann-Whitney, p>0.05). All lesions ≥ 2 
mm in diameter (≥ 4 mg) were detected as separate lesions with immuno-SPECT. 
Tumour uptake, as determined by immuno-SPECT and ex-vivo counting, showed 
a good correlation (Pearson’s r = 0.99, p<0.05; Figure 4). Furthermore, the absolute 
values (%ID) of both methods showed good agreement, with a mean difference of 
only 13 ± 38% (Bland-Altman analysis). In all tumours ≥ 22 mg (=median tumour 
weight), the difference between the two measurements was <25%. In smaller 
tumours, the uptake measured with immuno-SPECT was less reliable, where uptake 
measured by SPECT in 40% of the lesions was > 25% different.
Pretargeted radioimmunotherapy studies 
In two animals in the PBS group and in three animals in the PRIT group the 
baseline or follow-up scans did not disclose any tumours. These animals did not show 
any tumours at dissection 120 days after tumour inoculation. In the majority of the 
Figure 3: 3D-volume rendering of pretargeted immuno-SPECT/CT images of a tumour-bearing mouse 
(A) and a non-tumour-bearing mouse (B). The animals were imaged one hour after 111In-IMP288 in-
jection. Corresponding digital pictures are shown, that were made during dissection to localize and 
measure individual tumours. All dissected tumours (T1-4) are very clearly distinguishable on the pre-
targeted immuno-SPECT/CT images, with low normal tissue uptake.
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animals, micro-SPECT scans directly after therapy revealed multiple tumour lesions 
per animal: the median number of visualized tumours per animal was 4 (range 1- 10). 
One mouse in the PBS group had to be euthanized before the first follow-up scan (14 
days p.i.), because of excessive tumour growth. 
Tumour growth was monitored with immuno-SPECT after therapy by measuring 
the fraction of the injected dose 111In- and 177Lu-IMP288 for each lesion, drawing 
VOIs around the tumours in the baseline and in the follow-up scan.  Figure 5 shows 
a typical example of an animal of the control group that received non-pretargeted 
177Lu-IMP288. Tumour activity concentrations were similar in both scans, but the 
fraction of the injected dose per lesion was 10-fold higher in the follow-up scan on 
day 14 (Figure 5A and 5B). The excessive tumour growth that was prospectively 
monitored by imaging was confirmed when the animal had to be euthanized due to 
abdominal distension and ascites, nine days after the follow-up scan. Dissection of 
this animal revealed 2.0 gram of tumour tissue (Figure 5C).  
PRIT resulted in a significant delay in tumour growth, demonstrated in the 
follow-up scans 14 days after therapy. Tumour uptake calculated as fraction of the 
administered dose increased 13- to 16-fold in the non-pretargeted group and the 
PBS group, respectively (mean 1289% (SEM 154%) and 1584% (SEM 167%), 
respectively), while in the PRIT group a 5-fold increase (535% (SEM 118%)) in 
tumour growth was observed 14 days after therapy (Mann Whitney, p<0.05) (Figure 
6). At time of the second follow-up scan (45 days after therapy), only 1-3 mice per 
group were still alive. 
Delayed tumour growth due to PRIT resulted in a median survival of 50 days (95% 
Figure 4: Correlation between tumour 
uptake measured in the pretargeted 
immuno-SPECT images (y-axis) and 
by ex vivo biodistribution (x-axis) 
(Spearman’s rho = 0.99, p<0.05). 
Values are given for individual tumour 
lesions. Dotted line is linear fitted 
trend-line. 
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Figure 5: 3D-volume rendering of pretargeted immuno-SPECT/CT images of a mouse that was 
treated with not-pretargeted 177Lu-IMP288 at the time of therapy (A) and the follow-up scan at 14 
days after therapy (B), which shows a 10-fold increase in tumour size in this animal. Corresponding 
digital pictures (C) were made when the animal had to be euthanized nine days after the follow-up 
scan, showing the multiple tumours (total weight: 2-g) that were dissected from the abdomen, with the 
arrows indicating one of the tumours in the images and pictures.
Figure 6. Difference in tumour 
growth between the therapy 
groups (TF2 and 177Lu-IMP288, 
not-pretargeted 177Lu-IMP288, or 
PBS), measured in the pretargeted 
immuno-SPECT images at time of 
therapy and follow-up scan made 14 
days after therapy, and calculated as 
% increase of fraction administered 
dose. Values are given as means ± 
SEM of all individual tumours per 
therapy group. 
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CI: 41-59 days), while the mice in the non-pretargeted group and the PBS group 
had a median survival of 22 and 19 days, respectively (95% CI: 15-29 and 9-29 days, 
respectively) (Figure 7). Kaplan-Meier survival analysis showed that overall survival 
curve of the groups treated with PRIT was significantly better than the overall 
survival of the group with non-pretargeted peptide (p<0.05). All animals in the PBS 
and non-pretargeted group had to be euthanized due to tumour progression; animals 
presented either with abdominal distension or with ascites. In the treated animals 
that had to be euthanized in the same period (<4 weeks after therapy), the main 
reason for euthanization was loss of body weight, while at dissection they had a low 
total tumour weight (9-fold lower than in the control animals).  
Two animals in the PBS group and three in the PRIT group survived for more than 
120 days after therapy. None of these animals had tumours visible in the scans or at 
dissection (134 days after tumour inoculation). As a result, Kaplan-Meier survival 
analysis of those two curves did not show significant differences. 
Discussion
The present study shows that pretargeted immuno-SPECT is an excellent 
imaging method for monitoring the therapeutic effect of PRIT or, for that matter, 
monitoring any form of therapy. The biodistribution showed that the 111In-labelled 
peptide is a reliable surrogate for the 177Lu-labelled peptide. Pretargeted immuno-
SPECT with TF2 and 111In- or 177Lu-IMP288 showed rapid and selective tumour 
targeting with very high tumour-to-background contrast as early as one hour after 
injection, which led to the detection of tumours as small as 2 mm. The activity in 
the tumour lesions as measured with SPECT correlated well with uptake measured 
Figure 7:  Kaplan-Meier survival 
curves for tumour-bearing mice 
that received pretargeted 177Lu-
IMP288, 177Lu-IMP288 alone, or 
untreated (PBS). PRIT resulted 
in a median survival of 50 days 
(95% CI: 41-59 days), while 
the mice in the non-pretargeted 
group and the PBS group had a 
median survival of 22 and 19 days, 
respectively (95% CI: 15-29 and 
9-29 days, respectively).
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with ex vivo biodistribution. In a previous study, we showed that successive 
administrations of PRIT within a three-day interval resulted in similar uptake 
in the tumours (5). Therefore, images acquired after diagnostic or therapeutic 
administrations of PRIT can be compared quantitatively. Furthermore, tumour size 
could be derived accurately from the activity uptake (%ID) measured with SPECT, 
as in small tumour lesions the uptake (%ID/g) is relatively independent of tumor 
size. This allowed monitoring of tumour growth. The delayed tumour growth due 
to PRIT corresponded to the prolonged survival in the treated group. Hence, this 
report shows the feasibility and additional value of imaging to monitor the efficacy 
of with the same pretargeting agents, TF2 and radiolabelled IMP288. 
The orthotopic LS174T human colon carcinoma model for peritoneal disease had 
been characterized previously (17).  This animal model is more relevant than the 
widely used models of subcutaneously growing tumours to investigate the sensitivity 
of an imaging method, because background activity levels can be better appreciated. 
Furthermore, it is also more clinically relevant to monitor therapy effects.
We radiolabelled IMP288 with 111In for pretargeted immuno-SPECT, because 
111In is used as a validated surrogate for 177Lu, as it has the same in vivo behavior. 
Both radionuclides are residualizing radiometals. Therefore, predictive dosimetry 
can be performed with 111In-data to estimate the radiation dose to the tumour. For 
calculation of absorbed doses, imaging during several days is required to determine 
the residence time of the radiolabell in the tissues. It would have been very interesting 
to estimate tumour and normal organ doses. However, for dosimetry multiple scans 
(≥ 3) are required within 7 days after injection, to calculate the area-under-the-curve 
for tumour/organ uptake. Multiple sessions of general anaesthesia within several days 
would have negatively affected the condition of the mice, which would have affected 
the toxicity and survival data. Therefore, we decided to acquire one SPECT scan 
1 h after injection, and not to perform dosimetry in this animal study. In patients 
multiple scans can easily be acquired to estimate the radiaiton dose to the tumour 
lesions and to the dose limiting tissues. 
The half-life of 111In perfectly matches the biological half-life of the radiolabelled 
peptide. Former studies showed pretargeted immuno-PET and -SPECT with 
radionuclides, such as 68Ga, 18F, 124I, and Tc99m (7, 12-14), but these methods cannot 
be used for dosimetric calculations for therapy. The half-life of  68Ga (68 min) is not 
matched with the therapeutic radionuclide. Using 99mTc for dosimetry on immuno-
SPECT images is not feasible either, because 99mTc clears more rapidly from the 
(tumour) cells after binding and internalization, in contrast to (residualizing) 
radiometals like 111In and 177Lu. 
The established valuable combination of imaging and therapy, designated as 
theranostics, could be a useful strategy in the clinical practice of PRIT. The 
therapeutic efficacy of PRIT with TF2 and 177Lu-IMP288 was demonstrated 
previously in mice with subcutaneous LS174T xenografts (5). Furthermore, several 
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clinical studies with bsMAb and 111In-labelled haptens for pretargeted immuno-
SPECT showed high sensitivity (18-21).  In patients, immuno-SPECT can be 
used to guide individual treatment, since this imaging modality can be repeated 
at multiple time points. In a pre-therapy diagnostic cycle, tumour targeting can be 
demonstrated in an imaging cycle with 111In-labelled peptide, and dosimetric analysis 
of multiple pre-therapy diagnostic scans can be used to adjust activity doses for 
subsequent therapy cycles. Furthermore, images can be acquired directly after therapy 
to observe the distribution of therapeutic injections and calculate their absorbed 
doses. In the follow-up period after therapy, the effect on disease progression can be 
evaluated by implementing a diagnostic cycle. 
In our institution, a phase I clinical study of pretargeted radioimmunotherapy 
with TF2 and 177Lu-IMP288 in colorectal cancer patients is ongoing, using pre-
therapy diagnostic cycles with TF2 and 111In-IMP288 for dosimetric calculations. 
Preliminary results of this clinical study for theranostics in PRIT are encouraging. 
This and other future studies will provide more information on dose-response rates, 
the predictive value of dosimetry, and how it can contribute to more personalized 
medicine, or  theranostics, in targeted radionuclide therapy. 
In conclusion, the present study showed that pretargeted immuno-SPECT with TF2 
and 111In- or 177Lu-IMP288 can be used to predict and confirm tumour uptake and 
monitor the therapeutic effect of pretargeted radioimmunotherapy.
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Development of an imaging-guided CEA-pretargeted 
radionuclide treatment of advanced colorectal cancer: 
First clinical results
84
. Abstract 
Background
Radiolabelled antibody targeting of cancer is limited by slow blood clearance. 
Pretargeting a non-radiolabelled bispecific antibody (bsMAb) followed by a rapidly 
clearing radiolabelled hapten-peptide improves tumour localization. The primary goals 
of this first pretargeting study in patients with the anti-CEACAM5 x anti-hapten 
(HSG) bsMAb, TF2, and the radiolabelled hapten-peptide IMP288, were to assess 
various pretargeting conditions and safety in patients with metastatic colorectal cancer 
(CRC).
Methods
Different dose schedules were studied in 4 cohorts of 5 patients (n=21): [1] shorten-
ing the interval between the bsMAb and peptide administration (5 days vs 1 day), [2] 
escalating the TF2 dose (from 75 to 150 mg), and [3] reducing the peptide dose (from 
100 to 25 µg). After confirmation of tumour targeting by 111In-IMP288, patients were 
treated with a bsMAb/177Lu-IMP288 cycle. Toxicity was evaluated according to the 
NCI-CTC v3.0.  
Results
Rapid and selective tumour targeting of the radiolabelled peptide was visualized within 
1 h with high tumour-to-tissue ratios (>20 at 24 h). Improved tumour targeting was 
achieved with a 1-day interval between the administration of the bsMAb and the pep-
tide, with the 25 μg peptide dose. High 177Lu-IMP288 doses were well tolerated with 
some manageable TF2 infusion reactions, and transient grades 3-4 thrombocytopenia 
in 10% of the patients who received 177Lu-IMP288. 
Conclusions
This phase I radioimmunotherapy study demonstrates for the first time that pretarget-
ing with TF2 anti-CEACAM5 bsMAb and radiolabelled IMP288 in patients with 
CEA-expressing CRC is feasible and safe. Tumours are specifically and rapidly tar-
geted with limited toxicity. 
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Introduction 
Tumour targeting with monoclonal antibodies is an attractive modality for targeted 
cancer therapy. For metastatic colorectal cancer (CRC), the anti-VEGF antibody, 
bevacizumab, and the anti-EGFR antibodies, cetuximab or panitumumab, can im-
prove patient outcome when combined with chemotherapy (1-7). Antibodies con-
jugated with cytotoxic agents, such as drugs or radionuclides, have shown promising 
results in several indications (8, 9). Radiolabelled antibodies have proven effective 
in patients with non-Hodgkin lymphoma (10-13), but, successful adaptation of ra-
dioimmunotherapy (RIT) in solid tumours has been challenging (9). An 131I-labelled 
anti-CEACAM5 IgG given as an adjuvant therapy to CRC patients after liver me-
tastasectomy improved survival compared to a comparable contemporaneous group 
of patients without adjuvant therapy (5-year survival, 42.1% vs. 15.8% for RIT vs. 
controls, respectively) (14, 15). In addition, a recent clinical trial reporting objective 
responses and disease control in patients with advanced pancreatic cancer using a frac-
tionated 90Y-labelled antibody to a pancreatic mucin, PAM4, combined with low-dose 
gemcitabine is another example of promising results in solid tumours (16). 
However, the slow blood clearance and delayed tumour uptake of directly radiola-
belled antibodies causes continuous radiation exposure to the bone marrow and a 
high background signal, limiting therapeutic dosage. Pretargeting techniques were 
developed to overcome these deficiencies. With pretargeting, a non-radiolabelled hu-
manized bispecific monoclonal antibody (bsMAb) is administered first intravenously. 
After the bsMAb localizes in the tumour and clears from the circulation, a smaller, 
radiolabelled molecule is given that is rapidly trapped in the tumour by the bsMAb, 
while the remainder clears from the blood very quickly, being eliminated via the 
kidneys. Pretargeting reduces the radiation exposure to radiosensitive normal tissues, 
such as bone marrow, as well as other tissues (17-21).  
In this first-in-man phase I study, we investigated pretargeting with the bsMAb, TF2, 
for targeting CRC. TF2 is a humanized bsMAb construct, which was produced using 
the Dock-and-Lock-technology, resulting in a stable humanized tri-Fab molecule (22). 
It contains two Fab fragments with high affinity for CEACAM5 and another Fab-
fragment with affinity for the hapten, histamine-succinyl-glycine (HSG). IMP288 is a 
peptide that contains two HSG moieties to preserve affinity enhancement properties 
for improved hapten-peptide uptake and retention (23, 24), and another moiety ca-
pable of stable binding of a radionuclide, in this case 1,4,7,10-tetraazacyclododecane-
1,4,7,10-tetraacetic acid (DOTA) for binding 90Y, 177Lu, and 111In (21, 22, 25, 26). The 
rapid and specific targeting of human tumour xenografts and the therapeutic potential 
of pretargeted, radiolabelled peptides were reported previously (27-29). The primary 
goals of this trial were to evaluate several pretargeting conditions and to assess the 
safety of pretargeting of CRC with TF2 and radiolabelled IMP288 in patients with 
metastatic CRC for whom no standard treatment was available. 
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Methods
Patient eligibility
Patients ≥18 years of age with progressive metastatic CRC for whom no standard treat-
ment was available were enrolled. Eligibility criteria included Eastern Cooperative 
Oncology Group (ECOG) performance status ≤1, no previous therapies within 
four weeks (bevacizumab within eight weeks), and adequate hematopoiesis (absolute 
neutrophil count ≥1.5 x 109/L; platelets ≥150 x 109/L without transfusion during 
the previous month; hemoglobin ≥5.6 mmol/L), hepatic (total bilirubin < 2 x ULN 
(upper limit of normal), aspartate transaminase (AST)/alanine transaminase (ALT) 
< 3 x ULN) and renal function (serum creatinine < 2 x ULN, Cockcroft clearance > 
50 ml/min). Evidence of CEA expression by tissue staining or elevated plasma levels 
was required. Patients with a life expectancy of less than six months, known brain 
metastases, or cardiac disease with New York Heart Association classification of III or 
IV, were excluded.  
The regional ethics review committee (CMO Regio Arnhem-Nijmegen) approved the 
study protocol and amendments. Written informed consent was obtained from all 
patients. The study was registered at ClinicalTrials.gov (NCT00860860) (30).
Study design
Preclinical studies showed successful pretargeting of tumours depends on three fac-
tors: the bsMAb dose, the interval between the administration of the antibody and 
the radiolabelled peptide, and the peptide dose (28, 31). Tumour targeting of the 
radiolabelled hapten-peptide will be affected by [i] the amount bsMAb in the tumour, 
which should be high enough to capture as much of the radiolabelled peptide as pos-
sible and [ii] the bsMAb concentration in the circulation, which should be as low 
as possible at the time of the radiolabelled hapten-peptide administration to prevent 
complex formation with the bsMAb in the circulation. This would increase the cir-
culatory half-life of the radiolabelled hapten-peptide, in turn increasing the radiation 
exposure to normal tissues. Additionally, animal studies showed that increasing the 
specific activity of the radiolabelled hapten-peptide increases the fraction that targets 
the tumour (28). On the other hand, a low peptide dose may result in a higher frac-
tion of the radiolabelled hapten-peptide dose being captured by circulating bsMAb, 
which again would result in more immune complex formation of the bsMAb and the 
radiolabelled peptide in the circulation.
To evaluate these interacting and interdependent factors relevant for tumour targeting, 
we studied four dose schedules in cohorts of five patients (Table 1). First, the effect of 
the interval between bsMAb and hapten-peptide was studied: cohort 1 received TF2 
(75 mg) and IMP288 (100 µg) with a 5-day interval, while cohort 2 received the same 
doses with a 1-day interval. Bispecific antibody dose also was examined, with cohort 3 
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receiving a higher bsMAb dose (150 mg TF2, 1-day interval, 100 µg IMP288). 
Finally, in cohort 4, a lower IMP288 dose was tested (75 mg TF2, 25 µg IMP288, 
1-day interval), with 25 µg being the minimal amount IMP288 required to prepare 
the maximum amount of administered 177Lu activity (7.4 GBq) per treatment. 
Patients first underwent a diagnostic imaging cycle with TF2 and 111In-IMP288. If 
tumour targeting of the radiolabelled peptide was observed, patients received a thera-
peutic cycle of TF2 and 177Lu-IMP288 the following week (Figure 1). By quantitatively 
analyzing the scintigraphic images and blood pharmacokinetics after the 111In-IMP288 
injection, the radiation doses to the kidneys and bone marrow were estimated. The 
safe starting therapeutic dose of 177Lu-IMP288 was calculated for each patient, being 
set at a threshold not to exceed a cumulative dose of 1.25 Gy to the bone marrow and 
15 Gy to the kidneys. This total dose was then split into four equally divided treatment 
cycles. Since the nadir of hematologic toxicity after RIT with directly radiolabelled 
IgG is reached at five to six weeks, each fraction was to be administered every 8 weeks. 
The maximum allowed dose per cycle was 7.4 GBq, but for safety reasons in the first 
cohort it was limited to 3.7 GBq.  
Table 1: Study design. Four cohorts were evaluated, using two TF2 dose levels, adjusting the interval 
between bsMAb and peptide administrations from five to one day, and reducing the peptide dose 
(i.e., increasing specific activity).
Cohort TF2 dose Interval IMP288 dose
(n=5) (mg) (days)  (µg)
1 75 5 100
2 75 1 100
3 150 1 100
4 75 1 25
Figure 1: Treatment schedule. 
Patients received an imaging cycle with TF2 and 111In-IMP288 to determine the pharmacokinetics 
and radiation doses to the red bone marrow and kidneys. A safe, cumulative 177Lu-activity dose was 
estimated, and one-fourth of this amount was administered in the first therapy cycle. 
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Investigational drugs
The clinical-grade trivalent anti-CEACAM5 x anti-HSG bsMAb construct, TF2, 
and the IMP288 hapten-peptide were provided by Immunomedics (Morris Plains, 
NJ, USA). TF2 (157 kD) is a recombinantly-engineered trivalent bsMAb composed 
of a humanized anti-histamine-succinyl-glycine (HSG) Fab-fragment derived from 
the 679 anti-HSG monoclonal antibody, and two humanized anti-CEACAM5 Fab-
fragments derived from the humanized anti-CEACAM5 MAb, hMN-14 or labetu-
zumab (Figure 2). The binding characteristics of the bispecific antibody, TF2, were 
described previously (22). IMP288 (molecular weight 1456 Da) was synthesized as 
described by McBride et al. (25).  
Preparation and administration of investigational drugs 
The TF2 dose (75 or 150 mg) was diluted in 60 mL 0.9% w/v NaCl, and administered 
by i.v. infusion over a period of two hours. Starting from the second patient of cohort 
2, all patients received a prophylactic dose of clemastine (2 mg) i.v. 15 min prior to 
start of the second TF2 infusion. Dexamethasone, 10 mg i.v., was added subsequently 
as an additional prophylactic medication prior to the second TF2 infusion, starting 
from the last patient of cohort 3.
Figure 2: Schematic representation of the pretargeting agents. The trivalent bispecific antibody con-
struct, TF2, binds divalently to CEACAM5, the tumour-associated antigen that is overexpressed on 
the cell surface of colorectal tumour cells. After the bsMAb has localized the tumour and cleared from 
the blood, a radiolabelled divalent peptide is given, substituted with the hapten, histamine-succinyl-
glycine (HSG). This is rapidly targeted to the tumours and bound by high affinity to the anti-HSG 
Fab-fragment of the bsMAb. Due to its bivalency, it has the ability to crosslink the bsMAbs at the 
tumour surface, forming a stable complex. The peptide is conjugated with the chelator, DOTA, which 
can be labelled with a wide variety of radionuclides. 
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IMP288 was labelled with either 111In, a gamma-emitter, or with 177Lu, a beta-emit-
ter, for imaging or radionuclide therapy, respectively, as described previously (28). 
IMP288 was labelled with 111In (Covidien, Petten, The Netherlands) at a specific 
activity of 1.9 or 7.4 MBq/µg (2.6 or 10.6 MBq/nmol), or with 177Lu (IDB Holland 
BV, Baarle Nassau, The Netherlands, and Isotope Technologies Garching GmbH, 
Garching, Germany) at a specific activity of 37-296 MBq/µg (53-423 MBq/nmol). 
Radiochemical purity (RCP) of the radiolabelled IMP288 was determined using 
instant thin-layer chromatography and reverse-phase high-performance liquid chro-
matography, as described elsewhere (28). RCP always exceeded 95%. 111 In-IMP288 
was dissolved in 10 mL 0.9% NaCl and 177Lu- IMP288 in 20 mL 0.9% NaCl, and 
administered by an i.v. 2-min bolus.
Pharmacokinetic assessment
TF2 pharmacokinetics were assessed by collecting serum samples after the end of the 
infusion, and then at 0.5, 1, 2, 4, 6, and 24 h, with the last sample shortly before the 
IMP288 injection. Serum concentrations were determined with a sandwich enzyme-
linked immunosorbent assay (ELISA) assay, using plates coated with an HSG-
conjugated peptide coupled to bovine serum albumin. After incubating with dilutions 
of the patient’s serum samples, binding was revealed with an anti-idiotype antibody 
directed against the humanized anti-CEACAM5 portion of TF2 (32).
111In- and 177Lu-IMP288 pharmacokinetics were determined by collecting blood sam-
ples 2 minutes, 0.5, 1, 2, 4, 24, and 72 h after injection, and counting in a gamma coun-
ter (Wizard, Pharmacia-LKB, Sweden) with standards prepared from the injected 
products, using appropriate energy windows for the radionuclide used. The percent-
age of the injected dose per gram tissue (% ID/g) in the blood samples was calculated. 
Scintigraphic assessment and analysis
Anterior and posterior whole-body planar scintigraphic images (Siemens Ecam, 
Hoffmann Estates, IL, USA) were acquired at four time points: within 5 min after the 
injection of IMP288 and before voiding, 3 h after injection, after voiding, and at 24 h 
and 72 h. SPECT scans were also taken of regions with ≥1 tumours in the field of view. 
Radioactivity concentrations were determined by drawing regions of interest at tu-
mours and  muscle in the psoas region in the SPECTs that were acquired 24 h after 
injection of 111In-IMP288. Tumour-to-normal tissue ratios were calculated. 
Patient evaluation and follow-up
Toxicity assessment, hematology, clinical biochemistry, physical examination and 
ECOG performance status were performed at baseline and weekly during follow-
up, up to eight weeks after therapy. As a measure for radiation-related renal toxicity, 
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weekly urinary analysis was performed to monitor proteinuria. Patients were moni-
tored closely during and up to five hours after the TF2 infusions and IMP288 injec-
tions. Toxicity was evaluated according to the NCI-Common Terminology Criteria 
for Adverse Events v3.0 (NCI-CTCAE). 
In the present study, no conventional one-drug dose escalation was performed, but four 
different dose schedules were studied cohort-wise, in which every cohort would ideally 
lead to a higher tumour-to-normal tissue ratio. Significant toxicities were defined as 
possibly or probably related to TF2 or 111In-IMP288/177Lu-IMP288 administration: 
any ≥ grade 3 non-hematologic toxicity, with the exception of nausea, vomiting, and 
diarrhea; thrombocytes <10 x 109/L, grade 4 thrombocytopenia lasting for ≥4 weeks, 
≥ grade 3 thrombocytopenia with bleeding; grade 4 neutropenia lasting for ≥7 days, or 
≥ grade 3 neutropenia with fever of at least 38.5 °C)
.To evaluate tumour response, a baseline FDG-PET/CT (contrast-enhanced) scan was 
performed within two weeks before therapy, and eight weeks after the 177Lu-IMP288 
injection. Responses were evaluated according to the Response Evaluation Criteria in 
Solid Tumours (RECIST). 
Human-anti-human-antibody (HAHA) measurements
HAHA serum concentrations were determined before each TF2 infusion and up to 
eight weeks after the last TF2 infusion. HAHA directed against TF2 was measured 
with a sandwich ELISA assay (Immunomedics, Inc.), adding serial dilution of patient 
serum TF2-coated plates and then probing with a TF2-horseradish peroxidase con-
jugate, with binding revealed using o-phenylenediamine dihydrochloride (Sigma). 
Concentration (ng/mL) of anti-TF2 responses were based on a standard curve using a 
rat anti-idiotype antibody specific to hMN-14, WI2 (Immunomedics, Inc.) (33). The 
detection limit of the assay is 50 ng/mL, and therefore a positive HAHA was arbitrar-
ily set as any value above this level.
Statistical analysis
Statistical analysis was performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego, CA). Means and standard deviations were used to 
describe continuous data, unless stated otherwise. Statistical analysis was performed 
to compare tumour targeting between the different cohorts, using a non-parametric, 
two-tailed Mann Whitney test. The level of significance was set at p<0.05.
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Results 
Twenty-one patients were enrolled in the study between July 2009 and July 2011. 
One patient (patient 1) was withdrawn from the study prior to the 177Lu-IMP288 
treatment. He experienced a hypoxia grade 2 during the second TF2 infusion, and 
therefore the TF2 infusion was discontinued and not restarted. 
Baseline characteristics of the patients who received TF2 111In/177Lu-IMP288 cycles 
are reported in Table 2. Most patients had large tumour loads, with many large lesions 
in multiple organs. The low estimated red marrow doses allowed administration of 
high activity doses of 177Lu-IMP288: four, two and three patients in cohort 2, 3 and 4, 
respectively, received 7.4 GBq. The other patients in cohort 2-4 received 177Lu activity 
doses ranging from 2.5 to 6.2 GBq to avoid exceeding one-fourth of the maximum 
cumulative red marrow absorbed dose (1.25 Gy). 
Table 2: Patient characteristics. Baseline patient characteristics are described: age, sex, site of primary 
tumour, sites of diseases at study entry, prior treatments, baseline CEA serum levels, and administered 
177Lu activity dose.
Age: Median (range) 63 (39-76) years
Male/Female: 12/9
Performance score: 01
8 (38%)
13 (62%)
Site of primary tumour: ColonRectum
15 (71%)
6 (29%)
Site of disease:
Primary
Liver
Lungs
Lymph nodes
Bones
Soft tissue
Peritoneum
8 (38%)
18 (86%)
14 (67%)
8 (38%)
4 (19%)
3 (14%)
1 (5%)
Tumour load: Baseline sum diameters of all lesions per patient, median (range) 27.6 (9.2-111.0) cm
Prior treatment:
Surgery
Chemotherapy 
Bevacizumab 
Anti-EGFR therapy
External radiotherapy
17 (81%)
21 (100%)
17 (81%)
7 (33%)
6 (29%)
CEA plasma level: Baseline, median (range) 120 (12-2200) µg/L
Administered 177Lu dose: Median (range) 5.6 (2.5-7.4) GBq
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Pharmacokinetic assessment
TF2 cleared rapidly from the blood, with 86% of the injected dose (ID) eliminated at 
6 h after completion of the infusion, and 99% ID after 24 h in all cohorts. TF2 clear-
ance was not related to the CEA plasma level at the time of infusion (data not shown). 
TF2 concentrations in the blood increased proportionally to the dose administered 
(Figure 3A). Radiolabelled IMP288 cleared the fastest in cohort 1, where the initial 
interval was 5 days (Figure 3B). Because TF2 cleared quickly, the interval was then 
adjusted to 1 day for cohort 2. In this cohort, the clearance rate of IMP288 slowed, 
but it was still very rapid. As conditions changed so the amount of TF2 in the serum 
at the time IMP288 was injected increased or the peptide dose was reduced, IMP288 
clearance gradually slowed. For example, IMP288 concentrations were twice as high 
in cohort 3 that received 150 mg vs 75 mg in cohort 2 (Figure 3B). Overall, most of 
the administered activity cleared from the blood at 24 h post-injection in all cohorts 
(100%, 99%, 98% and 98% ID, cohorts 1-4, respectively). 
Scintigraphic imaging analysis
In all patients, the 111In-IMP288 images showed clear and selective targeting of known 
tumour lesions, and thus all patients were eligible to receive a therapeutic TF2/177Lu-
IMP288 cycle. Primary tumours, as well as metastases in the lungs, liver, lymph nodes, 
Figure 3: Pharmacokinetics. 
A: Serum clearance of TF2 in cohorts 1, 2 and 4, 
that received 75 mg of TF2, and in cohort 3, 150 
mg (mean ± standard deviation; n=5 per cohort), 
determined by ELISA. TF2 cleared rapidly from 
the serum, with cohort 3 having twice as high 
serum concentrations.  
B: 111In-IMP288 blood clearance per cohort 
(mean ± standard deviation; n=5 per cohort). 
In all cohorts >98% ID was cleared at 24 h p.i, 
although peptide blood clearance was somewhat 
delayed by shortening the interval between 
bsMAb and peptide administration, and to a 
lesser extent due to a higher antibody and a lower 
peptide doses.  
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and soft tissue, were visualized as early as one hour after injection. Representative 
images of patient 21 in cohort 4 are shown in Figure 4.
The pre-therapy 111In-scans and the post-therapy 177Lu-scans were congruent, with 
somewhat stronger signal in the 177Lu-scans due to higher levels of activity given. After 
one day, most activity had cleared from the normal tissues, with very limited reten-
tion in the kidneys, resulting in high tumour-to-normal tissue ratios (>20:1 at 24 h) 
in all cohorts (Table 3). Although highly variable between patients, liver metastases 
had higher uptake of the radiolabelled peptide than lung metastases. Shortening the 
interval between the bsMAb and peptide administration in cohort 2 resulted in sig-
nificantly higher absolute activity concentrations in all tumours compared to cohort 
1 (p=0.0079) and in higher tumour-to-normal tissue ratios (p=0.046). Furthermore, 
all patients in cohort 4 with liver metastases (n=3) appeared to have higher tumour 
activity concentrations (6.3, 9.7, 23.6 %ID/kg) and tumour-to-normal tissue ratios 
(33, 38, 84) than the patients in cohort 2 with liver metastases (n=4) (tumour activity 
concentrations: 3.2, 4.7, 5.4, 5.7 %ID/kg, and tumour-to-normal tissue ratios: 20, 24, 
27, 29 at 24 h p.i.), indicating improved tumour targeting at the lower peptide dose 
(25 µg vs. 100 µg) due to a higher specific activity, although this was not statistically 
different (p=0.057). 
Overall, the combined effect of shortening the interval and reducing the peptide dose 
resulted in significantly higher tumour activity concentrations and tumour-to-normal 
tissue ratios (cohort 1 vs cohort 4, p=0.0079 and p=0.035, respectively). 
Figure 4: Scintigraphic images. The 
SPECT/CT image (A), acquired 24 h 
after injection of 111In-IMP288 (185 
MBq, 25 µg), pretargeted with 75 mg 
TF2 (1-day interval), in a 38-year-old 
patient (cohort 4), shows very clear 
tumour targeting of an axillary lymph 
node metastasis, with very low con-
centrations of radioactivity in normal 
tissues. Corresponding contrast-
enhanced CT scan and a fused FDG-
PET/CT scan are shown (B and 
C, respectively). The primary colon 
tumour (50 cm ab ano) also shows 
highly specific tumour targeting in 
the SPECT-image (D), confirmed by 
the CT-scan and FDG-PET/CT (E 
and F, respectively), with non-specific 
FDG-uptake in the ascending colon. 
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Table 3: Tumour targeting. Pretargeting conditions were varied in four cohorts: adjusting the interval 
between the bsMAb and peptide administration, escalating the bsMAb dose, and reducing the peptide 
dose. This resulted in improved tumour activity concentrations and tumour-to-normal tissue ratios. 
The uptake of 111In-IMP288 in tumour and muscle tissue was determined with SPECT 24 h post injec-
tion of the radiolabelled peptide. 
bsMAb dose / interval / peptide dose
75 mg /5 days/
100 µg
Cohort 1
75 mg/1 day/
100 µg
Cohort 2
150 mg/1 day/
100 µg
Cohort 3
75 mg/1 day/
25 µg
Cohort 4
Activity 
concentration
(%ID/kg, mean 
(range))
Tumour 1.4 (0.8-2.0)
4.4 
(2.7-5.7)
5.9 
(3.1-10.4)
9.4 
(2.2-23.6)
Normal 
tissue
0.068 
(0.042-0.093) 0.18 (0.12-0.24) 0.19 (0.08-0.31)
0.21 
(0.10-0.28)
Tumour-to-normal tissue 
ratio (mean (range))
20 
(17-22)
24 
(20-29)
32 
(22-43)
40 
(21-84)
Efficacy, safety, and tolerability
According to RECIST based on the FDG-PET/contrast-enhanced CT scans prior 
to therapy and eight weeks after therapy, all patients showed progressive disease eight 
weeks after the first therapy cycle with TF2 and 177Lu-IMP288, and therefore none of 
the patients was eligible for a second treatment cycle. Thus, only the safety and toler-
ability of just one of the four planned treatment cycles can be reported.
Toxicity was limited in most patients, with no apparent differences between cohorts 
(Table 4). The majority of the patients with liver metastases had liver enzyme elevations 
prior to drug administrations (e.g., 43% had grade 3-4 GGT elevation at baseline). 
In many patients, GGT increased during the trial, which was deemed to be disease-
related, since all patients had progression of liver metastases, as seen on the FDG-PET/
CT-scans. 
Seven patients (33%) experienced a mild grade 2 infusion reaction during onset of 
their second TF2 infusion. They experienced flushes, dyspnea, chest pain, back pain 
or coughing. They did not have cutaneous, cardiovascular or gastrointestinal signs or 
symptoms. All reactions were easily controlled by interrupting the infusion, and with 
intravenous administration of clemastine (2 mg) and dexamethasone (10 mg). Except 
for patient 1, with grade 2 hypoxia, the infusion was restarted in all patients at a slower 
infusion rate for fifteen minutes, and could be completed at the planned infusion rate 
without any recurrence of symptoms. After three infusion reactions (from patient 8), 
prophylactic intravenous clemastin (2 mg) was added prior to the patients’ second 
TF2 infusion. After patient 15, prophylactic intravenous dexamethasone (10 mg) was 
added. With this regimen, infusion reactions occurred in 2 out of 5 patients, but the 
TF2 infusions could be completed as described above. 
Following the single therapy cycle, bone marrow toxicity was mild in most patients 
(grade 1-2 in 30% of patients). More severe hematological toxicity (grade 3-4 throm-
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Table 4: Toxicity. All grade 2, 3 and 4 toxicities, as well related and unrelated, scored according to the 
Common Terminology Criteria for Adverse Events (CTCAE v3.0) (n=21).
Grade Total of 
grade 2-42 3 4
Category Adverse event (No. of patients) (%)
Blood/ bone marrow Platelets 1 1 1 14
Lymphocytopenia 1 2 14
Haemoglobin 2 1 19
Syndromes Acute infusion-related reaction 7 33
Constitutional symptoms Fatigue 4 19
Fever 1 5
Sweating 1 5
Pulmonary Dyspnoea 1 1 10
Gastrointestinal Nausea 1 5
Anorexia 4 19
Diarrhea 2 10
Pain Abdomen 3 1 19
Tumour 1 5
Neurology Somnolence 2 10
Pyramidal tract dysfunction° 1 5
Infection Biliary tree‡ 1 5
Musculoskeletal Arthritis (non-septic) 1 5
Renal Urinary frequency 1 5
Metabolic/ laboratory AST 4 1 24
ALT 2 1 14
Bilirubin 1 2 14
Albumin, serum-low 6 29
Alkaline phosphatase 5 5 48
GGT 4 7 3 67
‡liver metastases with biliary tract obstruction confirmed by PET/CT
° brain metastases confirmed by MRI-cerebrum
bocytopenia, and grade 3 lymphopenia) occurred in two patients (10%; 1 in cohort 
2 and 1 in cohort 3), with the nadir 5-6 weeks after 177Lu-administration. Recovery 
was rapid, returning to grade ≤ 1 level at 7-8 weeks after therapy. None of these pa-
tients had complications or needed intervention. None of the patients showed signs or 
symptoms of renal toxicity. 
One patient (in cohort 3) was admitted to the hospital due to severe dyspnea four 
days after the administration of 177Lu-IMP288. High-resolution CT of the chest was 
unremarkable, lung function tests were normal and blood or sputum cultures, as well 
as viral serology, remained negative. The event was reported as probably related to the 
drug administrations, either TF2 or 177Lu-IMP288, and thus recorded as a Suspected 
Unexpected Serious Adverse Reaction (SUSAR). The patient’s dyspnea decreased, 
but remained at a lower level, which might have been related to rapid progression of 
disease, since this patient had progressive lung metastases.
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HAHA measurements
Human antibodies against TF2 >50 ng/mL were detected in 11 of 21 patients, starting 
one week after the second TF2 infusion, gradually increasing in the follow-up period 
of eight weeks, indicating that the humanized trivalent bsMAb TF2 was immunogenic 
in ~50% of the patients upon repeated injection, but without clinical sequelae. Titers 
varied widely amongst patients (mean 386 ng/mL, range 53-800 ng/mL). 
Discussion 
Pretargeting was developed to improve the efficacy of tumour targeting with mono-
clonal antibodies. Recently, Kraeber-Bodéré et al. reported the efficacy of pretargeted 
RIT with an 131I-di-DTPA-peptide (1.9-5.5 GBq) in patients with medullary thyroid 
carcinoma (34, 35). In this study, a survival benefit was observed compared with a 
historical untreated control group (36). 
The pretargeting system described in this study, with the new bsMAb construct TF2, 
and HSG-substituted hapten-peptide IMP288 (21, 22), can utilized various chelating 
moieties (DTPA, NOTA, DOTA, N3S-chelates, etc.) and radionuclides for PET or 
SPECT imaging (25, 26, 37, 38), or for pretargeted radioimmunotherapy (27, 28, 31, 
39). Accurate dosing of the bsMAb and the radiolabelled peptide was demonstrated to 
be crucial for improved tumour targeting (28). 
In this first-in-man pretargeting study with the new bsMAb construct, TF2, and 
111In/177Lu-labelled IMP288, we showed that pretargeting provided rapid and ef-
ficient targeting of CEACAM5-expressing tumours with low normal tissue activity 
levels. The main objective of this study was to evaluate several dosing conditions to 
assess their effect on biodistribution and tumour targeting. The starting interval of 5 
days was selected based on blood clearance studies of TF2 in rabbits (32), but when it 
became clear that TF2 cleared rapidly in humans, the interval was reduced to one day. 
The blood clearance of TF2 was much faster than that of similarly-sized IgG molecules 
(157 kD and 150 kD, respectively), which could be explained by the fact that TF2 
lacks a CH2 domain (40, 41). In nude mouse-human tumour xenograft models, an in-
terval of 16-24 h was favorable, also because the bsMAb cleared very quickly from the 
blood (>99% cleared) (28, 31). In addition, TF2’s peak tumour uptake occurred ~6 
h postinjection in these models, decreasing gradually over time, and thus minimizing 
the interval allowed the hapten-peptide to be captured when more bsMAb is present 
in the tumour. 
Overall, we found that reducing the interval and the IMP288 dose improved tumour 
targeting. Higher bsMAb doses also can enhance tumour uptake of the radiolabelled 
peptide (26, 28). While we did not observe improved tumour uptake by increasing the 
TF2 dose 2-fold at a 1-day interval (75 to 150 mg), these patients all had considerable 
tumour burden, suggesting that higher bsMAb doses could further improve tumour 
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targeting. However, we did observe a trend toward increased tumour uptake using 
75 mg of TF2 when the IMP288 dose was lowered from 100 to 25 μg. Thus, further 
studies need to be performed before we are able to select the most appropriate set of 
conditions for pretargeting. 
This study demonstrated the safety of pretargeted RIT with TF2 at doses of 177Lu-
IMP288 ranging from 3.7 to 7.4 GBq. The immune responses, i.e., symptomatic 
infusion reactions and the formation of anti-TF2 antibodies that were observed fol-
lowing the administration of the 2nd TF2 infusion, were unexpected, since TF2 is a 
humanized antibody construct. Murine precursors of anti-CEA bsMAb frequently 
showed immune responses (42, 43), which was reduced by using chimeric and human-
ized antibodies (34). However, the mild, grade 2, acute infusion related reactions that 
were observed in one-third of the patients at the second infusion of the humanized 
bsMAb did not preclude continuation of treatment, except for one patient who had 
extensive pulmonary metastases. We expect that reducing the infusion rate and the 
pre-administration of prophylactic antihistamines and corticosteroids will reduce this 
adverse event, and this is advised for future studies. The human antibodies against 
TF2 detected in half the patients were not yet present at the time of the second TF2 
infusion (i.e., therapy cycle), so the TF2 pharmacokinetics was not affected. No cor-
relation was found between the infusion reactions and the anti-TF2 antibody titers 
that started to increase only one week after the second TF2 infusion. In future studies, 
treatment should be more condensed to prevent accelerated TF2 blood clearance due 
to the presence of HAHA in part of the patients at subsequent cycles.
Overall, hematological toxicity of pretargeted RIT was minimal, particularly when 
considering that these patients all had received several lines of chemotherapy and up 
to 7.4 GBq of 177Lu-IMP288. The two patients with transient grade > 3 bone marrow 
toxicity had a somewhat higher bone marrow absorbed dose after administration 
of 177Lu-IMP288. However, the radiation dose to the red marrow was very low, and 
therefore we suspect that underlying patient specific factors (age, performance status, 
effects of prior treatments on hematopoietic stem cell reserve) likely contributed to 
these toxicities. The dosimetric analysis has been reported previously (44), and will be 
described in more detail elsewhere. 
The only unexpected major toxicity was severe dyspnea in one patient four days post 
TF2 infusion. However, several other reasons might have contributed to the adverse 
event, such as very high CEA serum levels, pre-existing pulmonary atelectases, and 
prior cardiac history. Since we could not identify the exact pathophysiological or im-
munological mechanism, it is unclear if this single case represents a truly drug-related 
adverse event. Of note, this patient appeared to have rapidly progressive disease and 
died within 14 weeks after study entry.
This trial was designed with the intent to administer high levels of 177Lu-IMP288 using 
dosimetry to predict a safe dose. The radiolabelled hapten-peptide used in pretargeting 
can be viewed in a similar manner as radiolabelled peptides that are being used to treat 
neuroendocrine tumours (45) where dosimetry has gained a role in predicting the 
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potential for renal toxicity. In our protocol design, we determined the total therapeu-
tic dose based on a pre-therapy imaging study and using conservative estimates of the 
red marrow and renal doses that should not be exceeded. However, for further safety, 
this total dose was to be split into four fractions, allowing sufficient time between 
each treatment to monitor toxicity, primarily hematological toxicity. Unfortunately 
our study population had extensive metastatic disease, and thus all patients showed 
disease progression at first evaluation eight weeks after the first therapy cycle with TF2 
and 177Lu-IMP288, before subsequently planned additional treatment cycles could be 
given. 
Previously, RIT has been shown to be more effective in small-volume disease (14, 15, 
46), but the phase I character of the current study prevented us from studying pre-
targeted RIT in a less heavily pretreated patient population. Recent clinical data in 
patients with advanced pancreatic cancer suggest a fractionated dosing regimen using 
a 90Y-labelled antibody given in combination with low-dose (radiosensitizing) gemcit-
abine can provide disease control and even objective responses (16), giving credibility 
to pursuing 90Y instead of 177Lu for patients with advanced metastatic disease. Indeed 
90Y’s physical half-life (64 h) matches the residence time in the tumour better than 
177Lu-IMP288 (6.7 days).  
In conclusion, the results of this phase I clinical study with pretargeted RIT showed 
rapid and specific tumour targeting of the anti-CEA x anti-HSG bsMAb TF2 and the 
111In- or 177Lu-hapten-peptide IMP288. Tumour targeting was improved by shorten-
ing the interval between the bsMAb and peptide administration, and by lowering the 
peptide dose. The procedure is safe, and infusion reactions are transient and manage-
able with appropriate medication and lowering the infusion rate. Further studies will 
be needed to determine if improvements in targeting can be obtained by additional 
adjustments to the pretargeting conditions, as well as revising the protocol design to 
allow full treatment to be given over a shorter duration, most likely retaining a frac-
tionated regimen. Continuation with 177Lu-IMP288 would be warranted for patients 
with less bulky disease. 
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Predictive patient-specific dosimetry and individualized 
dosing of pretargeted radioimmunotherapy in patients 
with advanced colorectal cancer 
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. Abstract  
Background 
Pretargeted radioimmunotherapy (PRIT) with bispecific monoclonal antibodies 
(bsMAb) and a radiolabelled peptide reduces the radiation dose to normal tissues. 
Here, we report the accuracy of an  111In-labelled pre-therapy scout dose for person-
alized dosing and prediction of radiation dose of  PRIT with the anti-CEA x anti-
hapten bsMAb TF2 and the 177Lu-labelled hapten-peptide IMP288 in a phase I study 
in metastatic colorectal cancer (CRC) patients.
Methods
Twenty patients received an imaging cycle with TF2 and 111In-IMP288 followed by 
PRIT with TF2 and 177Lu-IMP288.  Absorbed doses to bone marrow and kidneys 
were predicted based on blood samples and scintigrams acquired after 111In-IMP288 
injection, and individual 177Lu activity doses were determined. Different dose sched-
ules were studied varying the interval between the bsMAb and peptide administration 
(5 days vs 1 day), increasing the bsMAb dose (75 mg vs 150 mg), and lowering the 
peptide dose (100 µg vs 25 µg). Toxicity was scored using NCI-CTC v3.0. 
Results
TF2 and 111In/177Lu-IMP288 clearance was highly variable, although a strong correla-
tion was observed between peptide residence times and individual TF2 blood con-
centrations at the time of peptide injection (Spearman’s ρ=0.94, p<0.0001). Specific 
tumour uptake of 111In/177Lu-IMP288 was visualized as early as 1 h p.i. High tumour-
to-background ratios were observed. Therapeutic 177Lu activity doses resulted in low 
absorbed radiation doses to normal tissues (red bone marrow <0.5 Gy, kidneys <3 
Gy). In the majority of patients who received 7.4 GBq or adjusted 177Lu activity doses, 
red marrow doses did not exceed 0.31 Gy as predicted (11/13, 85%). Simulated 177Lu-
IMP288 absorbed red marrow doses were in good agreement with the actual meas-
ured doses (mean difference -0.0026 mGy/MBq, SD 0.028 mGy/MBq). Hematologic 
toxicity was mild in most patients, with only two cases (10%) of grade 3-4 thrombocy-
topenia. Most importantly, platelet toxicity correlated significantly with red marrow 
dose (Spearman’s ρ=0.58, p=0.008). 
Conclusion
These results show that individual high therapeutic activity doses in pretargeted radio-
immunotherapy in patients with CEA-expressing CRC could be safely administered, 
by predicting the radiation dose to red marrow and kidneys based on dosimetric analy-
sis of a scout dose of TF2 and 111In-IMP288. 
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Introduction
Selective targeting of tumour-associated antigens with radiolabelled antibodies can be 
used for diagnosis and therapy of cancer. In combining imaging with treatment, a con-
cept designated as theranostics, targeted radionuclide therapies can be personalized. 
For example, diagnostic information obtained from pre-therapeutic PET or SPECT, 
can be used to predict the efficacy of the treatment. In this way, patients can be selected 
for radioimmunotherapy by estimating the probability of tumour control versus the 
risk of toxicity of a planned treatment. This analysis might also aid in identifying the 
most appropriate radionuclide (90Y, 177Lu, 213Bi, etc.) to deliver the therapeutic dose 
to ensure that the patient receives a unique dose optimized for their  radionuclide 
therapy (90Y, 177Lu, 213Bi, etc.). Finally, imaging data could potentially  assess therapeu-
tic response.  The feasibility of this approach has been demonstrated in patients with 
neuroendocrine tumours using 111In- or 68Ga-labelled somastatin analogues for diag-
nosis and the same peptides labelled with 177Lu- or 90Y for radionuclide therapy (1, 2). 
In this clinical study, the potential of theranostics for combined pretargeted radio-
immunoscintigraphy and –therapy was evaluated. Pretargeting is a strategy that was 
developed to improve the imaging and therapeutic characteristics of directly radiola-
belled monoclonal antibodies. Radiolabelled antibodies require several days to effec-
tively target tumours, due to the slow pharmacokinetics and slow accretion of intact 
antibodies in tumours. This slow uptake and clearance rate delays the optimal timing 
for imaging and increases bone marrow toxicity for therapy. Pretargeting techniques 
achieve rapid accretion of the radionuclide in the tumour in combination with rapid 
blood clearance by first administering a non-radiolabelled bispecific monoclonal anti-
body (bsMAb). After the bsMAb has localized in the tumour and has cleared from the 
circulation, a small radiolabelled hapten-peptide is administered, which extravasates 
quickly, is trapped in the tumour by the bsMAb, while the remainder is cleared rap-
idly from the blood and is excreted via the kidneys. The retention of the radiolabelled 
hapten-peptide in the tumour is increased when the peptide carries two haptens (3). In 
our pretargeting system, peptides are substituted with the hapten histamine-succinyl-
glycine (HSG), creating a flexible pretargeting system. The peptide can be conjugated 
with various chelating moieties (DTPA, NOTA, DOTA, N3S-chelates, etc.), so that it 
can be radiolabelled with a variety of radionuclides, such as 111In and 99mTc for SPECT 
imaging (4), 18F and 68Ga for PET imaging (5-8), or 131I, 90Y, and 177Lu for pretargeted 
radioimmunotherapy (PRIT) (9, 10). 
Until recently, bsMAbs used in pretargeting were either produced by chemical conju-
gation of Fab-fragments or via the quadroma technology. A novel method, the Dock-
and-Lock (DNL) technology, has been developed to produce humanized trivalent Fab 
bsMAb constructs with two binding Fab’s for the tumour-associated antigen and one 
for the hapten on the radiolabelled peptide (11, 12).  Using DNL constructs to target 
B-cell lymphoma and pancreatic cancer, significant therapeutic responses have been 
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reported in animals with subcutaneous xenografts, using di-HSG-peptide (9, 13).  
In preclinical studies, we applied the fully humanized anti-CEA x anti-HSG DNL-
constructed bsMAb (TF2), and a HSG-substituted hapten-peptide (IMP288) in a 
nude mouse model for peritoneal presentation of human cancer (11, 14). These studies 
showed the enhanced sensitivity and specificity of this pretargeting system compared 
to FDG-PET (8, 15, 16). Furthermore, we showed that PRIT with TF2 and 177Lu-
peptide can be an effective treatment modality of colon cancer with limited toxicity 
(9). Pretargeted immuno-SPECT images acquired after diagnostic 111In-IMP288 or 
therapeutic 177Lu-IMP288 administrations could be quantitatively compared and 
could be used to predict and monitor the therapeutic effect of PRIT. Therefore, to 
administer an appropriate activity dose, an individual pre-therapy diagnostic cycle 
with the same compounds can be used to estimate absorbed doses (17, 18).
Here, we report the accuracy of an 111In-labelled pre-therapy scout dose for personal-
ized dosing and prediction of radiation dose of  PRIT with TF2 and the 177Lu-IMP288 
in a first-in-man study in metastatic colorectal cancer (CRC) patients.
Methods
Patients
Inclusion criteria included age ≥18 years, histologically or serologically confirmed 
CEA-expressing advanced colorectal malignancies refractory to conventional treat-
ment or without any standard therapeutic option, Eastern Cooperative Oncology 
Group performance status ≤1, no chemotherapy, external beam radiation, immu-
notherapy or prior angiogenesis inhibitors within four weeks prior to study entry, 
adequate hematopoietic function (absolute neutrophil count ≥1.5 x 109/L; platelets 
≥150 x 109/L without transfusion during the previous month; hemoglobin ≥5.6 
mmol/L), hepatic (total bilirubin <2x upper limit of normal (ULN), aspartate 
transaminase (AST)/alanine transaminase (ALT) <3 x ULN) and renal function 
(serum creatinine <2 x ULN, Cockcroft clearance >50 ml/min). Exclusion criteria 
were a life expectancy ≤ 6 months, known brain metastases, cardiac disease with New 
York Heart Association classification of III-IV, or any other illness significantly affect-
ing the patients’ clinical condition. The protocol (ClinicalTrials.gov NCT00860860) 
was approved by the Institutional Review Board of the Radboud University Nijmegen 
Medical Centre. Written confirmed consent was obtained from all patients prior to 
any study-related procedures.
Preparation and administration of investigational drugs 
The pretargeting agents were provided by Immunomedics (Morris Plains, NJ, USA). 
The clinical grade trivalent anti-CEACAM5 x anti-HSG bsMAb construct, TF2, is 
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an engineered trivalent bsMAb composed of a humanized anti-histamine-succinyl-
glycine (HSG) Fab-fragment derived from the 679 anti-HSG monoclonal antibody, 
and two humanized anti-CEACAM5 Fab-fragments derived from the humanized 
anti-CEACAM5 MAb, hMN-14 antibody or labetuzumab. Their binding character-
istics have been described previously (12). 
The IMP288 peptide (molecular weight 157 kDa) was synthesized and purified as 
described by McBride et al. (7). IMP288 was labelled with 111In (Covidien, Petten, 
The Netherlands) at a specific activity of 185 MBq/100 or 25 µg (2.6 or 10.6 MBq/
nmol) and with 177Lu (IDB Holland BV, Baarle Nassau, The Netherlands, and Isotope 
Technologies Garching GmbH, Garching, Germany) at a specific activity of 3.7-7.4 
GBq/100 or 25 µg (53-423 MBq/nmol). Radiochemical purity of the radiolabelled 
IMP288 preparations was determined using instant thin-layer chromatography and 
reversed phase high-performance liquid chromatography as described previously (9), 
and always exceeded 95%. 
The TF2 dose (75 or 150 mg) was dissolved in 60 mL 0.9% w/v NaCl, and was admin-
istered by intravenous infusion over a period of two hours. Patients received a prophy-
lactic gift of clemastine (2 mg) and dexamethason 10 mg intravenously 15 minutes 
prior to start of their second TF2 infusion to suppress infusion-related symptoms. 111 
In-IMP288 was dissolved in 10 mL 0.9% NaCl and 177Lu- IMP288 in 20 mL 0.9% 
NaCl, and administered by an intravenous bolus. 
Study design
Each therapy cycle patients received a pre-therapy cycle with TF2 and  111In-labelled 
IMP288. The 111In-IMP288 data were used to simulate absorbed doses of 177Lu-IMP288 
and to calculate a safe individual 177Lu activity dose (see paragraph: Dosimetric calcula-
tions and individual 177Lu doses). Subsequently, the therapy cycle was administered, 
with the same interval, bsMAb and IMP288 dose (Figure 1A). Four different dosing 
schedules were studied in cohorts of five patients per cohort (Figure 1B), varying the 
interval between the bsMAb and peptide administration (cohort 1: 5 days interval vs 
next cohorts: 1 day). TF2 dose was varied  (cohort 3: 150 mg TF2, vs other cohorts: 
75 mg).  Furthermore, two IMP288 doses were studied (cohort 4: 25 µg IMP288 vs 
other cohorts: 100 µg). 25 µg IMP288 was the minimal peptide dose required to label 
the peptide with the maximum 177Lu dose, 7.4 GBq. 
Pharmacokinetics 
Serum samples were collected at the end of the TF2 infusion, 30 min, 1 h, 2 h, 4 h, 6 
h, and 24 h after infusion, the last sample being taken shortly before peptide infusion. 
TF2 concentrations were determined with a sandwich enzyme-linked immuno sorb-
ent assay (ELISA) assay, using HSG-conjugated peptide as a catcher and anti-MN-14 
anti-idiotype antibody as a tracer antibody, developed at Immunomedics to determine 
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TF2 concentrations, as described previously (19). 
Blood samples were collected 2 min after 111In- and 177Lu-IMP288 injection, 30 min, 
1 h, 2 h, 4 h, 24 h and 72 h p.i., and counted in a gamma counter (Wizard, Pharmacia-
LKB, Sweden) with standards prepared from the injected products, using appropriate 
energy windows. The percentage of the injected dose per gram tissue (% ID/g) and 
blood residence time were calculated. 
Scintigraphy
Whole body planar scintigraphic images were acquired, directly followed by SPECT 
imaging  of kidneys and ≥ 1 tumour lesion in the same field of view, using a Siemens 
dual-head gamma camera (Ecam, Hoffmann Estates, IL), equipped with medium 
energy collimators. Symmetric 15% windows were used over both the 172 KeV and 
246 KeV energy peaks of 111In-scintigraphy, and over both 113 and 208 KeV for 
177Lu-scintigraphy. 
Scans were acquired within 15 min after the injection of IMP288 before voiding, 3 
h after injection after voiding, 24 h and 72 h after injection. If scintigraphic images 
showed adequate 111In-IMP288 accumulation in metastatic lesions, patients were eli-
gible for 177Lu-IMP288 therapy. 
Figure 1: Study design. A: Patients received an imaging cycle with TF2 and 111In-IMP288 to determine 
the pharmacokinetics and radiation doses to the red bone marrow and the kidneys. Based on the do-
simetric calculations a safe 177Lu-activity dose was estimated, which was administered in the therapy 
cycle one week later. B: Four cohorts in which different dose schedules of the pretargeting system were 
studied, varying the bsMAb dose, the interval between bsMAb dose, and the peptide dose.  
Cohort TF2 dose Interval IMP288 dose
(n=5) (mg) (days)  (µg)
1 75 5 100
2 75 1 100
3 150 1 100
4 75 1 25
A
B
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Dosimetric analysis and individual 177Lu doses 
111In-IMP288 data were used as surrogate to calculate predicted radiation dose of 
177Lu-IMP288, assuming identical pharmacokinetics and biodistribution of 111In-
IMP288 and 177Lu-IMP288. Simulation of the 111In scans and blood data for 177Lu 
and calculation of residence times were performed as described previously (18). In 
OLINDA, the dynamic bladder model was used, (bi-exponential model, bladder 
voiding at 3 h interval). 
The dose to the red bone marrow was calculated using two methods: (I) quantification 
of the radioactivity in an ROI over the cranium in the scintigraphic images (=im-
aging-based method), (II) based on the radioactivity concentrations in the blood as 
described by Shen et al (=blood-based method) (20). For the imaging method the 
residence time was divided by the fraction of the red marrow mass in the cranium to 
the mass in the total body, for which the default value 0.119 was taken from ICRP23’s 
Reference Man. For the blood method, a red marrow-to-blood activity concentration 
of 1 was applied, as was determined for 177Lu-peptide (21). 
As the red marrow and the kidneys were considered as the organs primarily at risk for 
radiation-induced toxicity, the simulated absorbed doses to these organs  were used to 
calculate a safe total activity dose of 177Lu that would guide no more than 1.25 Gy to 
the red marrow or no more than 15 Gy to the kidneys, as these thresholds are generally 
accepted to be below thresholds for radiation-induced toxicity (22, 23). For the red 
bone marrow, the radiation dose calculated with either the imaging or blood-based 
method was used, whichever was the highest. The calculated total 177Lu activity dose 
that could be administered safely was divided into four successive cycles, i.e. per cycle 
a quarter of the calculated total 177Lu activity dose would be administered. In the first 
cohort, the maximum total 177Lu activity dose per cycle was 3.7 GBq, even when dosi-
metric calculations would allow a higher 177Lu dose. In the next cohorts the maximum 
dose per cycle was 7.4 GBq.
Patient follow-up
Patients were closely monitored during and weekly up to eight weeks after therapy, 
with physical examination, clinical biochemistry, hematology, and toxicity assessment 
according to the Common Toxicity Criteria for Adverse Events (CTCAE v3.0). 
Significant toxicities were defined as: thrombocytes <10 x 109/L, grade 4 thrombocy-
topenia lasting for ≥4 weeks, grade 4 neutropenia for ≥7 days, ≥grade 3 thrombocyto-
penia with bleeding, ≥ grade 3 neutropenia with fever at least 38.5 °C, or any ≥ grade 
3 non-hematologic toxicity, with the exception of nausea, vomiting, and diarrhea. 
Therapeutic efficacy was evaluated by Response Evaluation Criteria in Solid Tumours 
(RECIST), comparing a baseline FDG-PET-CT scan performed within two weeks 
prior to start on study, and a FDG-PET-CT acquired eight weeks after 177Lu-IMP288 
injection.  
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Statistics
Statistical analysis was performed with GraphPad Prism software version 5.00 for 
Windows (San Diego USA), using two-tailed Mann Whitney test. Bonferonni correc-
tion was applied when multiple groups were compared, Spearman’s correlation tests 
were used for not normally distributed and categorical data, and Bland Altman plots 
were determined for agreement tests. The level of significance was set at p<0.05. 
Results 
The baseline patient characteristics are summarized in Table 1 for the patients that were 
treated with 177Lu-IMP288. Patient 1 had to be withdrawn and replaced for medical 
safety reasons. His second TF2 infusion had to be discontinued due to hypoxia grade 
2 as symptom of a grade 2 infusion reaction. Although this adverse event resolved 
rapidly, we decided not to restart the infusion. 
Pharmacokinetic assessment
Overall, TF2 showed fast blood clearance in all patients; >99% of the administered 
dose cleared in 24 h. A longer interval for antibody clearance (cohort 1: 5 days vs 
cohort 2: 1 day) resulted in even lower concentrations at the time of peptide injection 
(cohort 1: 5 days vs cohort 2: 1 day, p=0.01, Mann-Whitney) (Figure 2A). Patients 
that received a higher TF2 dose (cohort 3: 150 mg) showed a wide variation in an-
tibody blood concentrations compared to those that received the lower dose (cohort 
2 and 4: 75 mg)  at 24 h p.i  (range 0.077-1.2 µg/mL vs 0.16-0.59 µg/mL in cohort 
3 vs cohort 2 and 4 respectively). Similar variations in peptide blood residence time 
were observed for the patients that had the higher bsMAb dose (cohort 3: 1.5-7.5 h 
vs cohort 2: 2.0-5.5 h), as well for the patients that received the lower peptide dose 
(cohort 4: 1.7-9.3 h) (Figure 2B). The individual peptide blood residence times cor-
related strongly with the individual TF2 blood concentration at the time of peptide 
injection, as compared within the cohorts that received the same peptide dose (100 µg 
in cohort 1-3) (Spearman’s ρ=0.94, p<0.0001) (Figure 2C). 
Scintigraphic images
Tumour lesions were visualised as early as one hour after injection of the radiolabelled 
peptide in all patients, with 111In-scans  and 177Lu-scans being highly congruent. The 
whole body planar and SPECT images of one of the patients are shown in Figure 3, 
along with the FDG-PET images. 111In- and 177Lu-IMP288 cleared from the blood 
and renal system within 24 h, with very limited kidney or other normal tissue reten-
tion, resulting in very high tumour-to-background ratios.  
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Figure 2: TF2 and IMP288 blood pharmacokinetics. 
A: TF2 blood concentration at the moment of IMP288 injection (individual patients). 
B: 111In-IMP288 residence times of the four cohorts (individual patients). 
C: Correlation between TF2 and IMP288 blood pharmacokinetics. Individual TF2 blood concen-
tration at the moment of peptide injection plotted against the blood residence time of 111In-IMP288 
(Spearman r=0.94, P<0.0001), with linear regression line (solid line) and the 95% confidence interval. 
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Absorbed doses and individual 177Lu activity doses
Kidney uptake of the radiolabelled peptide was low and the predicted kidney absorbed 
doses (<0.50 mGy/MBq) were not limiting the maximum acitivity doses that could 
be administered, as in none of the patients four cycles of 7.4 GBq 177Lu would exceed 
the limit of 15 Gy radiation dose to the kidneys. The predicted radiation doses to the 
red bone marrow were relatively low, and showed some increase in subsequent cohorts 
(mean ± SD of blood-based method: 0.008 ± 0.003, 0.034 ± 0.011, 0.045 ± 0.028, 
and 0.060 ± 0.040 for cohort 1, 2, 3 and 4 respectively, Figure 4), although the only 
significant difference was between cohort 1 vs cohort 2-4 (p= 0.02, Mann-Whitney, 
with Bonferonni correction). Individual patients in cohort 2, 3 and 4 showed a wider 
variation in red marrow doses, which corresponded with the larger range measured in 
the individual peptide blood residence times within these cohorts. 
The low predicted red marrow doses allowed high therapeutic doses to be adminis-
tered, up to 7.4 GBq (Table 1). In several patients of cohort 2-4, the  177Lu activity 
Figure 3: Scintigraphic images. Scintigraphic images acquired after injection of 111In-IMP288 (185 
MBq, 100 µg), pretargeted with 150 mg TF2 (1-day interval), in a 52-year-old patient (cohort 3), with 
a primary colon tumour, liver, lymph nodes (mediastinum) and bone (lumbar vertebrae) metastases. 
A: Whole body planar anterior and poster images (10 min p.i., 3 h p.i., 24 h p.i., 72 h p.i.) with an 
aliquot of the injected dose was kept near the feet in all scans. B: corresponding FDG-PET. 
B: SPECT images of same patients, acquired directly after planar images (3D volume rendered, 1 h p.i., 
4 h p.i., 24 h p.i., 72 h p.i.). D: corresponding FDG-PET. 
The scintigraphic images show very clear tumour targeting and low concentrations of radioactivity in 
normal tissues. 
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doses were adjusted to keep the red marrow dose below 1.25 Gy in four successive 
cycles (0.31 Gy per treatment cycle), as defined in the per protocol. The results of two 
different methods that were used to estimatered marrow doses (blood- versus image-
based method) were in good agreement (mean difference: 0.0040 mGy/MBq, SD: 
0.017 mGy/MBq, Bland-Altman).  
Patient 20 and 21 were also allowed to receive 7.4 GBq, but due to lower labelling 
efficiency, they only received 5.6 GBq 177Lu. The radiolabelling of 7.4 GBq 177Lu to 25 
µg IMP288 had been successful in pre-study tests procedures and for patient 19. 
The red marrow doses that were measured after administration of 177Lu-IMP288, were 
in good agreement with the predicted absorbed doses. The Bland-Altman plot in 
Figure 5 shows a mean difference of -0.0026 mGy/MBq (SD: 0.014 mGy/MBq). As a 
consequence, the measured red marrow doses did not exceed the aimed 0.31 Gy in the 
majority of patients (11 out of 13 patients (85%); excluding cohort 1, patient 20 and 
21 from the analysis, as described above). 
Hematologic toxicity
Hematologic toxicity was limited in most patients (grade 1-2 in 30% of the patients). 
Only two patients (10%) had ≥ grade 3: patient 10 (cohort 2) and patient 16 (cohort 
3) had grade 3-4 thrombocytopenia, and grade 3 lymphopenia. The nadir was 5-6 
weeks after 177Lu-IMP288 administration, and both patients showed fast and com-
plete recovery at 7-8 weeks p.i., without any complications or need for intervention. 
Figure 4: Simulated 177Lu absorbed doses. The simulated 177Lu-IMP288 absorbed doses for kidneys (A), 
and red marrow (blood-based (B), image-based (C)) (individual patients per cohort). 
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Table 1: Baseline patient characteristics and individual 177Lu administered activity doses based on the 
individual dosimetric calculations of the 111In-imaging cycle.
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2 1 60 M Colon Liver, lungs, 
lymph nodes
Surgery, external radiotherapy, 
chemotherapy, immunotherapy
820 3.7
3 1 63 F Colon Liver Surgery, chemotherapy, 
immunotherapy
990 3.7
4 1 54 F Colon Liver, lungs Surgery, chemotherapy, 
immunotherapy
1600 3.7
5 1 68 F Rectum Liver, lungs, lymph 
nodes, bone
Surgery, external radiotherapy, 
chemotherapy, immunotherapy
13 3.7
6 1 61 M Colon Liver, lungs, 
lymph nodes
Chemotherapy, 
immunotherapy
79 3.7
7 2 63 F Rectum Peritoneum, 
soft tissue
Surgery, chemotherapy 140 6.2
8 2 63 M Rectum Rectum, liver, lungs External radiotherapy, 
chemotherapy, immunotherapy
12 7.4
9 2 72 M Rectum Rectum, liver Surgery, external radiotherapy, 
chemotherapy, immunotherapy
150 7.4
10 2 70 M Colon Liver Surgery, chemotherapy, 
immunotherapy
120 7.4
11 2 55 F Colon Liver Surgery, chemotherapy, 
immunotherapy
220 7.4
12 3 70 M Colon Liver, lungs, bone Surgery, chemotherapy, 
immunotherapy
2200 7.4
13 3 76 M Colon Colon, lungs, lymph 
nodes, bone
Chemotherapy, 
immunotherapy
280 7.4
14 3 52 F Colon Colon, liver, lungs, 
lymph nodes, 
bone, soft tissue
Chemotherapy, 
immunotherapy
85 4.0
15 3 58 M Colon Liver, lungs Surgery, chemotherapy, 
immunotherapy
16 5.9
16 3 76 M Colon Colon, liver, 
lymph nodes
Surgery, chemotherapy, 
immunotherapy
140 4.6
17 4 73 M Colon Lungs, liver Surgery, chemotherapy, 
immunotherapy
32 4.5
18 4 63 F Colon Colon, lungs, liver Surgery, chemotherapy, 
immunotherapy
81 2.5
19 4 66 F Rectum Rectum, lungs, liver, 
lymph nodes
Surgery, chemotherapy, 
immunotherapy
28 7.4
20 4 72 M Colon Lungs Surgery, chemotherapy, 
immunotherapy
60 5.6
21 4 39 F Colon Colon, liver, lymph 
nodes, soft tissue
Surgery, external radiotherapy, 
chemotherapy, immunotherapy
17 5.6
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Remarkably, those two patients has somewhat higher 177Lu absorbed doses than pre-
dicted by the imaging cycle (0.45 and 0.48 Gy for patient 10 and 16, respectively), 
while the red marrow dose of all other patients, did not exceed 0.31 Gy and only had 
grade 0-2 thrombocytopenia. The measured 177Lu-IMP288 absorbed doses correlated 
significantly with platelet toxicity (Spearman’s ρ=0.58, p=0.008) (Figure 6).
Therapeutic efficacy
At evaluation by FDG-PET/CT-scan eight weeks after the first therapy cycle with 
TF2 and 177Lu-IMP288, all patients still had progressive disease, therefore none of the 
patients could receive a next therapy cycle. 
Discussion 
Patient-specific treatment planning in radioimmunotherapy is an attractive strategy 
to reduce the risk of hematologic toxicity. In this study, we showed that individual-
ized dosing of PRIT with TF2 and 177Lu-IMP288 at fixed radiation dose thresholds, 
estimated using a pre-therapeutic scout dose of TF2 and 111In-IMP288 is feasible 
Figure 5: Agreement between predicted and measured 177Lu doses. Bland-Altman plot showing the dif-
ference between the measured minus predicted data plotted against their average. Dashed line is mean 
difference (-0.0026 mGy/MBq), dotted lines are 95% agreement limits (-0.031 and 0.026 mGy/MBq). 
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and safe in patients with progressive metastatic CRC. Individualized activity dosing 
seemed essential, as relatively large inter-patient variations were observed in TF2 and 
IMP288 pharmacokinetics. We were able to identify those patients that were at the 
lowest risk for hematologic toxicity and who were eligible to receive the maximum 
activity dose of 7.4 GBq. At the same time, in those patients in which the peptide 
blood and marrow residence time was somewhat slower in the pre-therapy cycle, the 
177Lu therapeutic activity doses could be reduced to prevent toxicity. As a consequence, 
red bone marrow radiation doses were low (<0.5 Gy). 
Most importantly, our data showed a correlation between red marrow doses and bone 
marrow toxicity. This observation is in accordance with the results of some previous 
clinical radioimmunotherapy studies (18, 24, 25), while various other studies reported 
a lack of  correlation between dosimetric estimations and severity of toxicity (26-30). 
The discrepancy between the lack of correlation of the other studies and the correla-
tion in this study might be due to differences in dose rate (31-33).
Our study showed some interesting features of the bsMAb and peptide pharmacokinetics.
First, in all patients, the blood clearance of TF2 was much faster than that of similarly 
sized IgG molecules (157 kD and 150 kD, respectively), which could be explained by 
the fact that TF2 lacks a CH2 domain, while this part of an antibody enables recycling 
via FcRn-receptors (34). Our findings are in line with observation that CH2 domain-
deleted IgG variants (121 kDa) clear much faster from the blood than intact IgG (35). 
Due to the fast blood clearance of TF2, the interval between TF2 and IMP288 ad-
ministrations could safely be shortened from five days to one day. However, the short 
Figure 6: Correlation between 177Lu absorbed doses and platelet toxicity. The measured 177Lu-IMP288 
absorbed doses (calculated with blood-based method) correlated significantly with platelet toxicity 
(Spearman r=0.58, P=0.008).
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residence time of TF2 in the blood reduces the tumour uptake, as large molecules like 
antibodies have several barriers to cross that limit their localization in tumours (36). 
Rapid blood clearance reduces the driving force of tumour accumulation. In pretarget-
ing, it would be preferable to have a bsMAb construct with a longer circulatory half-
life, like IgGs, as this would result in higher antibody-concentrations in the tumour. 
Secondly, our data suggest that the inter-patient variety in peptide blood residence 
time could be explained by individual variation in bsMAb clearance rates, and con-
sequently the bsMAb blood concentration at the time of peptide administration. If 
the concentration of circulating bsMAb is relatively high at the time the radiolabelled 
peptide is injected, a larger portion of the injected peptide dose will form an immune 
complex with the antibody in the circulation, which will enhance the residence time 
of the radiolabelled peptide in the blood (and thus will enhance the red marrow dose). 
These data are in accordance with the clinical results of the phase I study, where pa-
tients with CEA-expressing tumours received an anti-CEA x anti-DTPA bsMAb in 
combination with an 131I-di-DTPA-hapten (37). 
In our study, no clear patient-specific distinctions were found that could explain dif-
ferences in bsMAb clearance rates. Theoretically, the variation in TF2 blood clear-
ance could be influenced by differences in individual baseline plasma CEA levels, as 
antigen-antibody complexes could be formed in serum, but no such correlation was 
observed (data not shown). Furthermore, TF2 clearance could be affected by liver 
function, as the antibody is captured and degraded in the liver. However, in this study, 
none of the patients showed impairment of hepatic function.
In the four patient cohorts we studied the effects of three important pretargeting 
paramaters: (1) the interval between injection of the bsMAb and the peptide,  (2) 
the bsMAb dose, and (3) the peptide dose (9). First, we aimed to determine the 
minimal interval required for sufficient serum bsMab clearance, to maximize uptake 
of the bsMAb in the tumour. Secondly, tumour uptake of the radiolabelled peptide 
could be improved by administrating a higher antibody dose. We also demonstrated 
that tumour uptake of the radiolabelled peptide increased at lower peptide doses. It 
remains to be established whether these parameters could be optimized any further, 
because at some point the residence time of the radiolabelled peptide will be enhanced 
to such an extent that it will cause enhanced red marrow toxicity. 
In our dosimetric calculations, we used two different methods to estimate the red 
marrow dose. Using blood concentrations as surrogate for bone marrow concentra-
tions was permitted, because the pretargeting agents  do not bind to any blood, marrow, 
or bone component, and metastatic bone involvement is limited in CRC. For imaging 
quantification the cranium was used, because this region does not have overlapping 
organs. For example, the use of lumbar vertebrae is hindered by overlapping intestines 
(38). We showed that both dosimetry methods are feasible and reveal similar results. 
Hematological toxicity was limited in most patients, with only two patients who had 
transient grade 3-4 thrombocytopenia. Several mechanisms may explain these two 
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sporadic cases. First, they had slightly higher measured than predicted red marrow 
doses, which was not the case in the other patients, who had grade 0-2 hematologic 
toxicity. Furthermore, patient specific factors can contribute to the risk of hematologic 
toxicity due to (P)RIT, such as age, prior treatments such as radio- or chemotherapy, 
or extensive bone marrow involvement. Both patients with grade 3-4 thrombocyto-
penia were ≥70 years (median age of the other patients: 63 years). They did not have 
bone marrow metastases, and they had received similar lines and cycles chemotherapy 
compared to the other patients, and had a similar interval between this study and their 
last treatment compared to the other study patients. 
In this study, 177Lu was selected as a radionuclide for radioimmunotherapy as it has 
several advantages over the use of other β-emitting radionuclides like 90Y and 131I. The 
low energy of the beta particles with a short tissue penetration range is ideally suited 
for treatment of smaller sized tumours and low radiation doses to adjacent normal 
tissues and red bone marrow. Its 11% abundance of photons allows scintigraphy to 
monitor the pharmacodynamics of therapeutic administrations. We performed a pre-
therapy imaging cycle with 111In-labelled IMP288, as 111In- and 177Lu-labelled peptides 
are known to have similar biodistribution. 177Lu is a residualizing radionuclide which 
means that the radionuclide is retained in tumour cells after internalization. The half-
life of 90Y (64.1 h) matches better with the residence time of the IMP288-peptide 
in the tumour, which will enhance the radiation dose to the tumour. Therefore, this 
could be an approach to further widen the therapeutic window to evaluate the safety 
and dose-escalation with TF2 and 90Y-labelled IMP288. Another advantage of 90Y is 
its longer tissue penetration range (maximum 12.0 mm), which could irradiate non-
targeted regions in the tumour in case of inhomogeneous intratumoural distribution 
of the radiolabelled peptide. 
In conclusion, these first clinical results show that pretargeted radioimmunotherapy in 
CEA-expressing CRC is feasible and safe. Individual high therapeutic activity doses 
could be safely administered, based on patient-specific dosimetry in a pre-therapy 
cycle with TF2 and 111In-IMP288. Tumours are specifically and rapidly targeted with 
TF2 and 177Lu-IMP288, with limited hematological toxicity. Further clinical investi-
gation should focus on therapeutic efficacy in patients with smaller volume disease and 
evaluating potential advantages of 90Y over 177Lu for labelling the peptide, especially 
when treating larger tumours with inhomogeneous uptake. 
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. Abstract 
Background
Red bone marrow (RBM) toxicity is a dose limiting factor in (pretargeted) radioimmu-
notherapy. Dosimetric analysis could be improved by using three-dimensional (3D)-
based methods instead of planar gamma camera imaging, avoiding organ overlap and 
to enable tumour dosimetry. Therefore, the aim of this study was to develop an RBM 
dosimetry approach using the Monte Carlo-based 3D-Radiobiological Dosimetry 
(3D-RD) software, and to determine its additional value for predicting RBM toxicity. 
Methods
RBM and tumour doses were determined by the 3D-RD for thirteen colorectal cancer 
patients after pretargeted radioimmunotherapy (PRIT) with the two-step administra-
tion of an anti-CEA x anti-HSG bispecific monoclonal antibody and a 177Lu -labelled 
di-HSG-peptide. The 3D-RD dosimetry was based on SPECT scans acquired directly, 
3 h, 24 h and 72 h after the 177Lu administration. 3D-RD RBM doses were correlated 
to the grade of thrombocytopenia after treatment, graded according to NCI Common 
Terminology Criteria v3. The results were compared with RBM doses calculated based 
on whole body planar scintigraphic images and blood samples that were also acquired 
after 177Lu-labelled peptide injection. Furthermore, tumour doses for the 177Lu-therapy 
were estimated and tumour-to-RBM dose ratios were simulated for PRIT with 90Y. 
Results
3D-RD RBM doses were higher (median 0.43 Gy) than the blood-based and 2D im-
age-based doses (median 0.21 and 0.20 Gy, respectively). 3D-RD RBM doses for the 
patients with thrombocytopenia (n=7) were higher (range 0.43-0.97 Gy) compared 
to patients  without gradable thrombocytopenia (n=6, range 0.12-0.39 Gy), except in 
one patient with a RBM dose of 0.48 Gy who had no thrombocytopenia, but a grade 2 
leukopenia. Blood- and 2D image-based RBM doses for patients with grade 1-2 RBM 
toxicity were in the same range as for the patients without toxicity (0.14–0.29 Gy 
and 0.11-0.26 Gy, respectively), whereas blood-based RBM doses for two grade 3-4 
patients were higher (0.66 Gy and 0.51 Gy, respectively).  The median 3D-RD tumour 
dose was 1.45 Gy (range 0.46-3.76 Gy) for the  177Lu-therapy. When simulated for 90Y 
instead of 177Lu the median increase in the tumour-to-RBM dose ratio was 21%.
Conclusion
3D-RD dosimetry based on the SPECT images may more accurately predict RBM 
toxicity than blood- or 2D image-based methods. The 3D image-based dosimetry has 
additional value to estimate tumour doses and to predict the benefit-versus-risk ratios 
for different radionuclides. 
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Introduction
The aim of radioimmunotherapy (RIT) is to selectively target radioactivity to tumour 
lesions, with limited radiation doses to healthy tissues. The absorbed dose (AD) de-
pends on the patient-specific pharmacokinetics of the tracer, the administered activ-
ity and the radionuclide. After pre-therapeutic diagnostic administration of a trace 
amount of the radiolabelled compound, dosimetric calculations lead to a patient-
specific insight in where which amount of energy is deposited. This information can 
be used to adjust the individual therapy dose, or even be useful to select the most 
suitable radionuclide for therapy. Ideally, this leads to an improved benefit-versus-risk 
ratio for individual patients. 
In external beam radiation, this patient-specific treatment planning is common prac-
tice, as quite some data on the AD and its effect on tumour and normal tissues are 
available. However, for RIT the information on dose-response correlation is hardly 
known, and dose estimations are les adequate. Therefore further investigation of dose-
response relations and development of accurate dosimetry methods for the clinical 
practice of radioimmunotherapy are required.
Since the red bone marrow (RBM) is often dose limiting in RIT (1-5), the focus of 
this work will be on the RBM dose calculation and dose-response relation. Commonly 
used methods to calculate the RBM AD are the blood-based method (1, 3, 6, 7), a 
two-dimensional (2D) image-based method, or a combination of these two methods. 
Although blood-based (or partially blood-based) dosimetry is an accepted method for 
estimation of the RBM dose (1, 3, 6, 7), the correlation with the observed hematologic 
toxicity is not sufficiently high for clinical use (5, 8). Especially when the radiophar-
maceutical shows RBM retention, 2D image-based dosimetry seems to be a better 
predictor for hematological toxicity (5). 
In our institution, both above-mentioned methods were prospectively applied in a 
clinical phase I pretargeted radioimmunotherapy (PRIT) study in twenty patients 
with advanced colorectal cancer (9). Dosimetric data based on a diagnostic adminis-
tration of an 111In-labelled tracer were used to predict the RBM AD in a subsequent 
treatment with the same tracer labelled with 177Lu. Despite low predicted RBM ab-
sorbed doses (<0.5 Gy), five patients developed a grade 1-2 and two patients a grade 
3-4 thrombocytopenia after treatment. The dosimetric results guided activity dosing 
to some extent, but no clear-cut discrimination could be made between the patients 
with or without toxicity.  This indicates that an improved dosimetry method for pre-
diction, and ideally prevention, of RBM toxicity is warranted.
A major improvement could be the use of three-dimensional (3D) images for do-
simetry (10-13) instead of planar scintigraphic images. It has been shown that single 
photon emission computed tomography (SPECT)-based dosimetry leads to smaller 
errors than planar image-based dosimetry (14). The major advantage of 3D dosimetry 
is that, due to the lack of overlapping organs and more adequate attenuation correc-
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tion, the output is a rather reliable measurement of the dose in a particular volume. 
The measured activity as well as the size of the volume of interest is more accurately 
estimated in 3D dosimetry. In contrast, using 2D dosimetry one has to rely on the 
extrapolation of the standard mean percentage RBM in the delineated area compared 
to the whole body RBM mass.
Therefore, we hypothesized that 3D SPECT-based RBM dosimetry results may better 
correlate with bone marrow toxicity. Although 2D image-based dosimetry is more 
and more replaced by 3D dosimetry in research settings, to date no 3D RBM dosim-
etry results have been validated and correlated to RBM toxicity. 
Only recently, Schwartz et al. (4) introduced a combined positron emission tomog-
raphy (PET) and blood-based RBM dosimetry method, mainly focusing on the red 
marrow-to-plasma activity concentration ratio. The activity in the lumbar vertebrae 
(LV) was used to calculate this ratio. Subsequently OLINDA (15) was used for 
S-factor-based dose calculation, using a phantom-based RBM mass, although a more 
patient-specific approach might be preferred (4). Therefore, a voxel based method 
using Monte Carlo simulations or dose-point kernel convolution would be advanta-
geous, because this directly leads to the RBM dose. However, more than two or three 
images are required for these methods, in contrast to the PET study. 
Here we applied a method for 3D RBM dosimetry, using the Monte Carlo-based 3D 
Radiobiological Dosimetry (3D-RD) software (16), to accurately estimate the RBM 
dose and the tumour dose in patients who underwent pretargeted RIT with a bispe-
cific antibody and a 177Lu-labelled peptide.
Materials and Methods
Patients 
In this report, data acquired in a phase I study in  metastasized colorectal cancer pa-
tients was used. Patients with advanced colorectal cancer gave informed consent to 
undergo pretargeted RIT. Patients received the anti-CEACAM5 x anti-hapten hu-
manized trivalent bispecific antibody TF2. One day later the 177Lu-labelled di-hapten 
peptide (2500-7400 MBq) was administered. Thirteen out of twenty patients had a 
complete image-data set, i.e. four SPECT scans and four whole-body planar scintig-
raphies acquired after treatment, and these patients were selected for 3D-dosimetry. 
Image acquisition and use in dosimetry
Anterior and posterior whole body planar images were acquired immediately (at 8 cm/
minu), 3 h (6 cm/min), 24 h and 72 h (both 4 cm/min) after administration of 177Lu-
labelled peptide, and followed by a SPECT scan made by continuous, circular scan-
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ning with a 180º scan arc, 64 views per camera head and 19s/view. For each patient 
a region for the SPECT scanning was selected that contained lumbar vertebrae (LV) 
and at least one tumour lesion. 
A Siemens dual-head gamma camera (ECAM, Hoffmann Estates, IL), equipped with 
medium energy collimators was used with a symmetric 15% window over the 208 keV 
energy peak for the SPECT scanning, and an additional 15% window over the 113 
keV peak for the planar images. 
Subsequently, these SPECT scans were used for tumour and bone marrow dosimetry 
of the 177Lu dose and simulation of 90Y doses (matched pair dosimetry). 90Y has a 
shorter half-life than 177Lu (2.66 days versus 6.71 days for 177Lu), which corresponds 
better to the peptide residence time in the tumour. Therefore, it was suggested to 
replace 177Lu with 90Y in pretargeted RIT. The longer range of β-radiation from 90Y 
versus 177Lu (maximum penetration range in tissue of 12 and 2.5 mm, respectively) 
lead to concerns about the influence on the RBM dose. This is why we simulated 90Y 
treatment with 3D-RD in order to estimate the effect on the tumour versus RBM dose. 
The planar 177Lu images were only used to calculate the 177Lu RBM dose. Due to organ 
overlap tumour dosimetry could not be performed on planar images.
A baseline FDG-PET – low-dose (130 kV, 50 mAs) computed tomography (CT), and 
a contrast enhanced diagnostic CT scan were performed within two weeks prior to 
study entry, and for follow up, eight weeks after 177Lu injection. For the PET-CT an in-
tegrated camera (Biograph BGO duo, Siemens Medical Solutions, Malvern, PA,USA) 
was used, after FDG administration according to the EANM guidelines (17).
2D image and blood-based bone marrow dosimetry
During the PRIT study the dose to red bone marrow was calculated with a blood-
based (3) and a 2D image-based dosimetry method (18). The blood-based RBM dose 
was based on blood samples collected 2 minutes, 30 minutes, 1 h, 2 h, 4 h, 24 h and 
72 h after peptide injection and the total body activity (retrieved from the whole body 
planar images). These samples were counted in a gamma counter (Wizard, Pharmacia-
LKB, Sweden) with reference samples prepared from the injected products, using 
appropriate energy windows. Whole body activities were calculated and combined 
with the blood counts for the final dose calculation as described by Shen et al.(3) This 
was performed with the SPRIND software (18) using a red marrow-to-blood activity 
concentration of one, as was determined for 177Lu-peptide (19). 
For the 2D image-based method, SPRIND was used to delineate the cranium, rep-
resenting the activity in the RBM and to calculate the residence times. The residence 
time of the cranium activity was divided by the fraction of the RBM mass in the cra-
nium to the mass in the total skeleton, for which the default value 0.119 was taken 
from ICRP23’s Reference Man. Subsequently, OLINDA software (15) was used to 
calculate the RBM dose. 
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SPECT image reconstruction
SPECT scans were reconstructed with the iterative reconstruction software ReSPECT 
(Scivis, Germany), in six iterations, without noise reduction, with background subtrac-
tion and attenuation correction of 0.13 cm-1, based on the results of Brown et al. (20).
Because attenuation correction with the Chang-like method (21) as used by ReSPECT 
is based on the body contours, a correct body contour is needed for quantitative use 
of the images. 
In ReSPECT the ‘threshold object background’ is used for definition of the body 
contour; voxels with a value higher than this threshold are assigned to the body. The 
contour can be defined correctly with the default threshold as long as the target 
(body)-to-background activity ratio is high enough. The scans acquired directly and 
3 h post-injection were reconstructed with ReSPECT’s default settings for ‘threshold 
object background’, because body-to-background activity ratios were sufficiently high. 
For the scans 24 h and 72 h post-injection the contour was fitted to the contour of the 
first scan, by lowering the threshold value, as the lower whole body activity would lead 
to a smaller body contour with the default settings. 
Calibration
For the callibration of the SPECT scans, a cylindrical phantom was filled with 440 
MBq 177Lu, dissolved in 9.1 L water, and imaged using the same scanning and recon-
struction protocol as used for the patient-SPECTs. The known activity at the time 
of acquisition, combined with the number of counts in a volume drawn around the 
phantom, resulted in a calibration factor of 6.23 x 10-6 MBq per count. 
Delineation and co-registration
Tumour orientated co-registration of the SPECT scans and the low-dose CT was 
performed with the HERMES Gold 2.10 software (HERMES Medical Solutions, 
Stockholm, Sweden). The co-registered CT was scaled to the same matrix size as the 
SPECT (128x128x78). 
For each patient VOIs were manually delineated for RBM in the LV (VOILV) on the 
SPECT scans, and for one tumour lesion (VOItumour) on the CT.  
For the VOILV, at each time point, the RBM rich parts of at least two LV were de-
lineated and further processed as one VOI. If delineation on the SPECT scans was 
not possible because the LV could not be distinguished from the background, the 
co-registered CT was used for delineation. 
To confirm the location and presence of tumour, the contrast-enhanced CT, SPECT 
and PET scans were used. To limit the impact of the partial volume effect, tumours 
with a diameter of at least 2 cm were selected. 
129
3D-RD
For the 3D dosimetry the Monte Carlo-based 3D-RD dosimetry package, developed 
by George Sgouros’ group at the Johns Hopkins Medical Institute (Baltimore, USA), 
was used (13, 16). The voxel values of the SPECT scans were multiplied by the cali-
bration factor, resulting in activity maps. The low-dose CT scan was used to assign a 
density and composition (soft tissue, lung or bone) to each voxel of the SPECT scans. 
The activity, density, and composition maps were the input for the Monte Carlo (MC) 
simulations.  For each SPECT scan 106 MC simulations were accomplished, using the 
spectra probability distributions obtained from MIRD (22), resulting in a dose rate 
per voxel for each scan. 
The dose per voxel was calculated by integrating the dose rates for each voxel after ex-
ponential extrapolation of energy deposition after the last scan, based on the third and 
fourth scan. This finally resulted in a dose map. Integration of the dose rates per VOI 
lead to the VOI specific mean absorbed doses.
3D tumour dosimetry
For the VOItumour the mean absorbed dose (ADtumour) and a dose volume histogram 
(DVH) were determined. The DVH provides insight in the heterogeneity of the AD 
in the tumour. For comparison, the AD in VOItumour were also calculated with the 
sphere model in OLINDA (15). Therefore, the mass of the VOI was calculated with 
the density map, created from the low-dose CT, and the total activity in the VOItumour 
at the four different time points (and extrapolated for the period after the last scan) 
was used to calculate the residence time. 
3D LV-based RBM dosimetry
The LV were delineated on each scan because the co-registration was tumour oriented, 
which meant that using one VOILV for all scans would introduce an additional error. 
Therefore, the integrated mean dose rate per VOILV was used. This gives a mean ab-
sorbed dose for the RBM (ADRBM), but no DVH. 
To investigate the biological effect of the dose rate, also the biological effective dose 
(BED) was calculated for the RBM:
      
     Eq. 1
with the radiobiological parameters from the linear quadratic equation model (α and 
β, and α/β = 10 Gy (23)), the absorbed dose (AD) and the Lea-Catchside G-factor 
(G(Tµ)), depending on the DNA repair rate (µ): 0.46 h (23).
ur
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The 3D LV-based ADRBM was compared to the blood-based and the 2D cranium-based 
RBM dosimetry results, and correlated with the grade of thrombocytopenia (graded 
according to NCI Common Terminology Criteria v3. 
Tumour-to-RBM dose ratios
In adequate treatment settings, the ADtumour is sufficiently higher than the ADRBM. To 
evaluate this, the tumour-to-RBM dose ratio (Rt-RBM) was calculated:
     
         Eq. 2
This calculation was done for the 177Lu dose and the simulated 90Y dose, because a 
higher ratio would indicate a more suitable radionuclide for this treatment. 
Results
Patients, VOIs and RBM toxicity 
To estimate the tumour dose we used liver metastases (8 patients), lung metastases (2 
patients) or the primary tumour or local recurrence (3 patients). The patient and VOI 
characteristics are summarized in Table 1. 
The hematologic toxicity is represented by the grade of thrombocytopenia. Of the 
included patients, three patients scored grade 4, grade 3 and grade 2 thrombocyto-
penia respectively, and three other patients grade 1 thrombocytopenia. One patient 
(patient 18) just without a thrombocytopenia (120 x 109 platelets/L, while <120 x 
109 platelets/L is defined as grade 1), did show a grade 2 leucopenia. Whereas in two 
other patients (patient 10 and 16) a leucopenia (grade 1 and 2 respectively) was seen 
complementary to the thrombocytopenia (grade 3 and 4).
3D tumour and RBM doses 
The 177Lu ADtumour ranged from 0.46 to 3.76 Gy (median 1.45 Gy). In the subgroup 
of patients with delineated liver metastases the mediantumour dose was 2.50 Gy. A 
typical DVH of a tumour is shown in Figure 1. 
The ADtumour calculated with 3D-RD was similar in most patients, and only slightly 
higher than with OLINDA (<5.0%), except for one patient (patient 10) who showed 
a 9% higher 3D-RD tumour dose and one patient (patient 18) who showed a higher 
dose (36 %) for OLINDA. 
RBM doses ranged from 0.12 to 0.97 Gy (median 0.43). In all patients the BED was 
very similar to the AD (≤0.1% difference) (data not shown).  
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Table 1: Patient, and VOItumour details and dose results
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RBM = red bone marrow. AA = administered activity, tox = toxicity: grade thrombocytopenia 
Figure 1: Dose volume histogram of the tumour volume 
of interest, located in the liver of patient 19.
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Correlation between RBM dose and RBM toxicity
All blood-based, cranium-based and 3D-RD-based RBM doses are plotted against the 
grade of platelet toxicity in Figure 2. 3D-RD-based RBM doses (Figure 2A) were in 
general higher  (median 0.43 Gy) than the doses calculated with the blood-based and 
2D-image-based methods (Figure 2B and 2C, median 0.21 and 0.20 Gy, respectively). 
The highest 3D-RD-based RBM dose without RBM toxicity was 0.39 Gy. All other 
patients, with RBM doses in the range of 0.43-0.97 Gy, showed RBM toxicity; the 
only patient in this range (0.48 Gy) without  thrombocytopenia had a grade 2 leu-
copenia. Blood- and 2D image-based RBM doses for patients with grade 1-2 RBM 
toxicity were in the same range as for the patients without toxicity (0.14–0.29 Gy 
and 0.11-0.26 Gy, respectively), whereas blood-based RBM doses for two grade 3-4 
patients were higher (0.51 and 0.66 Gy).
Tumour to RBM dose ratios for 177Lu compared to 90Y
The effect of 90Y versus 177Lu was shown by the simulated 90Y dosimetry based on the 
177Lu images, co-registration and VOIs (Table 2). The median tumour-to-RBM dose 
ratios was 5.08 for 177Lu and 4.97 for 90Y, with a  median percentage increase of 21%, 
though with a wide inter-patient variation (range -3-56%). 
Interestingly, patients with a high RBM dose using 177Lu treatment showed the largest 
percentage increase in tumour to RBM dose ratio when changing to 90Y (Figure 3). 
Table 2: The difference between the tumour-to-RBM dose ratios for treatment with 177Lu and simulated 
for  90Y. A positive difference represents a higher tumour to RBM dose ratio for 90Y compared to 177Lu.
Patient
Tumour-to-RBM  dose ratios Difference in tumour-to-RBM 
ratios for 90Y minus 177Lu (%)177Lu 90Y
7 1.88 2.13 13%
10 5.72 6.54 14%
11 8.84 9.78 11%
12 5.08 7.27 43%
13 4.33 4.33 0%
14 5.26 6.37 21%
15 1.49 2.29 54%
16 0.68 1.06 56%
17 1.46 2.02 39%
18 7.77 8.87 14%
19 5.11 4.97 -3%
20 0.64 0.99 54%
21 10.91 13.72 26%
Median
(range)
5.08
(0.64-10.91)
4.97 
(0.99-13.72)
21%
(-3-56%)
RBM = red bone marrow
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Figure 2: 3D-RD-based (A), blood-based (B) and cranium-based 
(C) absorbed dose in the red bone marrow, versus the grade of 
platelet toxicity. AD RBM = absorbed dose red bone marrow.
A
B
C
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Discussion
Accurate dosimetric calculations of tumour and RBM doses are essential for patient-
specific treatment planning in pretargeted RIT. In this study, we demonstrated how 
3D-RD can be used for advanced quantification of the tumour and RBM dose and the 
prediction of RBM toxicity.
With 3D-RD all patients with RBM toxicity (including grade 1-2) had a higher RBM 
dose than  the patients without any RBM toxicity. This distinction was not observed 
with the blood-based and 2D-cranium-based methods. RBM doses were in most pa-
tients higher when calculated with 3D-RD than with the blood-based method (11 pa-
tients) and the cranium-based method (12 patients). In blood-based RBM dosimetry 
it is assumed that the blood activity concentration is an accurate surrogate for the bone 
marrow concentration at all time points. However, in some patients we observed some 
bone marrow retention at the later imaging time point (24 h and 72 h post injection). 
Therefore, the blood-based method could result in an underestimation for the ADRBM.
The 2D cranium-based dosimetry might also have resulted in an underestimation of 
the ADRBM. The fraction RBM in the cranium is used to represent the activity in the 
total RBM. In the SPRIND software package, this fraction was defined as 0.119, based 
on the ICRP23’s Reference Man, representing a 40-year old male. For our patient-
population (median age 63 year), this might have been an overestimation. Since the 
distribution of the RBM over the skeleton is age and patient-specific, ideally this frac-
tion should be individually measured, and a patient-specific percentage of the RBM in 
a certain VOI should be used for this method. 
In addition, the difference between the 3D LV-based and 2D cranium-based ADRBM 
could be explained by inhomogeneous uptake in the RBM (2, 5), and the influence 
of activity surrounding the LV on the ADLV. We would have preferred to use the same 
Figure 3: Per patient RBM doses plotted versus the percentage difference in 
tumour-to-RBM dose ratios for 90Y (simulated)  minus 177Lu (measured). 
A positive difference represents a higher ratio for 90Y compared to 177Lu.
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VOI for both methods. Unfortunately, it is not feasible to use a VOI for the lumbar 
vertebrae in the SPRIND software, because an appropriate background ROI could 
not be defined. The cranium does not suffer from overlapping organs, which is an 
important criterium in planar image dosimetry.  For the 3D dosimetry, it is more fa-
vorable to use the lumbar vertebrae, as the larger bone marrow volume is less affected 
by the partial volume effect.
An absorbed dose of 2 Gy in the RBM is a generally accepted limit above which 
RBM toxicity could occur. Nonetheless, based on the 3D-RD dosimetry we observed 
thrombocytopenia or leukocytopenia (≥ grade 1) in all patients receiving >0.4 Gy on 
the RBM, while none of the patients had bone marrow involvement or marrow reserve 
reducing treatments within 4 weeks before entering the study. 
Bone marrow toxicity has been described before in patients receiving doses lower 
than 2 Gy (6, 24). This might suggest that to avoid any grade of toxicity, a limit lower 
than 2 Gy should be used for some dosimetry methods,  radiolabelled compounds, 
or patient populations. This might be due to methodological differences in the do-
simetry, i.e. correction for the partial volume effect.  Furthermore, dose rate might be 
an important factor influencing the dose-reponse correlation (25-27). Some patient 
specific factors are also likely to contribute to the risk of hematologic toxicity, such 
as age, previous treatments influencing the bone marrow reserve, elapsed time since 
the last chemotherapy, etc (28, 29). Therefore, the dose-toxicity correlation found for 
a certain compound in a specific patient population  cannot easily be generalized for 
other studies. However, the intra-study results in a large group of patients calculated 
with the same dosimetry method can lead to adequate treatment planning for that 
specific (experimental) treatment. 
3D-image based dosimetry, either PET, or SPECT-based, is methodologically the 
most direct approach for RBM dose calculation in pretargeted RIT. Morover, 3D 
dosimetry above 2D dosimetry in bypassing the influence of overlapping organs, the 
advantage of 3D-RD LV dosimetry is the more accurate VOI drawing. and provides a 
result that contributes to the general knowledge about RBM response. Therefore, we 
advocate that further investigation of the dose-response relation in the RBM should 
be 3D-based. Nevertheless, it seems reasonable not to disqualify the simpler methods 
for future use in the clinic.  These less demanding methods might, combined with 
3D-imaging based methods (i.e. as in the method described by Schwartz et al.(4), be 
sufficient and better suited for use in daily practice. 
The OLINDA-based results of the tumour absorbed doses were comparable to the 
3D-RD results. In general OLINDA leads to a somewhat lower dose, which can be 
explained by the influence of activity surrounding the VOI. For use of the OLINDA 
sphere model, the VOI is assumed to be isolated. In 3D-RD, surrounding activity does 
contribute to the tumour dose, which is more realistic. 
On the other hand, using the OLINDA sphere model instead of MC simulations is 
much faster, it only provides a mean dose, and therefore might be less useful for dose-
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response monitoring. Besides this, OLINDA RBM dosimetry, or in general S-factor-
based RBM dosimetry, is not feasible without a known (or model based) RBM mass. 
Therefore, the MC-based dosimetry is advantageous for RBM dosimetry.
The results of the 90Y simulation that replacing 177Lu by 90Y would lead to a percentage 
increase in the tumour-to-RBM dose ratio, especially in patients with a higher RBM 
dose. The increase in tumour-to-RBM dose ratio for 90Y suggests that the impact of 
the shorter half-life of 90Y for the tumour dose is somewhat larger than for the RBM 
dose in most patients. However, with the low tumour doses and tumour-to-RBM dose 
ratio that were obtained with 177Lu and 90Y, a clinically relevant increase seems out of 
reach. 
It seems that matched pair dosimetry, as shown for 177Lu and 90Y, could be a conveni-
ent and relatively inexpensive alternative for an animal or patient study, in order to 
investigate the effect of a different radionuclide on the tumour-to-RBM dose ratio. 
However, simulation does not account for therapeutic differences due to inhomogene-
ous distribution of the radioactivity within the tumour.
Conclusions
This work outlines how patient-specific dosimetry with 3D-RD can quantify RBM 
absorbed doses based on the lumbar vertebrae and tumour doses. The 3D-RD RBM 
doses seem to be a more sensitive predictor for patients showing any grade of RBM 
toxicity than blood-based and planar image-based RBM doses. 
In addition, with comparing the 177Lu doses with the simulated 90Y doses, it was shown 
that matched pair dosimetry with both RBM and tumour dose calculation might be 
useful for the selection of a radionuclide for therapy. 
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. The working hypothesis for this thesis was that pretargeting could improve radioim-
munotherapy (RIT) of tumours. RIT is the selective targeting of tumour-associated 
antigens expressed on the tumor cells with radiolabeled antibodies. However, the slow 
uptake and clearance rate of intact antibodies delays tumour detection by imaging 
and increases bone marrow toxicity during therapy. Pretargeting techniques were 
developed to overcome these problems, and to allow rapid and selective delivery of ra-
dionuclides to tumours. In this approach, a bispecific monoclonal antibody (bsMAb) 
is administered intravenously and given time to accumulate in the tumour and clear 
from the circulation. Subsequently, a radiolabeled hapten-peptide is given that clears 
rapidly from the blood and body, but is trapped in the tumor by the anti-hapten bind-
ing arm of the bsMAb.
We investigated pretargeting for carcinoembryonic (CEACAM5)-expressing tumours 
with the bsMAb TF2, and the peptide IMP288. TF2 is a humanized anti-CEACAM5 
x anti-HSG bsMAb construct produced using the Dock-and-Lock-technology, result-
ing in a stable humanized tri-Fab molecule. TF2 contains two Fab fragments with 
high affinity for CEACAM5 and another Fab-fragment with affinity for the hapten, 
histamine-succinyl-glycine (HSG). IMP288 is a peptide that contains two HSG 
moieties for improved hapten-peptide uptake and retention, and the chelating moiety 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), capable of stable 
binding of a variety of radionuclides, such as 111In for SPECT imaging, with 18F and 
68Ga for PET imaging, or 90Y and 177Lu for pretargeted radioimmunotherapy (PRIT). 
First we studied this pretargeting system in murine tumour models, to guide the trans-
lation into the clinical situation. In our animal studies we used BALB/c nude mice 
with small CEA-expressing LS174T human colonic tumours either subcutaneously 
(s.c.) or intraperitoneally (i.p.). 
In the studies described in Chapter 2 and 3 the effects of the antibody and peptide 
dose on their uptake in the tumour and normal tissues was investigated. The TF2 and 
IMP288 dose were escalated to find which administered dose resulted in the maxi-
mum amount that could be targeted specifically to the tumours. We found that the 
optimal dose of TF2 was 5.0-6.0 nmol/mouse and the optimal dose of IMP288 was 
0.28 nmol/mouse. 
In Chapter 2 we studied the specificity of pretargeted immuno-PET with TF2 and 
68Ga-labelled IMP288 in BALB/c nude mice with a s.c. LS174T tumour, a s.c. CEA-
negative tumour, or an inflammation in thigh muscle. Within one hour, the PET-
images and dissected tissues showed high and specific targeting of the 68Ga-IMP288 
in the tumour and very low uptake in normal tissues, in a CEA-negative tumour, 
and inflamed muscle. The same mice were also imaged after injection of 18F-FDG. 
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18F-FDG localized efficiently in the tumour, but also in the inflamed muscle and in 
various normal tissues (brain, myocardium, kidney, focally in intestines). A similar 
hapten-peptide was labelled with 18F and tested in mice with a s.c. LS174T tumour.  
18F-labelled peptide distributed similarly in the tumour and normal tissues as the 68Ga-
labelled peptide, indicating that either radiolabelled hapten-peptide could be used. It 
was concluded that pretargeted immuno-PET with TF2 and a 68Ga- or 18F-hapten-
peptide is a rapid and highly specific imaging modality for the detection CEA-positive 
tumours, and is more specific than 18F-FDG-PET.   
The advantages of an orthotopic animal model compared to a s.c. tumour model for 
demonstrating the sensitivity of a new imaging method are that such a model also in-
cludes the effect of tumour-to-background ratios, and tumours of variable sizes within 
one animal can be studied. Therefore, in Chapter 3, we assessed the sensitivity of the 
pretargeted immuno-PET with TF2 and 68Ga-IMP288 in mice with small intraperi-
toneal xenografts. Again, we compared pretargeted immuno-PET with 18F-FDG-PET. 
After injection of the 68Ga-labelled peptide high tumour-to-background ratios were 
observed, resulting in clear visualization of the tumours, and detection of all intra-
abdominal tumour lesions ≥ 10 µL. 18F-FDG also visualized some of these tumours, 
but also showed physiological uptake in various normal tissues, with lower tumour-to-
intestines ratios. These results suggest that pretargeted immuno-PET with bsMAb and 
a 68Ga-labelled peptide could be a very sensitive imaging method for colonic cancer. 
After having optimized the TF2 and IMP288 doses and having demonstrated the 
potential of pretargeted immuno-PET imaging, in Chapter 4 the therapeutic efficacy 
and toxicity of pretargeted radioimmunotherapy (PRIT) with TF2 and 177Lu-labelled 
IMP288 was determined in mice with s.c. LS174T tumours. Because pretargeting 
reduced the radiation dose to the bone marrow, the total amount of radioactivity that 
could be administered in one treatment cycle was much lower than the maximum 
tolerable dose. Therefore, the tumour targeting of two regimens of repeated admin-
istrations of radiolabelled IMP288 were investigated in a biodistribution experiment. 
The first regimen consisted of one TF2 injection followed by multiple IMP288 ad-
ministrations in a 3 hour interval. The second regimen consisted of multiple cycles 
where each IMP288 administration was preceded by a new TF2 injection (72 hour 
interval). The last dosing schedule resulted in the highest radioactivity dose delivered 
to the s.c. tumours. In the therapy experiment, mice received one, two or three suc-
cessive treatment cycles. PRIT effectively delayed tumour growth and significantly 
prolonged survival significantly, with longer survival of the groups that received suc-
cessive cycles without relevant toxicity. No relevant changes in mean body weight, 
leukocyte or platelet counts, or serum creatinine were measured. This study indicated 
that in mice PRIT could be an effective treatment modality against colon cancer with 
limited toxicity.
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To predict the efficacy of pretargeted radioimmunotherapy, diagnostic images can be 
acquired after injection of the radiolabeled agent. This strategy of combining imaging 
with therapy is designated as theranostics, and was the subject of the study described 
in Chapter 5. The prospects for using pretargeted immuno-SPECT with TF2 and 
IMP288 labelled with 111In to monitor the response to PRIT using 177Lu-IMP288 
in mice with i.p. growing LS174T tumours was examined. In this model pretargeted 
immuno-SPECT showed rapid and selective tumour targeting with very high tumor-
to-background contrast, which led to the detection of very small tumours. The activity 
in the tumour lesions as measured with SPECT correlated well with uptake measured 
in dissected tissues. A survival study was performed in mice that received TF2 and 
177Lu-IMP288, non-pretargeted 177Lu-IMP288, or PBS. In the treated group, immu-
no-SPECT-imaging allowed non-invasive monitoring of the delayed tumour growth 
non-invasively which corresponded to prolonged survival. These results showed the 
feasibility and additional value of imaging to monitor the efficacy of with the same 
pretargeting agents, TF2 and radiolabelled IMP288. 
The preclinical studies were used to translate the pretargeting system into a first-
in-men phase I study (Chapter 6). The main objectives of this study were to assess 
various pretargeting conditions and safety in patients with metastatic colorectal cancer 
(mCRC). For the participating patients no standard treatment options were available. 
Different dose schedules were studied in four cohorts of five patients [1] shortening 
the interval between the bsMAb and peptide administration (5 days vs 1 day), [2] 
escalating the TF2 dose (from 75 to 150 mg), and [3] reducing the peptide dose (from 
100 to 25 µg). Rapid and selective tumour targeting of the radiolabelled peptide was 
visualized within one hour with high tumour-to-tissue ratios (>20 at 24 h). Improved 
tumour targeting was achieved with a 1-day interval between the administration of 
the bsMAb and the peptide, with the 25 μg peptide dose. High 177Lu-IMP288 activity 
doses were well tolerated with some manageable TF2 infusion reactions, and transient 
grades 3-4 thrombocytopenia in two patients. It was concluded that pretargeting with 
TF2 and 177Lu-IMP288 in patients with CEA-expressing mCRC is feasible and safe. 
In Chapter 7 the dosimetric analysis that was performed based on the whole body 
planar scintigraphic images and blood sampling was described. Before each therapy 
cycle patients received an imaging cycle with TF2 and  111In-labeled IMP288. The 111In-
IMP288 data were used to simulate absorbed doses of 177Lu-IMP288 and to calculate 
the maximum 177Lu activity dose that could be administered safely. Individualized ac-
tivity dosing seemed essential, as relatively large inter-patient variations were observed 
in TF2 and IMP288 pharmacokinetics in the phase I study. A strong and significant 
correlation was observed between IMP288 residence times and individual TF2 blood 
concentrations at the time of IMP288 injection. Therapeutic 177Lu activity doses re-
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sulted in low absorbed radiation doses to normal tissues. In the majority of patients 
who received the maximum or adjusted 177Lu activity doses, the measured red bone 
marrow (RBM) doses did not exceed the threshold set in the protocol. Simulated 
177Lu-IMP288 absorbed red marrow doses were in good agreement with the actual 
measured doses.  Hematologic toxicity correlated significantly with RBM dose. 
The SPECT images acquired in the phase I study were also analysed with a new, so-
phisticated method,  the Monte Carlo-based Three-Dimensional -Radiobiological 
Dosimetry (3D-RD) method (Chapter 8). The voxel values of the SPECT scans 
were converted to activity maps and a low-dose CT scan was converted to a densitiy 
map, and both maps were the input for the Monte Carlo simulations. This resulted 
in the energy deposition per voxel per scan time, and combining the results of the 
four SPECT scans per injection led to a dose map per VOI. In contrast to the previ-
ous described dosimetry methods, for 3D-RD the SPECT scans were used instead 
of the whole body planar images, and the lumbar vertebrae instead of cranium for 
RBM dosimetry, and 3D-RD allowed tumour dosimetry. Furthermore, this new do-
simetry method did take in account tissue density and showed tumour heterogeneity. 
The feasibility of the 3D-RD software and its value for predicting RBM toxicity and 
therapeutic efficacy in the phase I clinical study of PRIT were studied and compared 
with the blood-based and planar image-based results. 3D dosimetry showed 2-fold 
higher RBM doses compared to the blood-based and planar image-based methods, 
and a better RBM dose-toxicity correlation. Furthermore, tumour and RBM 177Lu 
doses acquired by the 3D-RD method were simulated for 90Y. The mean increase of 
tumour-to-RBM ratio when simulating for 90Y compared to 177Lu was 21%. These 
results suggest that the 3DRD software may more accurately predict bone marrow 
toxicity and tumour doses than blood or 2D-image-based methods. 
In chapter 10 the results are discussed and future perspectives are outlined. 
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General discussion and future prospects
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. High morbidity and mortality rates of patients with metastatic colorectal cancer 
(mCRC) (1) demonstrate the need for better, effective imaging and therapeutic strate-
gies. Despite the increase of treatment options since 2000 (2-6), eventually the disease 
progresses in most patients. In addition, current therapeutic regimens cause significant 
early and sometimes late toxicity, negatively affecting the patient’s quality of life (7). 
Several therapies that have been approved as standard treatment for mCRC, such as 
cetuximab or panitumumab, show only limited increase of median overall survival 
(5, 6). Curative liver metastatectomy is an established approach (8, 9). Unfortunately, 
large population data revealed high recurrence rates (>50%) (10). Other attempts to 
combine different treatments, such as pre-operative concomitant chemo-radiation in 
advanced stage rectal cancer, have improved surgical results, but do not result in cure 
of all patients. 
The prognosis of mCRC patients can be improved by early detection of disease, i.e. small 
tumour lesions that allow minimal invasive but adequate surgery (11). Furthermore, 
targeted systemic therapies with limited side effects are preferred to widen the arsenal 
of therapies and to circumvent drug resistance. Radionuclide targeting  using mono-
clonal antibodies or receptor binding peptides could be a very effective technique, as 
has been demonstrated for non-Hodgkin’s lymphoma and neuroendocrine tumours. 
However, for mCRC the results of radioimmunotherapy (RIT) with radiolabelled 
monoclonal antibodies are modest (12). In general, solid tumour lesions are less ra-
diosensitive than hematologic tumours. So, in RIT further activity dose escalation is 
required to guide therapeutic radiation doses to these tumours. However, the long-
circulating radiolabelled antibody causes continuous irradiation of the bone marrow. 
This results in dose-limiting bone marrow suppression before sufficient radiation doses 
can be delivered to solid tumours. Therefore, to maintain acceptable normal tissue 
absorbed doses, the tumour-to-normal tissue ratio should be improved.
A very promising strategy to improve this ratios is pretargeting, in which the targeting 
of the tumour and the radionuclide delivery are separated in two steps. 
In this thesis, we have studied such a pretargeting system in preclinical  studies, to 
guide the translation into the clinical situation. To develop a sensitive and specific 
imaging modality, tumour-to-normal tissue ratios should be maximal, and to achieve 
therapeutic efficacy, the amount of activity targeted to the tumours should be maxi-
mized, without increasing normal tissue radiation doses. Important pretargeting pa-
rameters to be optimized are: the bsMAb dose, the interval between injection of the 
bsMAb and the radiolabelled peptide and the peptide dose. As these parameters are 
interdependent, the process of optimization is rather challenging.
As pretargeted imaging/therapy is a two-step strategy including the subsequent ad-
ministration of two agents, the first parameter to be examined is the optimal interval 
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between the bsMAb and radiolabelled peptide. Ideally, the peptide should be admin-
istered at the time that the highest amount of bsMAb is in the tumour, whereas it 
should be low in the circulation. At later time points, when blood concentration is low, 
bsMAb concentration in the tumour can also start to decrease. However, if the inter-
val would be too short, and the bsMAb is not sufficiently cleared from the circulation 
yet, the antibody and the peptide will complex in the blood. This will not only reduce 
tumour targeting, but will also increase the circulatory half-life of the radiolabelled 
hapten-peptide complex. Thus, the optimal interval is the best compromise between 
the time at which the highest amount of bsMAb is in the tumour and the time needed 
required to have a low bsMAb concentration in the blood. 
The amount of the bsMAb in the tumour can be enhanced by increasing the dose of 
bsMAb. It should be noted that when administering a higher bsMAb dose, a longer 
interval could be required to allow the bsMAb to clear from the blood. Furthermore, 
when the antigen sites on the tumour are saturated at a certain bsMAb dose, the maxi-
mal amount of bsMAb targeted to the tumour is achieved and a further increase of the 
bsMAb dose does not result in further improvement. 
Another important factor in pretargeting is the peptide dose. The minimum peptide 
dose is determined by radiochemistry: the radiolabelling procedures determine the 
minimum amount of peptide that is required to label the amount of radioactivity that 
needs to be administered. For imaging, the radioactivity dose should be sufficiently 
high for reasonable image statistics, while for therapy it should be sufficient to guide 
a therapeutic radiation doses to the tumour. Conversely, a lower peptide dose radio-
abelled with a fixed amount of radioactivity, will increase the fraction of the radio-
activity that will be delivered to tumour. On the other hand, a low peptide dose may 
result in a lower ratio between the circulating bsMAb and the administered peptide 
dose. Consequently, a higher fraction of the radiolabelled peptide in the blood could 
be captured by the circulating bsMAb, increasing the circulatory half-life of the radi-
olabelled peptide. 
In our studies in mice, we investigated the optimal conditions for the pretargeted im-
aging and therapy application. The interval between TF2 and IMP288 administration 
we used in mice was 16 hours, as this was already studied by Sharkey et al. First, we 
escalated the TF2 dose to find which administered dose resulted in the maximum 
amount of TF2 that could be targeted specifically to the tumour and its effect on 
IMP288 tumour capture (chapter 2 and 4). We found that the optimal TF2 dose was 
5.0-6.0 nmol per mouse, as higher TF2 doses did not result in a higher tumour uptake 
of TF2 or IMP288. Apparently, at higher doses saturation of CEA antigens in the 
subcutaneous xenografts occurred. 
Subsequently, we determined the optimal peptide dose in this mouse model. For the 
application of micro-PET-imaging, the minimal IMP288 dose (400 ng) to be admin-
istered  was determined by the amount required for a minimum of 68Ga activity dose (5 
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MBq) to make high quality PET-images (chapter 2). For therapeutic application, we 
aimed at to find the maximum absolute amount of radioactivity that could be deliv-
ered to the tumour lesions. Therefore, we increased the IMP288 dose to determine the 
dose at which the maximum absolute amount of peptide was specifically targeted to 
the tumor. We found that the optimal dose was 0.28 nmol IMP288, and 26 MBq 177Lu 
could be radiolabelled to this amount of peptide. In our preclinical therapy study, we 
observed that this activity dose was well below the maximal tolerable dose. Therefore, 
our treatment strategy included the use of repeated treatment cycles. 
After the successful dose optimization in our preclinical studies, we showed that pre-
targeted immuno-PET with an anti-CEA bsMAb and a 68Ga- or 18F-hapten-peptide is 
a rapid, highly specific and sensitive imaging modality for the detection CEA-positive 
tumours (chapter 2 and 3).  Within 1 h, tumour lesions showed high and specific 
uptake of the radiolabeled IMP288, while its uptake in normal tissues and inflamed 
muscle was low. This resulted in clear visualization of small intra-abdominal tumour 
lesions by pretargeted immuno-PET. In the same animal models, 18F-FDG showed 
uptake in tumours as well as in various normal tissues (brain, heart, intestines) and the 
inflamed muscle, which complicated tumour discrimination. Although a high sensi-
tivity and specificity for FDG-PET in detecting recurrent colorectal cancer lesions 
has been reported in patients, FDG-PET images could lead to diagnostic dilemmas in 
discriminating malignant from benign, highly metabolic lesions, such as inflamed tis-
sues. Therefore, we concluded that pretargeted immuno-PET with bsMAb and a 68Ga-
labelled peptide could be an imaging method of additional value for colonic cancer.
Short-lived radionuclides, such as 68Ga and 18F, are ideally suited for pretargeted PET 
imaging, and their half-lives match the pharmacokinetics of the peptide for imaging. 
In our preclinical studies we showed similar if not identical distribution in vivo of 
the 18F-labelled peptide and the 68Ga-labelled peptide (chapter 2). The selection of 
the most suitable radionuclide depends on multiple factors. 68Ga can be eluted twice 
daily from a 68Ge/68Ga generator, avoiding the need for an on-site cyclotron. For these 
studies, the procedure to label IMP288 with 68Ga was optimized, resulting in a one-
step labelling technique that could be completed within 45 minutes. 18F, the most 
widely used radionuclide in PET, has an even more favourable half-life for pretargeted 
PET imaging (t½ = 110 min). Its shorter positron range in tissue (median 0.62 mm), 
results in better image quality in preclinical imaging. It is abundantly available and 
inexpensive. However, the chemistry involved in preparing 18F-labelled products can 
be challenging. McBride et al. recently reported a simplified approach for preparing 
18F-labelled peptides that involves the formation of 18F-aluminum complexes that can 
then be simply chelated by a chelate like NOTA (13). Translation to the clinical situ-
ation will show the feasibility of upscaling the radiolabelling procedure, and the effect 
of the intrinsic resolution of the clinical PET-scanner in combination with the spatial 
resolution of the radionuclides on imaging tumours. 
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To study the therapeutic effect of PRIT with TF2 and 177Lu-IMP288, we compared 
the tumour growth and survival in mice with subcutaneous colorectal xenografts after 
PBS versus one, two or three cycles of PRIT.  We demonstrated that using the optimal 
dose schedule and multiple treatment cycles of PRIT, it could be an effective treatment 
modality with limited toxicity for CEA-expressing human colonic tumours (chapter 
4). Higher activity doses, administered in successive cycles, resulted in significantly 
longer survival compared to PBS, while the repeated treatment cycles did not cause 
significant changes in body weight, blood counts or acute kidney function. 
In addition, we showed that pretargeted immuno-SPECT is an excellent imaging 
method  to monitor the therapeutic effect of  PRIT, using the same pretargeting 
agents (chapter 5). The pretargeted immuno-SPECT images showed rapid and selec-
tive tumor targeting with very high tumor-to-background contrast as early as one 
hour after injection. The successive images of the treated mice showed delayed tumor 
growth in the PRIT group, which corresponded with their prolonged survival. The 
combination of pretargeted immuno-SPECT during PRIT, as tested in our preclinical 
model, could also be a valuable strategy in clinical practice. The efficient combination 
of imaging and therapy using the same agents is designated as theranostics. Diagnostic 
information obtained from pre-therapeutic PET or SPECT, can be used to ensure that 
the radionuclide is specifically targeted to tumours, which guides patients selection. 
Dosimetric analysis of the images can be used to predict the benefit/risk ratio of a 
planned radionuclide therapy. Moreover, it can be crucial to estimate the optimal dose 
or radionuclide in radioimmunotherapy studies. Furthermore, imaging data can be 
used to assess therapy response. 
The knowledge acquired in the preclinical studies was used to design the phase I study 
with TF2 and IMP288 in patients with progressive mCRC. The main objective of this 
first-in-men study was to optimize the dose schedule for tumour targeting in patients, 
while maintaining tolerable and reversible toxicity. Therefore we studied different 
dose schedules in four cohorts of five patients, assessing the effect of  shortening the 
interval between the bsMAb and peptide administration (5 days vs 1 day), escalating 
the TF2 dose (from 75 to 150 mg), and reducing the peptide dose (from 100 to 25 µg). 
We demonstrated that PRIT with these agents in patients with CEA-expressing CRC 
is feasible and safe. Tumours were targeted specifically and rapidly. Tumour targeting 
was improved targeting when the interval between the bsMAb and peptide adminis-
tration was reduced and at a lower peptide dose (chapter 6). In an attempt to reach 
higher concentrations in the tumour, we tested a 2-fold higher TF2 dose, but we did 
not observe improved tumour targeting. For future studies, it might be interesting to 
study the effect of a further TF2 dose escalation, e.g. 300 mg.  However, with a higher 
infused TF2 dose a 2-day interval might be required to ensure rapid blood clearance 
of the radiolabeled peptide.
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Overall, our preclinical and clinical studies indicated the limited uptake of radioactiv-
ity in normal tissue and limited radiation related toxicity in PRIT. Low normal tissue 
absorbed radiation doses were measured at high therapeutic 177Lu activity doses (chap-
ter 6), which resulted in minimal hematologic toxicity. The sporadic cases of grade 3-4 
bone marrow toxicity correlated significantly with absorbed red marrow dose (chapter 
7). 3D voxel based patient-specific dosimetry was shown to be a more accurate method 
for predicting bone marrow toxicity than the blood based and 2D methods (chapter 
8). Therefore, PRIT will allow further activity dose escalation, which is required to 
achieve therapeutic radiation doses in solid tumours like CRC. 
Apart from the hematologic toxicity, that was clearly radiation-induced, we monitored 
patients for potentially immunologic responses to the antibody infusions. Despite  the 
fact that TF2 is a fully humanized antibody construct, infusion reactions were ob-
served in one third of the patients at the second infusion of the bsMAb, which could 
not be completely prevented by prophylactic medications. The infusion reactions 
were transient and manageable by lowering the infusion rate and adding appropriate 
medication, and did not preclude continuation of treatment in most patients. In fact, 
further analysis of the serum samples acquired up to 24 h after the infusions, suggested 
that the allergic reactions are most likely due to  complement-activation, rather than 
histamine release (data not shown). Therefore, critical situations with anaphylaxis 
upon repeated exposure are considered unlikely.  So, the clinical relevance of this ad-
verse event should be evaluated in larger patient groups and infusion schedules can be 
further optimized. 
Another immunologic adverse effect was the formation of  human antibodies against 
TF2 in ~50% of the patients after two infusions with the bsMAb. Increasing HAHA 
titers during at least eight weeks after the second administration were observed (chap-
ter 5). No correlation was found between the formation of anti-TF2 HAHAs and the 
observed infusion reactions. High HAHA levels could further accelerate TF2 blood 
clearance at subsequent injection, which would further reduce tumour accumulation 
of TF2 at subsequent cycles. 
Despite improved tumour targeting in the four successive patient cohorts, absolute 
tumour concentrations remained relatively low, and tumour retention was relatively 
short. The 3D voxel based dosimetry method confirmed the tumour absorbed doses 
to be sub-therapeutic, and no clinical therapy responses were measured by successive 
FDG-PET/CT. 
This lack of efficacy could be due to various factors. First, all patients had gross meta-
static disease, with mostly large tumours. MAb uptake in those larger lesions is known 
to be limited and inhomogeneous, due to high interstitial pressure. In the current first-
in-man study, we were allowed only to include patients who had already been treated 
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with all standard therapies. For CRC, many lines of therapy were recently added to 
the list of approved treatments. Medical oncologist and patients consider experimen-
tal therapies only after standard treatment options. The long period of less effective 
treatment, in general results in large volume of disease at the time the patient is fit for 
experimental therapies. By then, only a small fraction of the patients is in a physical 
condition to be safely included in phase I clinical trials.  
Due to the fast progression of disease in our patient population, patients could not be 
given the subsequently planned additional treatment cycles, while the therapy trial was 
designed to offer four repeated dosing cycles every eight weeks. So, all patients only 
received a quarter of the planned activity dose. However, in this first-in-men study a 
safe interval of eight weeks between treatment cycles was required to allow evaluation 
of the myelotoxicity of each treatment cycle. As we have confirmed the initial safety 
of PRIT with these agents and high acitivity doses, in future studies patients can be 
treated with a shorter interval between the treatments.
Another way to improve therapeutic efficacy could have been to switch from 177Lu 
to 90Y as a therapeutic radionuclide. 90Y’s physical half-life (64 h) better matches the 
residence time in the tumour (6.7 days), which would enhance the radiation dose to 
the tumour.  However, the tissue penetration range of both radionuclides is markedly 
different (maximum: 12.0 vs 2.5 mm, respectively). And the retention in the bone 
marrow of the pretargeted radiolabeled peptide might be low but not negligible. 
Therefore, the radiation dose to the bone marrow might also be enhanced using 90Y 
instead of 177Lu. So, the safety profile of 90Y could be different as well. The 3D-RD do-
simetry results predicted that the tumor-to-red marrow dose ratios would not improve 
when switching to 90Y. Unfortunately, we could not test these effects in our preclinical 
studies. Due to the major effect of the difference in tissue penetration range, and the 
inevitably differences in size between mice and humans, the experimental data from 
mouse models are challenging to extrapolate. For example, in mice the retention of a 
radiolabelled compound in the kidneys could be the radiation source of adjacent liver 
tissue and cause liver toxicity, as was shown in preclinical studies with radiolabelled 
Fab-fragments (14), while this would not be the case in humans due to the larger dis-
tance between those organs. 
Furthermore, the current pretargeting system based on TF2 and radiolabelled IMP288 
could be substantially improved by enhancing the circulatory half-life of bsMAb. High 
amounts of bsMAb in the tumour are required to capture as much of the radiolabelled 
peptide as possible, and to fully exploit the pretargeting technique of a two-step tar-
geting of radioactivity. This can only be achieved by sustained high antibody blood 
levels during multiple days, as this is the driving force for accumulation of the bsMAb 
in the tumor. However, in patients the blood clearance of TF2 was much faster than 
that of similarly sized IgG molecules. This unexpected result could be explained by the 
fact that TF2 lacks a CH2 domain (15, 16). 
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In conclusion, based on the knowledge acquired in this thesis, pretargeted immuno-
PET with TF2 and IMP288 could be a very powerful imaging modality in patients 
with mCRC. Further studies should determine its added value in specificity compared 
to FDG-PET, and potentially similar or superior sensitivity in (CRC) patients. 
As a therapeutic option, we did not find any evidence that PRIT with TF2 and 177Lu-
IMP288 can be effective in patients with advanced large-volume metastatic disease. 
However, in future studies several factors can be varied to increase the therapy effect, 
like testing PRIT in patients with smaller volume disease, and using a bsMAb with 
enhanced circulatory half-life. 
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. De studies in dit proefschrift beschrijven radioimmunotargeting (RIT) van tumoren 
door middel van een pretargeting methode/benadering. Bij RIT worden radioactief 
gelabelde antilichamen toegediend, die gericht zijn tegen antigenen op tumorcellen en 
die daardoor specifiek in tumoren accumuleren. Omdat intacte antilichamen slechts 
langzaam in tumoren accumuleren en traag uit het bloed worden geklaard, kunnen de 
tumoren pas enkele dagen na injectie gedetecteerd worden en worden tijdens therapie 
het beenmerg aan een relatief hoge stralendosis blootgesteld. Om deze problemen te 
omzeilen zijn nieuwe pretargeting technieken ontwikkeld die zorgen voor een snelle 
en selectieve opname van de radioactiviteit in tumoren. Bij deze toepassing wordt 
eerst een niet-radioactief bispecifiek monoclonaal antilichaam (bsMAb) toegediend. 
Er wordt gewacht tot het antilichaam is geaccumuleerd in de tumor en geklaard uit de 
circulatie. Daarna wordt een radioactief gelabeld hapteen-peptide toegediend dat snel 
wordt geklaard uit het bloed en lichaam, maar wordt gebonden in de tumor door de 
anti-hapteen arm van het bsMAb.  
Wij hebben een pretargeting systeem onderzocht gebaseerd op het bsMAb TF2 en 
het peptide IMP288 voor carcinoembryonic antigen (CEACAM5)-expresserende 
tumoren. TF2 is een gehumaniseerd anti-CEACAM5 x anti-HSG bsMAb dat is 
geproduceerd door middel van de zogenaamde Dock-and-Lock technologie, met een 
stabiel tri-Fab-molekuul als resultaat. TF2 bestaat uit twee Fab-fragmenten met hoge 
affiniteit voor CEACAM5 en een  Fab-fragment met hoge affiniteit voor het hapteen 
histamine-succinyl-glycine (HSG). IMP288 is een peptide met twee HSG-groepen, 
met als doel een verbeterde hapteen-peptide opname en retentie in de tumor. Ook 
heeft IMP288 een chelator 1,4,7,10-tetraazacyclododecaan-1,4,7,10-tetraacetic acid 
(DOTA) die een groot scala aan radionucliden stabiel kan binden, zoals 111In voor 
SPECT scans, 18F en 68Ga voor PET scans of 90Y en 177Lu voor pretargeted radioim-
munotherapie (PRIT). 
Allereerst hebben we het pretargeting systeem onderzocht in diermodellen ter oriën-
tatie voor de translatie naar de klinische situatie. In deze dierexperimenten maakten 
wij gebruik van naakte BALB/c  muizen die werden geïnoculeerd met  een LS174T-
tumorcellen, van een CEA-expresserende, humane, colorectale cellijn. De subcutane 
(s.c.) injectie van 1 x 106 LS174T cellen resulteerde in s.c. tumoren van ongeveer 
0.1-0.3 gram in 10-14 dagen. Hetzelfde aantal LS174T cellen werd intraperitoneaal 
geïnoculeerd, wat 2-3 weken na injectie resulteerde in peritoneale carcinomatosis met 
meerdere solide tumoren in het abdomen die veel variatie vertoonden in gewicht (0.3-
650 mg), zonder tekenen van ongerief of verandering in lichaamsgewicht. 
In de studies beschreven in hoofdstuk 2 en 3 werd onderzocht wat het effect van de 
dosis van het bsMAb en het peptide was op de opname van het radioactief gelabelde 
IMP288 in de tumor en in de normale organen. De TF2 en IMP288 dosis werden 
opgehoogd om de dosis vast te stellen waarbij een maximale hoeveelheid radioac-
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tiviteit specifiek naar de tumoren geleid kon worden. Uit deze studies bleek dat de 
optimale TF2 dosis in dit model 5.0-6.0 nmol/muis is en de optimale IMP288 dosis 
0.28 nmol/muis. 
In hoofdstuk 2 hebben we de specificiteit van pretargeted immuno-PET met TF2 en 
68Ga-gelabelled IMP288 onderzocht in BALB/c naakte muizen met een s.c. LS174T-
tumor, een s.c. CEA-negatieve tumor, of een steriele ontsteking in de dijbeenspier. In 
minder dan een uur toonden de PET-scan en de gedissecteerde weefsels een specifieke 
opname van het 68Ga-IMP288 in de LS174T-tumor en zeer lage opname in de normale 
organen, in de CEA-negatieve tumor en in de ontstoken spier. Dezelfde muis werd ook 
gescand na injectie van 18F-FDG. 18F-FDG accumuleerde efficiënt in de tumor, maar 
ook in de ontstoken spier en in meerdere normale weefsels (hersenen, myocard, nieren 
en focaal in de darmen). Een soortgelijk hapteen-peptide werd radioactief gelabeld 
met 18F en getest in muizen met een s.c. LS174T-tumor.  18F-gelabeld peptide accumu-
leerde op dezelfde manier in de tumor en de normale weefsels als het 68Ga-gelabelled 
peptide. Deze studies toonden aan dat pretargeted immuno-PET met TF2 en 68Ga- of 
18F-hapteen-peptide een snelle, specifieke beeldvormende techniek is voor de detectie 
van CEA-positieve tumoren en dat het specifieker is dan 18F-FDG-PET.   
Voor het aantonen van de sensitiviteit van een nieuwe beeldvormende techniek heeft 
een orthotoop diermodel enkele voordelen in vergelijk met een s.c. tumormodel, nl. dat 
een dergelijk model ook de effecten van de tumor-vs-achtergrond-ratio’s en tumoren 
van verschillende groottes binnen één dier onderzocht kunnen worden. In de studie 
beschreven in hoofdstuk 3 werd de sensitiviteit van de pretargeted immuno-PET met 
TF2 en 68Ga-IMP288 onderzocht in muizen met kleine intraperitoneale tumoren. 
Ook in deze studie werd  pretargeted immuno-PET vergeleken met 18F-FDG-PET. 
Na injectie van het 68Ga-gelabelde peptide werd een hoog contrast tussen de tumor en 
de normale weefsels gevonden, wat resulteerde in een duidelijke afbeelding van alle 
tumoren in de buikholte met een volume ≥ 10 µL. Met 18F-FDG konden enige tu-
moren ook worden afgebeeld, maar werd ook fysiologische opname gezien in normale 
organen, waardoor bijvoorbeeld de tumoren moeilijker van de normale darm onder-
scheiden konden worden. Deze resultaten suggereren dat pretargeted immuno-PET 
met bsMAb en 68Ga-gelabeld peptide een zeer gevoelige beeldvormende techniek kan 
zijn voor het opsporen van colorectaal kanker. 
Nadat de TF2- en IMP288-dosis waren geoptimaliseerd en de potentie van pretar-
geted immuno-PET was aangetoond, werd de therapeutische effectiviteit en toxiciteit 
van pretargeted radioimmunotherapie (PRIT) met TF2 en 177Lu-gelabelled IMP288 
bepaald in muizen met s.c. LS174T-tumoren (hoofdstuk 4). Aangezien pretargeting 
een verlaging van de stralingsdosis naar het beenmerg gaf, konden veel hogere doses 
radioactiviteit aan de muizen worden toegediend dan met directe radioimmuno-
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therapie. Ook werden verschillende schema’s met herhaalde toediening van radioactief 
gelabelled IMP288 onderzocht in een biodistributie-experiment. Het eerste schema 
bestond uit één TF2-injectie gevolgd door meerdere IMP288-injecties (interval van 3 
uur). Het tweede schema bestond uit meerdere cycli waarbij elke IMP288 toediening 
werd voorafgegaan door een nieuwe TF2-injectie (interval van 72 uur). Het laatst-
genoemde dosisschema resulteerde in de hoogste opname van radioactiviteit in de s.c. 
tumoren. In het therapie-experiment kregen de muizen één, twee of drie opeenvol-
gende cycli. PRIT vertraagde de tumorgroei effectief en verlengde de overleving van 
de muizen met s.c. tumoren significant, waarbij de overlevingswinst groter was in de 
muizen die meerdere werden behandeld met meerdere cycli TF2 en Lu177-IMP288 
zonder dat relevante bijwerkingen gezien werden. Deze studie in muizen wijst erop 
dat PRIT bij colorectale kanker een mogelijk effectieve nieuwe behandeloptie met 
beperkte toxiciteit kan zijn.  
Om de effectiviteit van pretargeted radioimmunotherapie te kunnen voorspellen, 
kunnen diagnostische scans worden vervaardigd na injectie van het radioactief gela-
belde hapteen-peptide. De strategie waarbij beeldvorming en behandeling worden 
gecombineerd, wordt ook wel ‘theranostics’ genoemd. Dit was het onderwerp van 
de studie die wordt beschreven is in hoofdstuk 5. De mogelijkheid om pretargeted 
immuno-SPECT met TF2 en IMP288 gelabeld met 111In te gebruiken voor moni-
toring van het therapeutisch effect van PRIT met 177Lu-IMP288 werd onderzocht in 
muizen met intraperitoneaal groeiende LS174T-tumoren. In dit model toonde pre-
targeted immuno-SPECT een snelle en selectieve opname van het gelabelde hapteen-
peptide in de tumor. Hierdoor konden zeer kleine tumoren gedetecteerd worden. De 
radioactiviteit in de tumorlesies gemeten in de SPECT scans correleerde goed met de 
opname die werd gemeten in de gedissecteerde weefsels. Er werd een overlevingsstudie 
uitgevoerd in muizen die TF2 en 177Lu-IMP288, niet-gepretargeted 177Lu-IMP288, 
of PBS kregen toegediend gevolgd door immuno-SPECT scans direct, 14 en 45 
dagen na therapie. Tijdens PRIT met TF2 en 177Lu-IMP288 kon de tumorgroei in 
de proefdieren in de opeenvolgende scans worden gevolgd. De resultaten van deze 
studie toonden de toegevoegde waarde van beeldvorming voor het monitoren van de 
effectiviteit PRIT. 
De kennis die werd verzameld in de  pretargeting studies in muizen-modellen werd 
gebruikt om een een fase I studie in patiënten met dikkedarmkanker in een vergevor-
derd stadium te ontwerpen (hoofdstuk 6). Het belangrijkste doel van deze studie was 
het bepalen van [1] de verschillende variabelen die bij pretargeting een rol spelen en 
[2] de veiligheid in patiënten met gemetastaseerd colorectaal carcinoom (CRC). Voor 
patiënten die in aanmerking kwamen voor deze studie waren geen standaard thera-
peutische opties meer beschikbaar. Er werden verschillende dosisschema’s bestudeerd 
in vier cohorten van vijf patiënten door [1] het inkorten van het interval tussen de 
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toediening van het bsMAb en het peptide (5 dagen vs 1 dag), [2] het verhogen van 
de TF2 dosis (van 75 naar 150 mg) en [3] het verlagen van de peptide dosis (van 100 
naar 25 µg). Er werd ook in de patiënten een snelle en selectieve tumoropname van 
het radioactief gelabelde hapteen-peptide waargenomen in minder dan een uur tijd 
met hoge tumor/normale weefsels ratio’s (>20 na 24 uur). De tumoropname van het 
radioactief gelabelde hapteen-peptide was hoger bij een interval tussen de toediening 
van het bsMAb en het peptide van 1 dag en bij een peptide dosis van 25 μg. Hoge 177Lu-
IMP288 activiteitsdoses konden veilig aan patiënten worden toegediend. Wel werden 
bij enkele patiente infusiereacties waargenomen na herhaalde toediening van het TF2. 
Deze infusiereacties konden goed worden behandeld. Ook werd in twee patienten 
een tijdelijk graad 3-4 trombocytopenie waargenomen. Er werd geconcludeerd dat 
pretargeting met TF2 en 177Lu-IMP288 in patiënten met CEA-expresserende CRC 
uitvoerbaar en veilig is. 
In hoofdstuk 7 is de dosimetrische analyse van de planaire scintigrammen en bloed-
samples beschreven. Voorafgaand aan elke behandelcyclus kregen patiënten een 
diagnostische cyclus met TF2 en 111In-gelabeld IMP288. De 111In-IMP288 data 
werden gebruikt om de stralingsdosis van het 177Lu-IMP288 te voorspellen,  om zo 
te berekenen welke 177Lu activiteitsdosis veilig kon worden toegediend. Er werd een 
sterke correlatie gevonden tussen de TF2 bloedspiegel op het moment van IMP288 
toediening en de verblijftijd van het IMP288 in het bloed.  Therapeutische 177Lu activ-
iteitsdoses resulteerden in lage stralingsdoses in de normale weefsels. In de meerder-
heid van de patiënten die de maximale of aangepaste 177Lu activiteitsdoses ontvingen, 
overschreed de gemeten beenmergdosis niet de in het protocol vastgestelde limiet. Er 
was goede overeenstemming tussen de gesimuleerde 177Lu-IMP288 beenmergdoses en 
de werkelijk gemeten doses. De hematologische toxiciteit correleerde met de stralen-
dosis naar het beenmerg. 
De SPECT-scans die werden verkregen in de fase I studie werden ook geanalyseerd 
met een nieuwe, geavanceerde methode, de Three-Dimensional Radiobiological 
Dosimetry (3D-RD) methode die gebaseerd is op Monte-Carlo simulaties (hoofd-
stuk 8). De voxel-waarden van de SPECT scans werden gebruikt om de activiteits-
verdeling in de scan te bepalen en een CT-scan om de dichtheid van de weefsels te 
bepalen. De data van deze scans vormden de input van de Monte Carlo simulaties, die 
resulteerden in een schatting van de  energie-depositie per voxel per scan. Met de com-
binatie van de resultaten van de vier SPECT-scans na een injectie werd de dosis binnen 
een VOI berekend. In tegenstelling tot de eerder beschreven dosimetrie-methodes, 
werden voor 3D-RD de SPECT-scans i.p.v. de planaire scintigrammen gebruikt en 
de lumbale wervels i.p.v. het cranium voor de beenmergdosis. Bovendien kon met 
de 3D-RD dosimetrie-methode naast de beenmergdosis ook de tumordosis worden 
bepaald. Daarnaast werd met  3D-RD ook rekening gehouden met het effect van de 
weefseldichtheid en heterogeniteit van de stralingsdosis binnen een tumorlesie. De 
uitvoerbaarheid en de voorspellende waarde van deze 3D-RD software methode werd 
bestudeerd voor het voorspellen van beenmergtoxiciteit en therapeutische effectiviteit 
in de fase I klinische PRIT-studie en vergeleken met de resultaten van de methodes 
gebaseerd op de planaire scans en de bloedsamples. De 3D-dosimetrie toonde twee 
keer zo hoge beenmergdoses in vergelijking met de bloed- en planaire methode en 
een betere dosis-toxiciteitscorrelatie. Ook werden de tumor en beenmergdoses van 
het  177Lu verkregen d.m.v. de 3D-RD methode gesimuleerd voor 90Y. De tumor-vs-
beenmerg-ratio van de data gesimuleerd voor 90Y in vergelijking met 177Lu lagen in 
dezelfde range. Er werd geconcludeerd dat met de 3D-RD methode de beenmergtoxi-
citeit en de stralingsdoses naar de  tumoren beter voorspeld kunnen worden dan met 
de conventionele methoden. 
In hoofdstuk 9 worden de studies in het Engels samengevat en in hoofdstuk 10 
worden de resultaten bediscussieerd en het toekomstperspectief uiteengezet. 
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van de Clinical PhD Council geweldig en ik heb het heel leuk gevonden dat ik daarna je 
stokje mocht overnemen, bedankt voor je vertrouwen. 
Sandra, Messie, het was heel fijn om af en toe mijn hart bij je te luchten over gedeelde 
frustraties en daarna weer met frissere moed door te gaan. 
En natuurlijk alle andere Aquarium-genoten, Maarten, Stijn, Inge, Willem, Cathelijne, 
Janneke, Desirée, Lieke, Danny, Peter (Z), Karolina, Mark, Edwin, Samantha, dank voor 
jullie hulp en gezelligheid! 
Bianca, Kitty, Henk en Iris, alleen dankzij jullie onvermoeibare en ervaren zorg voor de 
dieren is het mogelijk op een verantwoorde en zorgvuldige manier het onderzoek te doen! 
Carla, heel veel dank dat je mij onder je hoede hebt genomen en dat ik bij jouw fase I 
team mocht aansluiten! Je stond altijd klaar met raad en daad, om het allerbeste voor de 
patiënten te regelen. Ik heb veel geleerd van je doeltreffende aanpak.
Anja, bedankt voor al je geduld en verstandige woorden op de belangrijke momenten. Ik 
voel me al een beetje vóór-opgeleid en hoop dat we dat over een paar jaartjes voortzetten.
Marye, ik vond het fijn dat ik altijd bij je terecht kon bij fase I-dillemma’s, dank je wel!
Claudia, Iris, Michiel, Mirjam, Maartje, Researchvpk, jullie wisten altijd weer orde op 
zaken te stellen, als het in de praktijk nét weer even anders liep dan ik had gepland. 
Wilmy, Yvonne, Lidwien, Tonnie, Brechje, Mark, Riet, Ria, Eveline, Ine, verpleegkundigen 
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en secretaressen van de oncologische dagbehandeling en verpleegafdeling, zonder jullie 
grote inzet bij de planning en uitvoering van de infusies was het niet gelukt, dank! 
Maichel en Miranda, jullie zijn dé Hotlab-Helden, altijd bereid om de PRIT-medicatie 
op tijd te leveren, zelfs als wij haast onmogelijke eisen stelden aan de specifieke activiteit. 
Katja, dank je wel dat je hebt volgehouden ondanks de vaak moeizame samenwerking met 
de verscheidene andere partijen. 
Marjo en Eddy, bedankt voor al jullie hulp bij de opname- en scan-planning, ik heb jullie 
betrokkenheid erg gewaardeerd. 
Martin, English, jouw toewijding maakte de vele scanuren (187 uren in totaal) voor zowel 
de patiënten als voor de arts-onderzoeker een stuk dragelijker . Nog meer uren maakte je 
als mijn favoriete, kletsende wandelcoach, voor de Once-in-a-Lifetime-Experience! 
Michel, Bernadette, Marie Claire, Tineke, Peter K, Diane, Jurrian, jullie ook hartelijk 
bedankt voor jullie vaardige hulp bij de extra logistiek bij de scans. 
Eric, de analyse van de klinische scans bleek toch een beetje ingewikkelder dan ik als 
Dosimetrie-Dummie had gedacht. Dankzij onze complementaire kennis en doorzettings-
vermogen is het toch gelukt, met name dankzij de Technische Geneeskunde studenten: 
Karen en Wietske, jullie ook superbedankt voor jullie zeer zinvolle bijdrage bij mijn pro-
ject en de brug die jullie sloegen tussen techniek en kliniek. 
Dennis, Marcel en Martin G, dank jullie wel voor jullie klinisch wetenschappelijke input, 
die was onmisbaar voor dit proefschrift! 
Sandra, Jacqueline, Judith, Sylvia, Carola, Jolanda, Steven en Monique, jullie secretariële 
hulp heeft me zeer geholpen. 
CPC’ers, Dagmar, Nathalie en Mieke, ik vond het heel leuk om samen met jullie voor de 
UMCN-promovendi een netwerk, cursussen etc. op te zetten. 
Prof. Sgouros en Rob, thank you very much for your hospitality and for helping us to 
apply your 3D-RD-software on our data. It was a very worthy analysis for our research 
project, as it will be for many others in the future. Good luck with the validation and 
implementation.
Dr Sharkey, thank you very much for your throughout reviews of our data and manus-
cripts, You have taught me a lot about pretargeting specifically and (pre)clinical research 
in general. 
Lieve Ankie, Arjanne, Esther, Heleen, Irma, Jorien, Josje, Kristel, Lucie, Marieke, Tessa, 
en Willemien, wat ben ik blij dat jullie mijn vriendinnen zijn! Al zoveel mooie en soms 
moeilijke dingen samen meegemaakt. Al lopen onze levens soms geografisch wat verder 
uit elkaar, we komen toch altijd weer samen en dan voelt het weer als vanouds: fijn!
Lieve Mayk, Henry, Thijs, Mayk, Lot, San, Morten, Tes en Marnix, jullie zijn de fijnste 
zussen, broer, schoonzus en zwagers die je je maar kan wensen, bedankt gewoon voor alles!
Lieve pap & mam, jullie zijn de allerbeste ouders! Dank jullie wel voor jullie onvoorwaar-
delijke zorg en steun!
AllerLiefste, Paul. Gelukkig weet je wat het is, een proefschrift schrijven en heb je me 
daarom mijn mopper-momenten vergeven. Twee boekjes op de plank, wat een opluchting. 
En nu door met de uitdagingen die we hebben gevonden in onze nieuwe banen, maar 
vooral genieten van alles daarbuiten. Heerlijk om samen met jou door het leven te gaan!
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